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ABSTRACT 
Aggregated α-synuclein has emerged as the core constituent of the typical neuronal 
inclusions found in Parkinson’s disease and Lewy body dementia. Therefore, huge efforts 
have been made to unveil the mechanisms underlying α-syn toxicity. Accumulating evidence 
suggests extracellular α-synuclein oligomers (α-synOs) as potential culprits involved in the 
neurodegenerative process. To elucidate the pathways mediating α-synO non-cell-
autonomous actions, several mechanisms including uncontrolled neuroinflammatory 
responses and protein-protein interactions have been put forward.  
Through an acute model based on the intracerebroventricular (ICV) injection of α-synuclein 
monomers, oligomers or fibrils in C57BL/6N mice we demonstrate that only α-synOs impair 
memory establishment in association with glial activation. Furthermore, our findings 
identify neuroinflammation as a driving force of α-synO detrimental action on memory, and 
the involvement of the Toll-like receptor 2. Based on recent data depicting the cellular prion 
protein (PrPC) as an α-synO interactor, we have further investigated its role in fostering α-
synO harmful activities. We found that PrPC does not mediate α-synO toxicity in vitro or α-
synO-induced memory deficiency in vivo. In fact, PrPC knock-out mice ICV injected with 
α-synOs display both memory impairment and gliosis. Consistently, our in vitro biochemical 
studies do not reveal any direct PrPC-α-synO binding. 
To evaluate the influence of neuroinflammation on PD pathogenesis, we have developed a 
“double-hit” approach. Using an acute mouse model based on the peripheral administration 
of lipopolysaccharide (LPS) and subsequent ICV injection of α-synOs at an inactive dose, 
we demonstrate that the LPS induces a long-lasting neuroinflammatory response enhancing 
α-synO actions. Moreover, we show that the LPS peripheral administration worsens 
cognitive deficits even in an A53T PD mouse model. Altogether, by identifying 
neuroinflammation as an α-synO-mediator and as a factor influencing the 
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initiation/progressions of PD, we highlight it as a valuable research topic to identify potential 
targets for developing new therapeutic strategies. 
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1.1 A brief overview on the long history of Parkinson’s disease 
The first partial clinical descriptions of Parkinson's disease (PD) can be found in ancient 
Indian and Chinese populations, which have described both PD motor symptoms and 
therapeutic recommendations since 5000 B.C (Zhang et al., 2006a; Goetz, 2011; Goedert et 
al., 2017). 
Nevertheless, the complete clinical report of PD cardinal motor symptoms was provided in 
1817 by the London physician James Parkinson. In his monograph “Essay on the Shacking 
Palsy” he punctually described a series of six patients characterised by movement disorders 
which came to bear his name: “involuntary tremulous motion, with lessened muscular 
power, in parts not in action and even when supported; with a propensity to bend the trunk 
forward, and to pass from a walking to a running pace: the senses and intellect being 
uninjured” (Goedert et al., 2017; Fahn, 2018) 
A thorough description of PD was provided 50 years later by Jean-Martin Charcot (1872). 
He identified bradykinesia as a cardinal feature of the pathology and distinguished two 
prototypes of the disease: the tremulous and the rigid/akinetic type. Moreover, Charcot 
rejected the first designation of the disease (paralysis agitations or shacking palsy), and 
suggested the term already being used (PD). In fact, he observed that PD patients were not 
weak and did not necessarily display tremor (Charcot, 1875). The most important Charcot’s 
contribution to the study of PD is the definition of the different types of the disorder. For 
instance, he identified an atypical form of PD without tremor and with a stiff and extended 
posture (Figure 1). 
 
 
Figure 1. Charcot’s drawing of typical 
and atypical PD. Typical PD showing a 
flexed posture (left) and atypical (right) 
PD with absence of tremor and extended 
posture (modified from Goetz, 2011). 
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At the beginning of the XX century, Brissaud identified the Substantia nigra (SN) as the 
crucial brain region affected in PD. Soon after, Friedrich Lewy reported the typical 
intracellular inclusions in several brain regions (1912), that were named ‘Lewy bodies (LB) 
by Tretiakoff in 1919 (Goedert et al., 2017) 
Forty years later the studies by Carlsson and co-workers indicated the deficiency of the 
neurotransmitter dopamine as responsible of the motor symptoms in PD (Carlsson et al., 
1958; Carlsson et al., 2001). This possibility was subsequently confirmed by the evidence 
of dopamine being reduced in PD patients (Ehringer and Hornykiewicz, 1960), and by 
observations that SN, a brain region enriched in dopaminergic neurons (Dahlstrom and Fuxe, 
1964), was particularly damaged in PD patients.  
From the description of Parkinson and Charcot, motor symptoms clearly emerge as cardinal 
PD features. Although the relevance of motor symptoms in PD is widely accepted, nowadays 
non-motor symptoms acquire a significant relevance in terms of factors that largely impact 
life quality. Among non-motor symptoms, cognitive deficits have gained more and more 
attention as they have become a well-accepted parameter for differentiating between 
dementia associated to PD (PDD) and Dementia with Lewy Bodies (DLB) (McKeith et al., 
2004; Galasko, 2017). PD, PDD and DLB all share common neuropathological features 
including LBs, which at present has a history longer than one century. 
 
1.2 Neuropathological features 
Loss of dopaminergic neurons in Substantia Nigra pars compacta (SNpc) and intraneuronal 
proteinaceous inclusions are defining hallmarks of the progressive neurodegenerative 
disorder PD. 
The depletion of dopaminergic neurons in SNpc (Figure 2) accounts for changes in the 
nigrostriatal pathway which result in the typical PD motor symptoms (Lang and Lozano, 
1998; Sveinbjornsdottir, 2016). Dopaminergic neurons in SNpc are particularly affected in 
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PD, however other specific neurons (glutamatergic, GABA-ergic, cholinergic, 
noradrenergic and adrenergic) in selective brain regions can be progressively damaged. For 
instance, extranigral abnormalities have been observed within the entorhinal cortex, in the 
CA2 region of the hippocampus, in the amygdala, in the hypothalamus, in the nucleus 
basalis of Meynert and locus caeruleus (Lang and Lozano, 1998; Braak and Braak, 2000). 
 
 
 
 
 
 
 
 
Figure 2. Depletion of dopaminergic neurons in SN from a PD patient compared to healthy 
control. Macroscopic (inset) and coronal section of the midbrain upon immuno-staining for the 
limiting enzyme Tyrosine hydroxylase (Th) involved in dopamine synthesis. PD patients (right) are 
characterised by a significant loss of Th+ neurons compared to healthy controls (left). Modified from 
Poewe et al., 2017. 
The intracellular inclusions typically observed in post-mortem PD brains can be classified 
into Lewy bodies (LBs) or Lewy neurites (LNs) based on their localisation in the somata or 
neuronal processes respectively. Two distinct LBs can be identified. The brainstem-type 
(classical) LBs are easily seen upon haematoxylin and eosin staining. They appear as single 
or multiple spherical inclusions with a diameter between 5 to 25 µm and a central dense 
eosinophilic core surrounded by a peripheral pale halo (Figure 3A). Cortical-type LBs 
(Figure 3B) are eosinophilic like brainstem type LBs, but they have an irregular shape and 
they lack a dense central core and halo (Lang and Lozano, 1998; Wakabayashi et al., 2013). 
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Aside of classical and cortical LBs, a third intracellular inclusion type can be observable in 
the pigmented neurons of SNpc, the “pale bodies” (Figure 3C). Pale bodies are less 
eosinophilic with a glassy area and without halo. Pale bodies frequently occur with LBs in 
the same neurons (Figure 3C) and it has been proposed that pale bodies are linked to LBs 
formation (Wakabayashi et al., 2013). LBs have been detected for a long time by anti-
ubiquitin antibodies. In fact, both brainstem type and cortical LBs can be strongly 
immunostained with ubiquitin (Kuzuhara et al., 1988), 
Figure 3. Haematoxylin and eosin staining of LBs. (A) Classical LBs in the SN. (B) Cortical LBs 
indicated by arrowheads in the temporal cortex. (C) Pale body (asterisk) and classical LBs 
(arrowheads) within SN neurons. Scale bar 10μm. Modified from Wakabayashi et al., 2013. 
More than 90 elements have been identified in both LBs and LNs (Wakabayashi et al., 2013), 
among which alpha-synuclein (a-syn) emerges as a central component and building block 
(Figure 4) (Spillantini et al., 1997; Spillantini et al., 1998: Baba et al., 1998). 
 
 
 
 
 
 
 
Figure 4. α-syn is the main constituent of LBs and LNs. α-syn immunostaining of a post-mortem 
PD brain reveals the presence of α-syn in both LBs and LNs (Modified from Poewe et al., 2017). 
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1.2.1 The nigrostriatal pathway 
The idea of lesions in the SN as anatomical substrate of PD is due to Edouard Brissaud in 
1894, who knew well the previous study of Charcot as well as the work of Blocq and 
Marinesco (Spillantini and Goedert, 2018). The microscopic and macroscopic SNpc 
alterations reported by Trétiakoff, the reduction in dopamine levels in the striatum and in the 
SNpc (Przedbosrki, 2017), along with the efficacy of L-DOPA in alleviating motor deficits 
in PD patients, points towards an involvement of the nigrostriatal pathway in PD (Fahn, 
2015). This hypothesis had been built over the 20th century, when researchers established 
the link between dysfunctions in the basal ganglia-thalamo-cortical circuit and the motor 
defects typical of PD. In these studies, discrete lesions of the basal ganglia and chemical 
destruction of the nucleus subthalamicus (STN) led to abrogation of parkinsonisms and 
allowed the dissection of the functional neuroanatomy of the basal ganglia (Meyers, 1942: 
Bergman et al., 1990). Basal ganglia refers to those grey matter structures at the base of the 
cerebral hemisphere, encompassing a network of connected subcortical nuclei such as the 
striatum (nucleus caudatus and putamen), the SNpc and the Substantia Nigra pars reticulata 
(SNpr), the STN, and the Globus Pallidus pars externa (GPe) and pars interna (GPi).  The 
motor circuit of the basal ganglia is involved in the regulation of movements through the 
synergy of the nigrostriatal, and the “direct” and “indirect” motor loop pathways (Figure 5 
A). The motor cortex projects excitatory input to the striatum reflecting cortical somatotopic 
organisation (Takada, 1998). The striatum in turn, is modulated through dopamine release 
by the SNpc. The nigrostriatal pathway acts on two types of dopamine receptors, that define 
the overall final output from the basal ganglia to the motor nuclei. While the excitatory D1 
receptors are involved in the “direct” pathway which facilitates voluntary movements, the 
inhibitory effect of D2 receptors in the “indirect” pathway prevents unwanted movements. 
In the “direct” pathway, the excitatory effect of dopamine on D1 (Figure 5A) triggers the 
release of GABA that inhibits the GABAergic neurons of the GPi/SNpr (Figure 5A), 
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decreasing the final inhibition on the motor nuclei. This way the direct pathway generates a 
net excitatory effect that promotes movement initiation. On the other hand, in the “indirect” 
pathway dopamine dampens striatal GABAergic activity through D2 receptors. Because the 
“direct” pathway only involves a single synapse is commonly referred to as monosynaptic, 
whereas the “indirect” one includes polysynaptic projections that cross the GPe and the STN 
before reaching the output nuclei (GPi/SNpr) (Figure 5 A). The GPe, via GABAergic 
stimuli, acts as a negative regulator of the “direct” pathway by modulating the glutamatergic 
activity of the STN (red arrows), that ultimately reaches the output nuclei. Activated 
GPi/SNpr leads then to a net inhibition of movement (Galvan et al., 2015). 
In PD patients, the dopaminergic nigrostriatal pathway progressively degenerates (Figure 
5B), resulting in the decrease of dopamine levels. As a consequence, the activation of the 
“direct” and the inhibition of the “indirect” pathways are drastically reduced, leading to an 
overall strong inhibition of the motor activity (Przedbosrki, 2017). 
 
Figure 5. Schematic representation of the “direct” and “indirect” pathways of the basal ganglia 
motor circuits on healthy control (A) and PD patients (B). Green arrows represent excitatory 
pathways whereas red arrows are inhibitory. Modified from Maii et al., 2017. 
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1.3 Clinical features 
PD is a debilitating disease with a progressive worsening of symptoms that primary affect 
voluntary movements. Although motor symptoms are cardinal features of PD, a variety of 
non-motor symptoms have been described. Non-motor symptoms contribute to decrease the 
life quality and they can appear before the onset of motor-symptoms or during the 
progression of the disease (Sveinbjornsdottir, 2016). The dopaminergic neuronal loss in 
SNpc has been estimated to be 60 to 80% at the onset of motor symptoms (Fearnley et al., 
1991; Chung et al., 2001). At first, those symptoms appear asymmetrically, affecting the 
other side of the body within a few years. Postural changes, tremor, muscular rigidity, 
bradykinesia, and gait instability are defined as cardinal PD motor features. Postural 
deformities including flexion of the thoracic or lumbar spine, and forward flexion of the 
head and neck cause the body posture to become stooped (Sveinbjornsdottir, 2016). Resting 
tremor is one of the most obvious features of the disease, being one of the first and more 
distressing symptoms reported by patients. In most cases, a resting pill-rolling type tremor 
of the hands is present, whereas legs are involved only occasionally. Furthermore, about 
60% of patients experience tremor during voluntary movements (Heusinkveld et al., 2018). 
Bradykinesia describes slowness in carrying out rather than initiating movements, and it 
accounts for expressionless face (hypomimia) and smaller handwriting (micrographia). 
Conversely, gait disturbances include shuffling, blocking, freezing of movements, and 
festination, where steps become progressively smaller and rapid leading to loss of balance 
and falls (Virmani et al., 2015). Less common in PD is dystonia, a non-voluntary contraction 
of antagonist muscles leading to spasms with different degree of pain. Contractions can be 
associated with abnormal movements and posture. Dystonia is more often a consequence of 
PD treatment, although it rarely occurs in early onset PD patients (Tolosa and Compta, 
2006).   
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1.3.1 Non-motor symptoms of Parkinson’s disease 
As mentioned above, a variety of non-motor symptoms may appear in PD patients before 
the onset of motor symptoms and before the diagnosis. Particularly, it has been reported that 
non-motor symptoms may affect patients up to 10 years before the diagnosis of PD. These 
data allow the determination of a target temporal window, defined as pre-motor or prodromal 
phase, for preventive and disease-modifying treatments aimed at slowing or blocking the 
pathology progression (Schrag et al., 2015; Kalia and Lang, 2015). 
Like motor symptoms, non-motor ones get worse over the course of the pathology and they 
are described by patients as more troublesome than classical PD motor features 
(Sveinbjornsdottir, 2016). 
A large amount of various non-motor clinical features has been reported in PD patients 
including sensory dysfunctions, neuropsychiatric features, sleep disorders and autonomic 
dysfunctions (Kalia and Lang, 2015; Schapira et al., 2017). Sensory symptoms are virtually 
experienced by all PD patients as a part of their prodromal phase (Schapira et al., 2017). 
Among these, olfactory deficit has a higher prevalence being observed in 90% of subjects 
and it is generally considered as useful early pre-motor PD marker (Poewe, 2008; Schapira 
et al., 2017). Visual disturbances, and particularly visual hallucination, initially considered 
as an adverse effects of drug treatment in advanced PD, are now depicted as typical 
prodromal PD features and are reported in untreated patients. Of note, visual hallucination 
can be included among neuropsychiatric features of PD and is considered as a predictor of 
cognitive decline in the later stage (Jankovic, 2008; Schapira et al., 2017). 
Neuropsychiatric manifestations (e.g. anxiety, depression. sleep disorders...) occur both in 
the pre-motor and in the late phase of PD (Poewe, 2008). Anxiety is experienced by 60% of 
patients and comprises generalised anxiety, panic attacks and social phobias. Although 
anxiety is generally accompanied by depression, the latter may also occur alone. PD-related 
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depression is milder than depression occurring in non-PD affected subjects and it frequently 
involves apathy and anhedonia (Schapira et al., 2017).  
An increasing interest in non-motor PD features has been recently growing for sleep 
disorders. Sleep and wakefulness disturbances affect most PD patients and their prevalence 
increase with the disease duration and progression. Of note, rapid eye movement sleep 
behaviour disorder (RBD) is a parasomnia characterised by aberrant and abnormal 
behaviours (talking, sitting up to bed, gesturing...) which take place during rapid eye 
movement sleep. The interest in RBD comes from the evidence that it can appear even 12-
14 years earlier than motor manifestations. In addition, RBD is predictive of cognitive 
deficits.  In fact, patients with RBD show an increased risk of dementia (Kalia and Lang; 
2015; Schapira et al., 2017).                                                                                                                                   
Beside the various non-motor disturbances here reported, compelling data indicate that PD 
patients also experience dysfunctions affecting the autonomic system, which precede the 
onset of motor symptoms but become more frequent as the disease progresses (Poewe, 200S; 
Shapira et al., 2017). Autonomic dysfunctions include bladder disturbances, gastrointestinal 
dysfunctions (excessive salivation, dysphagia, impaired gastric emptying, constipation and 
bacterial overgrowth). 
Of note, non-motor PD-related symptoms are now recognised as component of PD that is 
not solely a CNS disorder but, more likely, a multisystem pathology (Lee and Koh, 2015)                                                                                                                            
 
1.3.1.1 Cognitive impairment in Parkinson’s disease 
Cognitive decline is one of the most common PD-related non-motor symptoms and it 
contributes in a significant manner to morbidity and mortality (Aarsland et al., 2017; 
Hanagasi et al., 2017). In addition, cognitive impairment has acquired an increasing clinical 
interest because of its heterogenous manifestation, and the risk of evolving in dementia in a 
large number of PD patients (Biundo et al., 2016). Cognitive deficiencies in PD affects a 
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variety of domains and it generally worsens with disease progression leading to a clinical 
status known as PDD. Dementia stands for a sufficient level of cognitive impairment that 
results in a significant reduction in the ability to perform normal daily activities. As dementia 
in PD accounts for high public health cost and is a frequent cause of patient 
institutionalisation, it is an urgent issue to cope with (Emre, 2003; Biundo et al., 2016; 
Hanagasi et al., 2017; Aarsland et al., 2017). 
As mentioned above, the clinical manifestation of cognitive deficits in PD are numerous and 
involves several domains. Executive functions such as the ability to plan activities, the 
organisation and the regulation of specific behaviour aimed at a specific goal are generally 
impaired (Emre et al., 2003). In addition, PD patients are defective in their working memory, 
in memory recall and in verbal fluency. Furthermore, patients experience attention problems 
with vigilance reduction and fluctuating levels of alertness (Biundo et al., 2016). Another 
affected domain includes the visuospatial and the perceptive ability. In fact, PD patients 
report difficulties in the perception of the extra personal space and in the recognition of 
objects from their shape (Biundo et al., 2016; Aarsland et al., 2017). 
Based on the heterogeneity of cognitive deficits it is possible to distinguish two independent 
and partially overlapping syndromes: I) an early stage syndrome characterised by fronto-
striatal dysfunction which is accompanied by working memory deficits, as well as attention 
and planning problems; II) a late stage syndrome involving a more posterior cortical 
degeneration with loss of cholinergic neurons that may evolve in PDD (Biundo et al., 2016; 
Hanagasi et al., 2017). 
  
1.3.2 Dementia with Lewy bodies 
Beside PDD, a second dementia subtype among α-synucleinopathies is the DLB. Initially 
described as rare, DLB is now depicted as the second most common type of degenerative 
dementia in elderly after Alzheimer’s disease (AD) (McKeith et al., 2004; McKeith et al., 
Introduction: Chapter 1 
 
12 
 
2017). The core feature of DLB is the occurrence of dementia that, as previously described, 
stands for a progressive deterioration of cognitive functions with a magnitude sufficient to 
interfere with normal social and occupational functions, as well as with usual daily activities 
(McKeith et al., 2017). 
The recognition and the final diagnosis of DLB can be only done through post-mortem 
assessment of the LB and LN distribution in demented subjects, and the retrospective 
analysis of their clinical history (Outeiro et al., 2019).  
In addition to dementia, a wide spectrum of symptoms occurs in DLB. Fluctuating levels of 
cognitive impairments with spontaneous alterations in cognition and attention are usual. 
They may vary over minutes, hours or days and include waxing and waning episodes of 
inconsistent behaviour, speech and altered consciousness (McKeith et al., 2004: McKeith et 
al., 2017). Psychiatric manifestations are common and, although they occur in early stage, 
are persistent during the progression of the pathology (McKeith et al., 2017, Outeiro et al., 
2019). DLB patients experience delusions, apathy anxiety and recurrent visual hallucination 
which are complex and described in 80% of subjects. Visual hallucinations are well-formed, 
featuring animate figures (people, children and animals) and generally accompanied by 
sense of presence and visual illusions (McKeith et al., 2004; Outeiro et al., 2019). Of note, 
although DLB and AD share common clinical manifestations that may overlap and make the 
correct clinical diagnosis difficult, the occurrence of visual hallucination is more common 
in the former and should be taken into account for a DLB rather than an AD diagnosis 
(Outeiro et al., 2019). A further core feature of DLB is the RBD which is characterised by 
recurrent dream behaviour that includes movements mimicking dream content and is 
associated with loss of the normal REM sleep atonia (McKeith et al., 2004). Additionally, 
DLB patients may present parkinsonism, autonomic failures (e.g. orthostatic hypotension, 
urinary incontinence ...) and hypersomnia (McKeith et al., 2017; Outeiro et al., 2019). 
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1.3.3 Dementia in Parkinson's disease and Dementia with Lewy bodies 
As mentioned above, dementia and LB pathology are features shared by two pathologies, 
PDD and DLB, which are commonly defined with the “umbrella” term Lewy body dementia 
(LBD) (Sanford, 2018). 
Since PDD and DLB share common symptoms, and in later stages they are indistinguishable, 
an arbitrary “1-year rule” based on the relationship between cognitive decline and motor 
symptoms has been introduced. While onset of cognitive decline within 12 months of motor 
symptoms defines DLB, more than 12 months of motor symptoms before cognitive decline 
identify PDD. In other words, in DLB the cognitive decline precedes or accompanies the 
first motor symptoms. Conversely, in PDD motor symptoms precede the cognitive decline 
by at least one year (McKeith et al., 2004; Galasko, 2017). 
As previously described, cognitive impairment in both PDD and DLB consists in deficits 
involving the attention, the visuospatial functions and the executive functions. Patients fail 
in the evaluation of distance, they show impairment in judgment and become unable to 
organise and plan activities. On the other hand, in PDD and DLB cognitive deficits are 
similar across multiple domains. Damages in working memory, long-term memory, 
visuospatial memory and procedural learning are reported in both PDD and DLB (Emre, 
2003; Jellinger 2018). Moreover, memory impairment generally worsens with progression 
in both pathologies (Galasko, 2017; Jellinger, 2018). 
PDD and DLB patients experience complex hallucinations that involve the visual system, 
and that they can remember in detail. Fluctuation in attention or alertness is also a common 
feature, but it is more frequently reported in DLB than PDD patients (Galasko, 2017; 
Jellinger et al., 2018). 
Loss of smell and constipation can be found in both DLB and PDD, and they may precede 
the onset of cognitive and motor symptoms. 
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For a comprehensive view of overlapping and discriminating clinical features between DLB 
and PDD refer to Table 1, where motor and cognitive aspects of the pathologies are 
described. 
The overlap between DLB and PDD includes more than LB pathology and symptoms. Both 
DLB and PDD have indeed synaptic dysfunction in the hippocampus and the typical brain 
lesions associated to AD (amyloid-b deposits and neurofibrillary tangles) (Jellinger, 2018). 
Although the AD pathology is commonly observable in DLB and PDD, the load of amyloid-
b deposits is significantly higher in DLB than PDD patients (Hepp et al., 2016). Moreover, 
the load of a-syn lesions in the CA2 region of the hippocampus and in the entorhinal cortex 
is higher in DLB than PDD (Jellinger, 2014). These significant differences may account for 
the different severity and progression of dementia, and they point out the possible synergistic 
activity of LBs and AD pathology in cognitive impairment (Jellinger, 2018).  
Overlap Dissimilarities 
 
Rigidity, akinesia 
Cognitive impairments 
Frontal executive dysfunction 
Visual-constructive impairment 
Mild language impairment 
Visual hallucinations  
Delusions (less frequent) 
Depression, anxiety 
RBD 
Neuroleptic sensitivity 
 
Some cognitive dysfunctions: deficiencies of 
attention greater, episodic verbal memory tasks 
lower in DLB 
Tremor significantly less frequent in DLB 
Hallucinations more frequent in DLB 
Onset of dementia later in PDD 
Orthostatic hypotension more frequent in DLB 
Frontal/temporal-associated cognitive subsets more 
severe in DLB, cognitive decline is faster in 
DLB than in PDD 
Delusions, attentional fluctuation and visual 
hallucinations more frequent in DLB 
Visual hallucinations: spontaneous in DLB; after L-
dopa therapy in PDD, but also in drug-naïve 
patients 
 
Table 1. Clinical overlap and dissimilarities between DLB and PPD patients. Modified from 
Jellinger, 2018 
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1.4 The Braak staging of Parkinson’s disease 
In 2003 Braak and colleagues proposed a unifying staging scheme to determine the 
progression and severity of PD. The theory implies that the Lewy pathology spreads with a 
specific pattern in anatomically connected brain regions and it is supported by the evidence 
of cell-to-cell transfer of misfolded a-syn (Jang et al.,2010; Halliday et al., 2011). 
The Braak’s staging of PD counts six stages (Figure 6). In stage I and II, LBs and LNs affect 
the olfactory region, the dorsal motor nucleus of the vagus and the locus ceruleus. These 
stages are characterised by non-motor symptoms that involve autonomic and olfactory 
functions. Stages III and IV have Lewy inclusions in the SNpc, in the trans-entorhinal cortex 
and in the CA2 region of the hippocampus. Patients at this stage display classical motor 
symptoms. Stages V and VI with depositions in cortical association areas such as temporal, 
insular and anterior cingulate cortices and a progression in the entire neocortex. Clinically, 
these stages account for the emotional and cognitive disfunctions (Braak et al., 2003). 
Although the Braak’s staging has been initially accepted with enthusiasm, several lines of 
evidence suggest that this staging scheme cannot be always applied. In fact, there are three 
different PD phenotypes which differ in timing, age of symptoms onset, and severity of 
cognitive impairment. These observations indicate that the distribution of LBs and LNs are 
not sufficient to explain such a diverse scenario like PD clinical features (Halliday et al., 
2011). 
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Figure 6. Schematic representation of the Braak staging of PD. Spreading of the Lewy pathology 
within different brain structures, based on the study of Braak. The progression of disease through the 
different brain regions increases over time (from left to right) with a progressive increase in the Lewy 
pathology. Abbreviation: AM, amygdala; BF, magnocellular nuclei of the basal forebrain; BNST, 
bed nucleus of the stria terminalis; Cl, claustrum; cp, cerebral peduncle; DMV, dorsal motor nucleus 
of the vagus; DRN, dorsal raphe nucleus; FCtx, frontal cortex; GP, globus pallidus; GPe, GP 
externa; GPi, GP interna; HN, hypoglossal nucleus; IC, internal capsule; ICP, inferior cerebellar 
peduncle; IL, intralaminar nuclei of the thalamus; ion, inferior olivary nucleus; IZ, intermediate 
reticular zone; LC, locus coeruleus and subcoeruleus; LCtx, limbic cortex; LH, lateral 
hypothalamus; mcp, middle cerebellar peduncle; MRN, median raphe nucleus; OB, olfactory bulb; 
opt, optic tract; OT, olfactory tubercle; PAG, periaqueductal grey; PBN, parabrachial nucleus; 
PGRN/GRN, paragigantocellular and gigantocellular reticular nucleus; PPN, pedunculopontine 
nucleus; PRN, pontine reticular nucleus; pt, pyramidal tract; RM, raphe magnus; RRF/A8, 
retrorubral fields/A8 dopaminergic cell group; SC, superior colliculus; Se, septum; SNc, substantia 
nigra pars compacta; SNr, substantia nigra pars reticulata; SO, solitary tract nuclei; STN, 
subthalamic nucleus; Str, striatum; SVN, spinal vestibular nucleus; T, thalamus; VTA, ventral 
tegmental area; ZI, zona incerta. From Surmeier et al., 2017 
 
1.4.1 The controversial role of Lewy Bodies  
Despite LBs are considered being the histopathological hallmarks of PD, PDD, and DLB, 
their role in neuronal cell death has long been a matter of intense debate. Evidence 
supporting the cytotoxicity of LBs stems from observations including: I) neuronal loss peaks 
in those regions characterised by stronger accumulation of LBs; II) in patients with a mild 
pathology the number of neurons with LBs is higher than those found in patients with severe 
pathology, implying that inclusion-containing cells are dying neurons; III) LB density at the 
cortex might be one of the major correlates of cognitive impairment in PD and DLB; IV) 
LBs seem to affect neuro-vesicle transport (Wakabayashy et al., 2013).  
In stark contrast, other findings suggest that LBs might arise as a secondary effect of the 
pathology with marginal, if at all, involvement in neuronal loss. In fact, it has been shown 
that neurons in the SNpc undergo apoptotic-like cell death regardless of whether or not they 
contain LBs (Tompkins et al 1997; Milber et al, 2012). Furthermore, LBs have been found 
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in healthy individuals and the LB load poorly correlates with the severity of symptoms such 
as cognitive impairment and dementia (Parkkinen et al., 2005; Parkkinen et al., 2008; 
Frigerio et al., 2011). Alternatively, LBs could represent a protective mechanism to 
segregate and enhance the degradation and clearance of damaged and cytotoxic proteins 
(Olanow et al., 2004; Chartier and Duyckaeerts, 2018).   
The controversial role of LBs has been partially overcome after the identification of 
insoluble and fibrillar a-syn as the main constituent of LBs (Spillantini et al., 1998). 
Specifically, studies on the different species of a-syn aggregates found the small soluble 
aggregates being more harmful than the larger ones (Winner et al., 2011). A detailed 
description of a-syn biology is provided in chapter II. 
 
1.5 Epidemiology of Parkinson’s disease 
PD is generally a late onset pathology that affects 1% of worldwide population above 60 
years of age. However, early onset PD cases may occur before 40 years old and it represents 
less than 5% of whole cases (Tysnes and Storstein, 2017). In light of the aetiology, PD can 
be distinguished in a familial/genetic or an idiopathic/sporadic form. The former is 
associated with genome alterations which frequently trigger to autosomal dominant or 
recessive inheritance of PD. The latter has a not well-defined cause and it may result from 
the interplay between several factors. Familial PD only represents 5-10% of all PD cases 
(Tysnes and Storstein, 2017).   
Although PD affects both genders, it is slightly more frequent in males than females with a 
male-to-female ratio of approximately 3 to 2 (Kalia and Lang, 2015; Bhat et al., 2018). 
The prevalence of PD is higher in Europe, North America and South America compared 
with Asian and African countries. The most widely accepted rate of prevalence in general 
population approximates to 100-200 cases for 100000 people. The global incidence ranges 
from 10 to 18 new cases for 100000 person-years (Kalia and Lang, 2015; Tysnes and 
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Storstein, 2017). Interestingly, PD incidence may be higher than the reported data. This 
concern comes from the possibility that incidence studies may be biased by the under-
diagnosing of PD, particularly in early onset PD cases or during early disease stages. 
Age is considered the main risk factor for developing PD. In fact, both prevalence and 
incidence increase with the aging of the general populations, where they peak after 80 years 
old (Figure 7) (Driver et al., 2009; Pringsheim et al., 2014). The drastic increase in 
prevalence after 80 years age cannot be linked with a comparable growth in incidence rate, 
but it can be ascribed to health care improvement (Poewe et al., 2017). 
Figure 7. Prevalence (A) and incidence (B) of PD in male and female. The graphs show the 
increase in incidence and prevalence of PD for 100000 persons in both men (green line) and women 
(blue line). Modified from Poewe et al., 2017. 
The worldwide increase in life expectancy and the aging of general population account for 
a significant increase in the frequency of neurodegenerative disorders. The number of PD 
patients is estimated to double in the next 10 years (Dorsey et al., 2007), bearing important 
implications on the management of the public health care.  
In PD patients the mortality does not increase within the first decade after disease onset, but 
it increases significantly thereafter with the pathology progression compared with global 
healthy control population (Poewe et al., 2017). 
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1.5.1 Epidemiology of Lewy body dementia 
The lack of well-defined criteria to clinically diagnose LBD makes the assessment of 
prevalence and incidence of the disease tough. Nevertheless, it is estimated that the 
prevalence of LBD in people aged 65 years is 1% (0.7 % affected by DLB and 0.3 % by 
PDD) and, it is widely accepted that LBD represents the second most common 
neurogenerative dementia subtype after AD (McKeith et al., 2004; Sanford, 2018). In a study 
performed from 1991 to 2005 on 542 cases of incident parkinsonism, the reported incidence 
for DLB is 3.5 and for PDD 2.5 out of 100000 person-years (Savica et al., 2013). Moreover, 
cognitive impairment in PD generally occurs in advanced age and it appears in 80% of 
patients during the course of the pathology (Hanagasi et al., 2017; Sanford, 2018). The risk 
to develop DLB seems to be higher in males than females, whereas not remarkable 
differences emerge among genders in PDD. 70% of DLB and 49% of PDD are indeed males. 
Disease onset is a further difference between DLB and PDD, with the former happening 
earlier (77 years of age) than the latter (82 years of age) (Sanford, 2018). 
 
1.6 Risk factors for Parkinson’s disease  
Since its first description by James Parkinson, PD has long been considered an 
environmental dependent pathology. However, it is now well accepted that PD is a 
multifactorial disorder that originates from the complex interplay between modifiable and 
non-modifiable risk factors. In particular, the former includes lifestyle and environment, the 
latter counts of age and genetic predispositions. 
 
1.6.1 Modifiable risk factors 
The study of environmental factors triggering to an increased risk to develop PD is difficult 
and elaborated. This complexity comes from the fact that environmental factors are generally 
ubiquitous, and this wide distribution makes difficult the identification of control cases not 
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exposed to the studied stressors. In addition, more than a single factor may be present at the 
same time and they may act synergistically to increase the risk of developing the pathology. 
Although the study of environmental risk factors for PD is not trivial, researchers have 
identified several key elements underlying and contributing to the pathogenesis of both 
sporadic/idiopathic and genetic PD (Cuenca et al., 2019).  
For instance, an increased risk of PD is associated with the exposure to pesticides such as 
paraquat and rotenone which lead to mitochondrial damage and oxidative stress (Tanner et 
al., 2011: Kalia and Lang, 2015). In particular, Paraquat has a similar chemical structure of 
the pro-parkinsonian molecule deriving from the metabolism of 1-methyl,-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). MPTP has been the first chemical compound linked to an 
increased risk of PD and its discovery triggers the investigation of the role of environmental 
chemicals in PD pathogenesis (Kalia and Lang, 2015; Ascherio and Schwarzschild, 2016). 
Modifiable factors positively correlated to the increased risk of PD include rural life, 
consumption of dairy products, well-water drinking, use of amphetamine and 
methamphetamine, prior head injury and systemic pathologies (Kalia and Lang, 2015; 
Ascherio and Schwarzschild, 2016; McKenzie et al., 2017; Cuenca et al., 2019). 
Intriguingly, brain injury and some systemic pathologies, including diabetes, trigger a long-
lasting neuroinflammatory response that has been correlated with an increased risk of 
developing PD (Ascherio and Schwarzschild, 2016; McKenzie et al., 2017). Despite being 
a common feature of numerous neurodegenerative disorders, neuroinflammation is not just 
a mere consequence of the disorder, but it may instead be a pivotal factor in PD pathogenesis 
and the linker between genetic predisposition and environmental factors (Gao et al., 2011; 
Kalia and Lang, 2015). In this regard, it has been demonstrated that induction of 
neuroinflammation, through the intraperitoneal injection of lipopolysaccharide (LPS), in a 
transgenic PD mouse model leads to an increased loss of SNpc dopaminergic neurons (Gao 
et al., 2011). On the same line, it has been reported that striatal administration of LPS in 
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wild-type (WT) mice leads to neuroinflammation and progressive dopaminergic 
neurodegeneration in SNpc (Choi et al., 2009). On the other hand, several lines of evidence 
indicate that neuroinflammation may represent a suitable therapeutic target to prevent or 
delay PD. As a matter of fact, it has been reported that the consumption of non-steroidal 
anti-inflammatory drugs (NSAIDs) is a protective factor against PD. Among NSAIDs, 
Ibuprofen has shown the highest protective effect. Moreover, the discordance in the 
protective effect of Ibuprofen compared with other NSAIDs, such as Aspirin, suggests that 
Ibuprofen acts via a specific mechanism that may not be shared among other NSAIDs 
(Hirsch et al., 2012; Ascherio and Schwarzschild, 2016).  
The role of neuroinflammation in PD will be further detailed in chapter III. 
 
1.6.2 Non-modifiable risk factors 
Age is considered the greatest risk factor for PD. In fact, several data from epidemiological 
studies clearly indicate an exponential rise of PD incidence and prevalence with advancing 
age (Kalia and Lang, 2015; Ascherio and Schwarzschild, 2016; Poewe et al., 2017). The 
biological mechanisms underlying the relationship between aging and PD are still largely 
unknown (Calabrese et al., 2018). It has been reported that aging may represent a pre-PD 
state. In this light, aging creates a vulnerable state that approaches the biological threshold 
required for PD pathogenesis (Collier et al., 2017). In such a scenario, inflammation has 
been identified as a key player. Indeed, aging is characterised by a progressive inflammatory 
state, also known as “inflammaging”, in which an equilibrium between pro- and anti-
inflammatory signals allows the mitigation of tissue degenerative processes. In PD the 
normal occurring inflammaging process is deregulated and lacks the homeostasis between 
pro- and anti-inflammatory signals with a progressive increase in levels of the pro-
inflammatory ones. The long-lasting increase in pro-inflammatory mediators may result in 
Introduction: Chapter 1 
 
22 
 
a deleterious microenvironment which in turn could trigger neurodegenerative processes 
typical of PD (Calabrese et al.,2-18).   
Genetic contribution is a further component among non-modifiable risk factors. The 
relevance of genetics in PD comes from the evidence that patients with a familial history of 
PD have an increased risk to develop the pathology (Kalia and Lang, 2015). The 
investigation of genetics in PD started in 1997 when Polymeropoulos and colleagues found 
the first mutation in the gene coding for a-syn (SNCA) linked to PD (Polymeropoulos et al., 
1997). As of 1997, mutations in several genes have been identified as causative for 
monogenic form of PD and, although genetic forms of PD account for only 5-10% of all 
cases, their investigation has shed new light into pathological mechanisms and molecular 
pathways which underlie the disease development and progression (Poewe et al., 2017). 
Genetic forms of PD are responsible for four different kinds of inheritance. Indeed, there are 
genes that when mutated lead to autosomal dominant, autosomal recessive, X-linked or 
unclear inheritance forms of PD (Cuenca et al., 2019). Since alterations causing X-linked 
and unclear inheritance forms of PD are not well understood, except for the fact that they 
cause a late onset PD, I will only focus on some of those involved in autosomal dominant 
and recessive PD. 
 
1.6.2.1 Genes involved in autosomal dominant forms of PD 
Affected genes causing autosomal dominant PD include SNCA, LRRK2 and VPS35 
(Hernandez et al., 2016). 
- SNCA is the first gene been linked to autosomal dominant inheritance PD. The gene 
is located on chromosome 4 and codes for a small protein of 140 aminoacidic 
residues (~14 kDa) a-syn (Spillantini et al., 1995; Lashuel et al., 2013). In familial 
forms of PD, six missense mutations which cause a single aminoacidic substitution 
have been reported: A53T, A30P, E46K, H50Q, G51D and A53E (Polymeropoulos 
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et al., 1997; Krüger et al., 1998; Zarranz et al., 2004; Proukakis et al  2013;  Kiely 
et al. 2013; Lesage et al., 2013; Pasanen et al., 2014). Missense mutations in SNCA 
lead to an early onset PD, and among them A53T is the most frequent (Hernandez et 
al., 2016). As mentioned above, the missense mutation A53T has been the first PD-
linked alteration identified in SNCA (Polymeropoulos et al., 1997). In the same year, 
Spillantini and co-workers (Spillantini et al., 1997) reported that a-syn was the major 
constituent of LBs in sporadic PD and in DLB. These distinct findings claimed the 
relevance of a-syn in PD pathogenesis for the first time, and they strongly suggested 
that common pathological molecular mechanisms may underlie the development of 
both sporadic and familial PD. In addition to missense mutations, reassembly of 
SNCA has also been found in PD. In particular, multiplication of the entire gene has 
been reported (Singleton et al., 2003; Chartier-Harlin et al., 2004; Ibáñez et al., 
2004). A gene dose-dependent effect of SNCA multiplication on PD phenotype has 
been argued. This hypothesis stems from the evidence that SNCA multiplication, 
duplication or triplication, leads to a form of PD with onset, progression and severity 
depending on the SNCA copy number (Figure 8) (Farrer, 2006; Hernandez et al., 
2016).  
 
 
 
 
 
 
 
Figure 8. SNCA copy number is linked to PD severity. Fluorescent in-situ hybridisation 
of SNCA. The images show nuclei containing a different number of SNCA copies (two, 
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three and four copies) in a normal diploid control (left panel), and in patients with SNCA 
duplication (middle panel) or triplication (right panel). Nuclear DNA is labelled in blue; 
SNCA is double labelled in red and green (Overlap between the probes appears as yellow). 
The increase number of SNCA copy is linked to a worsening in PD severity as shown in the 
table (Modified from Farrer. 2006). 
Intriguingly, alterations in SNCA are also associated with an increase risk to develop 
both PDD and DLB (Sironi et al., 2010; Schulz-Schaeffer, 2010; Galasko et al., 
2017: Jellinger et al., 2018). Although DLB is a relatively common disorder its 
distribution displays a little aggregation in families, thus making difficult to identify 
specific DLB risk factors (Outeiro et al., 2019). However, since PD, PDD and DLB 
share common neuropathological and genetic features, the investigation of the a-syn 
pathological role in these pathologies, also known as a-synucleinopathies, has 
gained strong interest over the last few years. 
- LRRK2 is located on chromosome 12 and encodes for a big multidomain protein 
(Leucine reach repeat kinase 2) of 2527 aminoacidic residues (Li et al., 2014). 
Variants in LRRK2 are recognised as the most common and frequent root cause of 
familial PD (Billingsley et al., 2018). More than 100 missense mutations have been 
reported in LRRK2 and they may be found in 10% of patients with an autosomal 
dominant inheritance and in 3.6% of patients with sporadic PD (Hernandez et al., 
2016; Lesage et al., 2006; Lesage et al., 2009). Among the many LRRK2 variants 
known, G2019S is the most common pathogenic variant, and it has been found in 
approximately 4% of patients with a family history of PD (Billingsley et al., 2018).  
LRRK2 has been implicated in autophagy, cytoskeletal dynamics, kinase cascade, 
mitochondrial functions and inflammatory reactions (MacLeod et al., 2006; 
Gloeckner et al., 2009; Parisiadou et al., 2009; Mortiboys et al., 2010; Orenstein et 
al., 2013; Li et al., 2014; Civiero et al., 2018). Since LRRK2 is involved in a large 
amount of cellular processes, a clear and univocal pathological mechanism for this 
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protein in PD is still missing and under investigation. Nevertheless, PD patients 
carrying LRRK2 variants show a LBs pathology like PD patients carrying SNCA 
variants. Therefore, it seems that common cellular pathways underlying a-syn 
aggregation are shared among different genetic PD variants (Spatola and Wider, 
2014). 
Clinically, patients with a LRRK2-linked PD show a late onset and slow progressive 
symptoms (Hernandez et al., 2016). Although PD is generally more frequent in 
males, it has been reported that female patients with the variant G2019S develop PD 
approximately 10 years earlier than men (Li et al., 2014). 
Autosomal dominant PD has also been linked to variants in VPS35 (vesicular protein sorting 
35) and EIF4G1(eukaryotic translation initiation factor 4-gamma 1). The former is involved 
in the endosomal-lysosomal trafficking complex and its variants are only linked to a slight 
number of PD cases. Indeed, approximately 0.1% of PD patients carry VPS35 variants 
(Spatola and Wider, 2014). The latter is involved in mRNA translation processes and 
accounts for 0.02-0.2% of all PD cases (Spatola and Wider, 2014).  
 
1.6.2.2 Genes involved in autosomal recessive forms of PD 
Genes involved in autosomal recessive forms of PD are PARK2, PINK1 and DJ-1. Among 
these, PARK2 variants are the most commonly observed in PD population (Spatola and 
Wider, 2014). 
- PARK2 (Parkin) is a 465 aminoacidic residues ubiquitin ligase protein involved in 
the control of mitochondrial functions. While in healthy condition PARK2 has a 
cytosolic localisation, in presence of mitochondrial damage the protein translocates 
to the mitochondrial surface and ubiquitinates membrane proteins leading to the 
mitophagy process (Hernandez et al., 2016). PARK2 has been the first gene linked 
to autosomal recessive forms of PD (Kitada et al., 1998). To date, more than 100 
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variants are known. Both point mutations and exons re-arrangement, deletion and 
duplication involving all 12 exons of the gene have been reported (Foroud et al., 
2003; Hedrich et al., 2004; Lesage et al., 2007). Parkin mutations are linked to early 
onset PD, and they account for 50% of familial early onset autosomal recessive cases. 
However, variants in PARK2 are also described in 77% of sporadic PD with an onset 
before 20 years (Lucking et al., 2000; Spatola and Wider, 2014). Of note, in PARK2-
linked PD the presence of LB pathology is not reported (Mori et al., 2003). While an 
explanation for this is still a matter of debate, it has been speculated that the absence 
of LB pathology is due to the very early onset of disease. In fact, post-mortem tissues 
of PARK2 linked PD cases with an older age of disease onset present the 
characteristic LB pathology of PD (Hernandez et al., 2016). 
- PINK1 has been the second gene identified in autosomal recessive PD cases (Valente 
et al., 2001; Valente et al., 2004). PINK1 encodes for a 581 aminoacidic residues 
Ser/Thr kinase (phosphatase tensin homologous-induced kinase 1) with a 
mitochondrial localisation and, like Parkin, with a role into the mitophagy pathway 
(Valente et al., 2004; Pickrell and Youle, 2015). Since the discovery of PINK1, a 
growing number of variants in the gene have been linked to early onset PD, and these 
account for the second most common cause of autosomal recessive PD (Gandhi and 
Plun-Favreau 2017) 
- DJ-1 is the third gene identified in autosomal recessive PD, where both missense 
mutations and exon deletion have been found (Bonifati et al., 2003). DJ-1 related PD 
has comparable phenotypic features to PINK1 and PARK2-related PD. In fact, PD 
linked to DJ-1 variants is characterised by an early disease onset (Hernandez et al., 
2016). Despite the three genes related to autosomal recessive inheritance PD are 
associated with an early onset of the pathology, their frequency varies within the PD 
populations. In particular, DJ-1 variants are rare and they account for less than 1% 
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of early onset PD cases (Pankratz et al., 2006). DJ-1 encodes for a 189 aminoacidic 
residues protein with a mitochondrial matrix and inter-membrane space localisation, 
in addition to its cytosolic expression (Zhang et al., 2005). Variants in DJ-1, like 
PARK2 and PINK1, are associated with a loss of the protein physiological activities 
(Hernandez et al., 2016). DJ-1 has been implicated in several protective cellular 
processes that, when altered, may be involved in PD pathogenesis. Indeed, DJ-1 may 
serve as a redox sensory molecular chaperone, but also as a transcriptional regulator 
of anti-apoptotic genes (Menzies et al., 2005: Xu et al., 2005).  
Recessive inherited forms of PD are also related to variants in ATPT3A2, PLA2G6 and 
FBXO7. These variants are rarer than the variants described above and are linked to atypical 
PD symptoms such as dystonia (Spatola and Wider, 2014).  
 
1.7 Diagnosis of Parkinson’s disease 
PD is not regarded as a single disease and the term may have a different meaning for 
clinicians and researchers. In fact, some use the term only for idiopathic parkinsonism 
associated with LBs inclusions in different brain regions, whereas others use the term as a 
strictly clinical diagnosis and may accept different pathological conditions underlying the 
syndrome (Tolosa et al., 2006). Although clinical criteria for the diagnosis of PD have been 
elaborated, the diagnosis of PD remains difficult especially at the early phases of the disease 
when symptoms of PD overlap with other forms of parkinsonism (Jankovic, 2008). The use 
of clinical criteria developed by the UK Parkinson’s Disease Society Brain Bank as well as 
those developed by the MDS International Parkinson and Movement Disorder Society, 
(Table 2) has significantly improved the accuracy of PD diagnosis. However, population-
based studies have revealed that 15% of patients with a diagnosis of PD do not fulfil the 
criteria for the disease and, 20% of patients are not formally diagnosed as PD patients 
(Tolosa et al., 2006; Poewe et al., 2017). In addition to the prominent motor symptoms, PD 
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patients may manifest a wide range of non-motor features (sleep disorder, reduced olfactory 
ability, constipation, anxiety, depression and cognitive decline) that should be considered in 
the diagnostic process (Cuenca et al., 2019). Even though clinical diagnosis of PD, which is 
based on the manifestation of typical motor features, is improved in its accuracy and 
sensitivity, the gold standard for PD confirmation remains the neuropathological 
examination of post-mortem brain samples. In particular, well accepted and widely used 
criteria consist in the presence of a moderate or severe loss of dopaminergic neurons in SNpc 
with LBs in the surviving neurons, and the absence of evidence for other diseases that may 
result in parkinsonism (Kalia and Lang, 2015).  
MDS diagnostic criteria for PD 
 
Step 1: diagnosis of parkinsonism (core feature)  
Presence of bradykinesia as a slowness of movement and a decrement in amplitude or speed (or progressive 
hesitations or halts) as movements are continued. In combination with at least one of: rigidity and/or rest 
tremor.  
 
Step 2: determining PD as the cause of parkinsonism with two levels of diagnostic certainty  
Diagnosis of clinically established PD requires all three of the below parameters:  
Absence of absolute exclusion criteria. These criteria include clinical or imaging evidence for alternative 
diagnoses of parkinsonism, such as atypical parkinsonism, drug-induced parkinsonism or essential tremor.  
 
Two or more supportive criteria. These include L-DOPA responsiveness, the presence of classic rest tremor, 
the presence of L-DOPA-induced dyskinesias, the presence of either olfactory loss or cardiac sympathetic 
denervation on metaiodobenzylguanidine (MIBG) scintigraphy.  
 
No red flags. This refers to features that are unusual but not absolutely exclusionary for PD, for example, 
the rapid progression of gait impairment that requires wheelchair use or the development of severe 
autonomic failure within 5 years after onset.  
 
Diagnosis of clinically probable PD requires:  
 
Absence of absolute exclusion criteria (mentioned above)  
Presence of red flags (mentioned above) that are counterbalanced by supportive criteria  
 
Table 2. MDS guidelines for the diagnosis of PD. Modified from Poewe et al., 2017. 
As mentioned above the diagnosis of PD is difficult. To further improve the diagnostic 
accuracy clinicians often use further diagnostic tests, and researchers are working at the 
identification of biological markers that may be useful for an early diagnosis (Poewe et al., 
Introduction: Chapter 1 
 
29 
 
2017). Among the additional tests that clinicians may adopt there are genetic tests and 
neuroimaging. 
Five to ten percent of PD cases have a genetic root cause. Since genetic related PD only 
account for a small percentage of PD cases, the genetic testing is not part of the routine 
diagnostic process. On the other hand, patients with a family history of PD or with an early 
onset of the pathology, which is generally present in autosomal recessive related PD (Poewe 
et al., 2017), are genetically investigated. 
Neuroimaging became relevant in PD after 1980, when for the first-time striatal dopamine 
depletion in PD patients was demonstrated through F-labelled L-DOPA and PET. Structural 
MRI is helpful to identify symptomatic parkinsonism, and it allows to evaluate macroscopic 
brain changes such as a deterioration of the SN. Furthermore, various MRI techniques (e.g. 
Neuromelanin-sensitive MRI) provide a valuable diagnostic support to reveal specific 
changes (Poewe et al., 2017; Cuenca et al., 2019). 
 
1.8 Diagnosis of Dementia with Lewy bodies and Dementia associated to Parkinson’s 
disease 
The clinical diagnosis of a probable DLB is based on the assessment of at least two of the 
core features of the disease, whereas the diagnosis of possible DLB is made when only one 
of the core features is presented (Table 3) (McKeith et al., 2004; Outeiro et al., 2019). 
DLB core features include fluctuating levels of cognitive impairments, visual hallucinations, 
sleep behaviour disorders (e.g. RBD, excessive daytime drowsiness). In addition, 
extrapyramidal motor feature may occur.  
DLB and PDD largely overlap in their clinical manifestations. A possible differentiation 
between the two pathologies may result from the assessment of extrapyramidal motor 
features. Indeed, DLB patients are characterised by an absence or a moderate grade of 
extrapyramidal motor features, at least until late stages. On the other hand, PDD patients 
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show prominent motor features, while cognitive impairments generally occur later (Outeiro 
et al., 2019). 
Revised criteria for the clinical diagnosis of probable and possible DLB 
Essential for a diagnosis of DLB is dementia, a progressive cognitive decline of sufficient magnitude to 
interfere with normal social or occupational functions, or with daily activities. Prominent or persistent 
memory impairment may not necessarily occur in early stages but is usually evident with progression. 
Deficits on attention, executive function and visuo-perceptual ability may be prominent and occur early. 
Core clinical features (Two core features are essential for the diagnosis of probable DLB, one for the 
diagnosis of possible DLB) 
Fluctuating cognition with pronounced variations in attention and alertness. 
Recurrent visual hallucinations. 
RBD which may precede cognitive decline. 
One or more cardinal feature of parkinsonism – these are bradykinesia (defined as slowness of movement 
and decrement in amplitude or speed), rest tremor, or rigidity. 
Supportive clinical features 
Severe sensitivity to antipsychotic agents, postural instability, repeated falls, syncope or other transient 
episodes of unresponsiveness, severe autonomic dysfunction (e.g. constipation, orthostatic hypotension, 
urinary incontinence) hypersomnia, hyposmia, hallucinations in other modalities, apathy, anxiety and 
depression. 
Table 3. MDS guidelines for the diagnosis of PD. Modified from Outeiro et al., 2019. 
Of note, post-mortem validation of the clinical diagnosis of DLB is limited, and it is 
compromised by the lack of defined neuropathological criteria. Autopsy of patients with 
non-DLB clinical manifestations have clearly shown LB depositions in different brain 
regions (McKeith et al., 2004). A recent UK study revealed that while only 4.6% of subjects 
are clinically diagnosed as DLB, LB pathology is presented in 20% of post-mortem brains. 
This indicates that an underestimation of DLB during life occurs, and that the clinical criteria 
are not yet sufficiently sensitive and specific. In fact, DLB may present features reminiscent 
of AD, and therefore misdiagnosed as AD (Outeiro et al., 2019). Generally, while AD 
patients are characterised by dysfunctions of episodic memory, DLB subjects have attention, 
executive and visuospatial deficiencies (Park et al., 2011). DLB and AD have somewhat 
specific patterns of deficits; people with AD often have better visuo-spatial and visuo-
constructional skills early in their disease, but poorer short-term memory. Hallucinations and 
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delusions are prominent, persistent and early features of DLB, while in AD they appear later 
in the course of the disease and are transient (Stavitsky et al., 2006; Tiraboschi et al., 2006). 
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2.1 The synuclein family: a brief overview 
Synuclein has been first identified in 1988 by Maroteaux and colleagues in the electric organ 
of the electric ray Torpedo californica. The protein was named after its cellular localisation 
in the pre-synaptic terminals (SYNapse) and on the nuclear envelope (NUCLEus) 
(Maroteaux et al., 1988; Lavedan, 1998). To date, synuclein refers to a family made of three 
distinct proteins that share common features: a-, b- and g-synuclein (a-, b- and g-syn) 
(Wales et al., 2013). In humans, a-syn was discovered during the investigation of the b-
amyloid plaque composition from AD patients. In fact, researchers identified a small peptide 
known as NAC (non-amyloidogenic component of amyloid plaques) within b-amyloid 
plaques. The precursor of NAC (NACP), was found to be homologous to the rat a-syn (Ueda 
et al., 1993), whereas the b-syn was first isolated as a bovine brain-specific phosphoprotein 
of 14 kDa (phosphoneuroprotein) (Lavedan, 1998). Therefore, NACP and the human 
ortholog of phosphoneuroprotein were recognised as two distinct synucleins and termed a- 
and b-syn, respectively (Jakes et al. 1994).  
Synucleins are soluble, heat-resistant and highly conserved proteins in vertebrates. In 
particular, all three synucleins share an amphipathic N-terminal domain, whereas they 
essentially differ in their acidic C-terminus (Figure 9) (George, 2002). 
 
 
 
 
 
Figure 9. Schematic representation of the α-, β-, and γ- synuclein isoforms. Synuclein isoforms 
consists of three domains. The conserved N-terminal amphipathic region is depicted in orange. In 
blue is the central hydrophobic NAC domain. In gold, the acidic C-terminal tail, whose length differs 
within the three forms (Wales et al., 2013). 
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With 140 aminoacidic residues in its primary structure, a-syn is the longest among 
synucleins. 134 residues make up b-syn, whereas g-syn is the shortest one with 127 residues. 
b-syn is closely comparable with a-syn, made exception for the lack of 11 residues in the 
NAC domain of  b-syn compared to a-syn (Wales et al., 2013). Of note, a-, b- and g-syn 
have different expression patterns. While a-syn and b-syn are predominantly expressed in 
the brain, g-syn is found in the peripheral nervous system and notably in malignant breast 
tumours (Jakes et al., 1994; Iwai et al., 1995; Buchman et al., 1998; Ji et al., 1997). 
 
2.2 Alpha-synuclein: a key protein in PD and a-synucleinopathies 
In the last twenty years huge efforts have been made to characterise the pathological roles 
of α-syn in PD, and more generally in a class of pathologies known as α-synucleinopathies.  
α-synucleinopathies refer to distinct clinical entities (e.g. PD, LBD, MSA) which share 
common neuropathological lesions (LBs and LNs) mostly consisting of fibrillar and 
insoluble α-syn (Spillantini et al., 1997; Spillantini et al., 1998; Baba et al., 1998; Wales et 
al., 2013; Alafuzoff and Hartikainen, 2018). 
The interest in studying α-syn in α-synucleinopathies stems from accumulating evidence of 
the potential harmful role of the protein including: I) missense points mutations in the gene 
encoding for α-syn in families with hereditary PD and DLB; II) α-syn as the main constituent 
of LBs and LNs; III) the fact that duplication and triplication of the entire SNCA locus lead 
to familial PD; IV) genome-wide association studies revealing that genetic variants in the 
SNCA locus represent a risk factor for sporadic PD; V) animal models overexpressing WT 
or mutant α-syn showing histopathological and some clinical features of PD (Deleersnijder 
et al., 2013; Bengoa-Vergniory et al., 2017). 
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2.3 Insight into α-syn structure and physiological functions 
As mentioned above, α-syn is the product of SNCA, a gene located at position 21 on the 
long arm of chromosome 4 (Figure 10) (Spillantini et al., 1995). α-syn expression and 
localisation change over time, with its levels increasing through the early weeks of 
development, while it diffuses from the soma to the pre-synaptic terminals (Burré et al., 
2015).  
Figure 10.  Schematic of the localisation and structure of SNCA. Modified from Venda et al., 
2010. 
Because α-syn lacks a well-organised secondary structure, it belongs to the intrinsically 
disordered protein family, and it is generally defined as a disordered or naturally unfolded 
protein (Deleersnijder et al., 2013; Theillet et al., 2016; Zhang et al., 2018). 
Three different domains can be distinguished within the primary structure of α-syn (Figure 
11A): I) the N-terminal domain (residues 1-60), II) the central hydrophobic region (residues 
61-95), and III) the C-terminal domain rich in prolines and the acidic residues aspartate and 
glutamate (residues 96-140) (Villar-Piqué et al., 2016). The N-terminal domain is 
characterised by a series of 11-residues imperfect repeats with a conserved hexameric motif 
(KTKEGV). While α-syn N-terminus remains unstructured in solution, it adopts an 
amphipathic α-helical secondary structure in presence of lipids (Figure 11B), which is a 
typical conformational feature of membrane recognition and binding (Eliezer et al. 2001; 
Deleersnijder et al., 2013; Wales et al., 2013; Zhang et al., 2018). 
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 Figure 11. Domain structure of α-syn. (A) Schematic representation of α-syn regions. The N-
terminus (residues 1-60) is amphipathic and responsible for the interaction of α-syn with membranes. 
It includes repeats of the KTKEGV motif (green rectangles). The central region (residues 61-95), 
termed NAC, is a hydrophobic region and it is involved in the aggregation process. The C-terminus 
(96–140) is characterised by the presence of acidic residues bearing a negative charge. (B) Schematic 
cartoon representation of micelle-bound α-syn. The N-terminal region (orange), the NAC region 
(blue) and the unstructured C-terminus (gold). Modified from Gallegos et al., 2015. 
Remarkably, all point mutations associated to familial PD (A53T, A30P, E46K, G51D and 
H50Q) clusters in the N-terminal domain (Bendor et al., 2013), suggesting that this region 
has an important function in regulating the α-syn propensity to aggregate, a process with 
strong implications in α-synucleinopathies pathogenesis (further details in section 2.4). 
The central hydrophobic portion of α-syn, also known as the NAC domain, is the second 
major component of Aβ-amyloid plaques in AD (Irizarry et al., 1996). It contains two 
KTKEGV motifs and accounts for the aggregation ability of the protein (Wales et al., 2013; 
Deleersnijder et al., 2013). Indeed, this portion may undergo a conformational change that 
generates a β-sheet structure in spite of its native random coil (Belluci et al., 2012). 
The acidic C-terminal region domain contains 5 proline, 10 glutamate, and 5 aspartate 
aminoacidic residues (Deleersnijder et al., 2013; Wales et al., 2013). Thus, because of its 
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low hydrophobicity and its overall net negative charge, the C-terminal domain is responsible 
for the naturally unfolded and disordered structure of α-syn (Figure 11B) (Deleersnijder et 
al., 2013). Of note, some residues within the α-syn C-terminus can be phosphorylated. 
Among these, Serine in position 129 is found phosphorylated in almost 90% of α-syn inside 
LBs, although the role of this post-translational modification is poorly understood and still 
under investigation (Gallegos et al., 2015; Anderson et al., 2006; Samuel et al., 2016). 
In conclusion, the secondary structure of α-syn lacks a unique and defined conformation, 
with the exception of some α-helical structures in its N-terminal portion. Such properties 
provide α-syn with some conformational flexibility, so that the protein can adopt a wide 
range of structures depending on the environment and binding partners (Jain et al., 2013). 
As protein structure and function are intimately linked, the versatile and dynamic structure 
of α-syn results in the multifunctional properties of the protein (Lashuel et al., 2013). Besides 
its unfolded nature, several challenges make the understanding of α-syn functions difficult: 
I) α-syn overexpression leads to neurotoxicity, and II) the complete depletion of α-syn does 
not lead to significant alterations but only causes an altered synaptic transmission, which 
may be compensated by the activity of other proteins (Burré et al., 2015; Villar-Piqué et al., 
2016). As a result, despite numerous hypothetical functions have been put forward and 
attributed to α-syn, none is fully consensual. Thus, α-syn functions in physiological and 
pathological conditions still remain controversial.  
Among the various functions proposed for α-syn, one of the most widely accepted is its role 
in pre-synaptic terminals and particularly in the regulation of synaptic transmission. Such 
functions are suggested by numerous experimental observations. Depletion of α-syn is not 
lethal and does not lead to a neurodegenerative phenotype, pointing out the possible 
redundant functions of α-,b- and g-syn (Lashuel et al., 2013; Wales et al., 2013; Calo et al., 
2016; Spillantini and Goedert, 2018). On the other hand, deletion of all the three synucleins 
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leads to a more severe, although yet viable, phenotype characterised by a deficient SNARE-
complex assembly and an increased striatal dopamine release (Wales et al., 2013; Calo et 
al., 2016). Beside the genetic manipulation of synucleins expression, supporting evidence 
for a synaptic function of α-syn includes the predominant localisation of the protein into pre-
synaptic terminals (Figure 12A, B), and the co-localisation with the vesicle reserve pool of 
synapses (Lee et al., 2008). Through its C-terminal domain, α-syn directly interacts with 
VAMP2 and, through a chaperone-like activity, promotes the SNARE complex assembly 
which is a component of the membrane fusion machinery (Figure 12C) (Burré et al., 2010).   
SNARE proteins include a large number of integral membrane proteins involved in the 
docking and fusion between pre-synaptic vesicles and the cell membrane. Two groups of 
SNARE proteins can be identified based on their localisation: v-SNARE proteins which are 
located into the pre-synaptic vesicle membranes, and the t-SNARE proteins placed into the 
pre-synaptic cell membrane.  
As α-syn promotes the SNARE complex assembly, its loss of function may trigger changes 
in neurotransmitter release, synaptic dysfunction and neurodegenerative processes (Burré et 
al., 2010). Consistently, over-expression of human WT α-syn has been linked to a reduction 
in vesicle release both in hippocampal neurons and in transgenic (Tg) mice. In this murine 
model, α-syn over-expression decreased the vesicle recycling pool size and the number of 
vesicles adjacent to the synaptic active zone. In fact, Tg mice over-expressing human α-syn, 
displayed a slight increase in the post-synaptic density and a reduction in proteins associated 
with synaptic vesicles, which may lead to an alteration of synaptic transmission and 
plasticity, essential physiological processes involved in the formation of new memories 
(Nemani et al., 2010). In addition, α-syn has been shown to regulate vesicles exocytosis via 
binding to exocytosis controlling proteins such as phospholipase D2 and the family of small 
GTPase Rab (Lashuel et al., 2013). These data suggest a possible detrimental role of α-syn, 
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which in pathological conditions may affect synaptic vesicles recycling (Figure 12C), hence 
synaptic activity/transmission and cognitive functions. 
 
Figure 12. Synaptic localisation and function of α-syn. (A, B) Immunostaining for MAP2 (red) 
and α-syn (green) reveal the pre-synaptic localisation of α-syn. (C) Schematic representation 
showing the roles of α-syn at the pre-synaptic terminal in the regulation of vesicle trafficking and 
vesicle refilling, as well as the interactions between t-SNARE and v-SNARE proteins and 
neurotransmitter release. Accumulation of α-syn prevents neurotransmitter release, vesicle recycling 
and trafficking between synaptic buttons and influences the stability of SNARE complex assembly 
(Lahuel et al., 2013).  
 
Introduction: Chapter II 
 
 
40 
 
As mentioned above, the first synuclein was found in both synaptic terminals and in the 
nuclear envelope. Nevertheless, the nuclear localisation of α-syn is not largely accepted and 
it remains controversial with some groups identifying α-syn in the nucleus and some other 
failing at the same purpose (Li et al., 2002; Yu et al., 2007; Zhang et al., 2008; Huang et al., 
2011; Burrè et al., 2018). Although the mechanisms driving the nuclear localisation of α-
syn are poorly understood, it seems that the N-terminal domain plays a key role, and PD 
related missense point mutations in α-syn as well as an increase in oxidative stress appear to 
increase the protein nuclear translocation (Wales et al., 2013). Transcription regulation is a 
putative function proposed for α-syn in the nucleus, where two different mechanisms may 
co-exist. Specifically, α-syn may bind directly the DNA and/or it may influence gene 
expression by interacting with transcription regulation factors. In this regard, it has been 
reported that α-syn co-localizes with histone-3 and inhibits its acetylation, leading to an 
aberrant transcriptional control, which may ultimately result in cell death (Kontopoulos et 
al., 2006). The transcriptional deregulation caused by α-syn triggers an alteration in the 
expression of several proteins involved in different signal pathways such as cyclic adenosine 
monophosphate (cAMP), and response element binding protein (CREB) (Wales et al., 
2013). Of note, cAMP and CREB are involved in long term potentiation (LTP), an 
experimental paradigm measuring synaptic plasticity, and memory formation (Silva et al., 
1998). Therefore, alterations in these pathways induced by α-syn may contribute 
synergistically with many other mechanisms to memory damage. 
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2.3.1 Memory, synaptic plasticity and LTP 
Learning and memory are the result of the interaction of millions of neurons in the brain and 
their coordinated activity (Stuchlik, 2014). 
While memory refers to a capability of virtually any animal to encode, store and retrieve 
information aimed at guiding behavioural output, learning is viewed as the acquisition and 
the encoding of information to form new memories (Stuchlik, 2014).  
Depending on their duration, memories can be classified into short- and long-term. While 
short-term memory is the ability to hold and recall information for a short period of time, 
usually for few seconds, long-term memory stores information for long-lasting periods, 
essentially for the entire lifetime span. Short-term memory relies on existing networks and 
post-translational modifications, whereas long-term memory is accompanied by structural 
and functional changes of neural networks that require de novo gene expression (Bisaz et 
al., 2014) 
Long-term memory allows us to store information for long periods of time. Information may 
be retrieved consciously (explicit memory) or unconsciously (implicit memory). Explicit 
memory refers to memories that can be consciously recalled such as the knowledge of facts, 
people and events, whereas the implicit memory represents those memories associated with 
skills and the ability to perform actions (Camina and Güell, 2017). 
From an anatomical/functional standpoint many areas of the brain contribute to the processes 
of learning and memory, but it has been shown that the hippocampus is the cerebral area that 
plays a key role in hosting the mechanisms related to memory (Scoville and Milner, 1957).  
A crucial point in the field of learning and memory is the concept of neuronal plasticity, 
which describes structural and functional changes in the brain linked to experience and 
development. Neuronal plasticity involves events at the synaptic level such as elimination, 
reinforcement and formation of new synapses.  
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It is believed that long-term memory is based on the process of synaptic transmission 
strengthening. Experimental supports to this hypothesis derive from the finding that 
repetitive activation of excitatory synapses in the hippocampus leads to an increase in 
synaptic strength that could last for hours and days (Andersen and Lomo, 1966; Bliss and 
Gardner-Medwin, 1973). This long-lasting synaptic change, known as LTP, has been 
extensively investigated and it is widely considered as an experimental paradigm for 
studying synaptic plasticity and molecular mechanisms at the base of learning and memory 
(Miller and Mayford, 1999; Citri and Malenka, 2008; Stuchlik, 2014). Following an intense 
stimulation of pre-synaptic neurons, for instance repetitive pre-synaptic tetanic stimulation, 
the amplitude of the response in post-synaptic neurons increases. In this process two 
different subtypes of glutamatergic receptors may be activated by the glutamate release: a-
amino-3-hydroxy-5-methyl-1-4-isoxazolepropionic receptors (AMPARs) and N-methyl-D-
aspartate receptors (NMDARs). AMPARs are channels permeable to monovalent ions, 
sodium (Na+) and potassium (K+), and provide an inward positive current leading to the 
depolarization of neurons. NMDARs, like AMPARs, are permeable to ions Na+, K+, but also 
calcium (Ca2+) (Baltaci et al., 2019). However, as the pore of NMDARs is blocked by the 
magnesium ion (Mg2+), their activation requires both the binding with glutamate and 
neuronal depolarization. In fact, during LTP induction, glutamate binds to AMPARs leading 
to a membrane depolarization that may be sufficient to dissociate Mg2+. This process allows 
the inward flux of Na+, K+ and Ca2+ through NMDARs causing a drastic increase in the 
intracellular concentration of these ions, especially in the post-synaptic terminals (Baltaci et 
al., 2019). Ca2+ is an important second messenger. Indeed, Ca2+ controls the activity of 
several enzymes via direct binding or indirectly through regulation of phosphorylation 
mechanisms. For instance, when four Ca2+ ions bind to calmodulin (CaM) the protein 
becomes active. Activated CaM may in turn activate other enzymes such as adenylate 
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cyclase and Ca2+/CaM-protein kinase II (CaMKII). The investigation of LTP uncovered two 
different phases taking place during the process (Baltaci et al., 2019). The early LTP 
(protein-synthesis-independent) phase starts immediately after LTP induction with a single 
train of high frequency stimulation, and it produces a brief duration synaptic facilitation by 
making pre-existing post-synaptic glutamatergic receptors more sensitive to the 
neurotransmitter (Baltaci et al., 2019). The late LTP (protein-synthesis-dependent) phase, 
for which a strong stimulation is mandatory, starts hours after the LTP induction. Along with 
this phase, new protein synthesis occurs, which requires gene transcription. The transcription 
cascade begins with the transcriptional factor CREB-1, that induces the transcription of 
genes responsible for the growth of new synaptic connections (Bailey and Kandel., 1993; 
Baltaci et al., 2019). 
 
2.4 The aggregation of a-syn and the oligomer hypothesis  
 
Protein misfolding and aggregation are shared features of neuropathological disorders such 
as AD, Prion diseases and a-synucleinopathies. Many research efforts have focused on the 
understanding of the mechanisms underlying the aggregation process and aimed at 
identifying the aggregates that are responsible for the diseases. 
The aggregation process of α-syn leads to the formation of β-rich fibrillary species from its 
native unfolded conformation. In pathological conditions a-syn undergoes to nucleation 
process fostering the formation of soluble oligomers, protofibrils and mature insoluble fibrils 
(Figure 13), which grow by monomers addition and finally make up LBs and LNs (Buell et 
al., 2014; Ono, 2017).   
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Figure 13. Schematic representation of α-syn aggregation process. Monomeric α-syn may 
aggregate and form different moieties. Two distinct pathways have been proposed: the off-pathway 
leads to the production of non-toxic aggregates, the on-pathway generates species which can be 
neurotoxic (Roberts and Brown, 2015).  
As previously described three distinct domains are found in a-syn. Since deletion or 
disruption of the hydrophobic 12-aminoacid-residue sequence in the central domain 
abrogates a-syn aggregation (Giasson et al., 2001), the NAC region had been initially 
identified as crucial for a-syn aggregation. However, deep investigations into a-syn in the 
recent years additionally claim a relevant role for the N-terminal domain. Of note, all of the 
point missense mutations related to PD are located within the N-terminus, and they have 
been shown to influence a-syn aggregation. A53T and E46K variants are widely assumed 
to increase the aggregation rate of a-syn compared to the WT protein, with A53T being 
more effective than E46K (Conway et al., 2000; Greenbaum et al., 2005). Intriguingly, either 
more rapid or slower aggregation kinetics have been reported for the A30P variant (Narhi et 
al., 1999; Lemkau et al., 2012). H50Q and G51D variants are the most recently identified 
point mutations linked to PD, and it has been demonstrated that they lead to a divergent 
effect on the aggregation process. Particularly, H50Q increases the rate of a-syn 
aggregation, whereas the G51D variant has the opposite effect (Rutherford et al., 2014). 
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During the aggregation process three different steps may be discerned: the initial formation 
steps, the growth of the fibrils (elongation), and their amplification (Flagmeier et al., 2016). 
The single point mutations in a-syn do not affect solely the overall aggregation rate, but they 
affect in a specific way the distinct steps underlying a-syn aggregation (Flagmeier et al., 
2016).  
Like the NAC and the N-terminal domain, the C-terminus has also been shown to modulate 
the aggregation of α-syn. Accordingly, antibodies against this region are able to inhibit the 
fibrillation of a-syn (Sahin et al., 2017). Taken together, these findings depict a complex 
context and highlight the need of further investigation aimed at a more punctual and 
comprehensive understanding of the interplay between the a-syn sub-regions and their 
impact on its aggregation. 
As mentioned above, a-syn oligomers (a-synOs) represent an intermediate aggregate in the 
process eventually leading to a-syn fibrils. The term “oligomer” is used to describe 
aggregates without a fibrillar conformation. a-synOs differ in their molecular composition 
(number of monomers) as well as in their conformation (b-sheets content and hydrophobic 
region exposure) (Bengoa-Vergniory et al., 2017). Although the mechanisms involved in a-
syn toxicity have not been completely elucidated, several data depict a-synOs as the main 
harmful moiety underlying a-syn deleterious effects. Indeed, a-syn detrimental activities 
seem to be independent of large a-syn aggregates and more closely associated to the 
oligomeric species. Exploiting a PD rat model based on the injection of lentiviruses 
expressing a-syn variants promoting either the oligomer or the fibril formation, Winner and 
colleagues first demonstrated that loss of dopaminergic neurons in the SN was induced by 
a-synOs, whereas the expression of the a-syn variant leading to fibrils formation was not 
effective (Winner et al., 2011). More recently, Cai and co-workers confirmed the role of 
oligomers in mediating dopaminergic neuronal loss in SN in a new mice model of PD (Cai 
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et al., 2018).  In this work, the SN was injected with adeno-associated viruses carrying a 
vector encoding the yellow fluorescent protein (YFP) fragmented into its N- or C-terminus 
separately fused with human WT a-syn to form a non-fluorescent-fusion protein. Through 
this approach, the authors were then able to show the formation of a-synOs through the 
observation of the fluorescence deriving from the reconstituted fluorescent protein upon a-
syn oligomerization. Furthermore, they found a time-dependent reduction in striatal 
dopamine levels as well as death of nigral dopaminergic neurons and neuroinflammation 
(Cai et al., 2018). On the same line, two different groups have found that a-synOs impair 
LTP in hippocampal brain slices, whereas monomers and fibrils were ineffective (Martin et 
al., 2012; Diógenes et al., 2012). Together, these findings support the “oligomeric 
hypothesis” allowing researchers to introduce a new definition of a-synucleinopathies as 
pathologies related to oligomers, and to classify them under the name of “oligomeropathies” 
(Forloni et al., 2016; Ono, 2017).  
As mentioned above, during the aggregation process several types of a-synOs may be 
formed, and their toxicity reflects such a heterogeneity. In this regard, it has been shown that 
different effects on cell survival result upon treatment of neuronal cultures with distinct a-
synO species (Danzer et al. 2007). Furthermore, the finding of tetrameric a-syn endowed 
with an a-helical stable conformation in living human cells supports the possible existence 
of oligomers with a physiological function (Bartels et al., 2011). This hypothesis posits that 
a-syn tetramers could exert a protective function counteracting the on-pathway of 
aggregation (the process in which oligomers precede fibrils formation and that is opposed to 
the off-pathway, where oligomers are stabilized and do not further aggregate). Accordingly, 
a-syn point mutations may result in the loss of the putative protective property of oligomers 
(Bartels et al., 2011; Roberts and Brown, 2015). 
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2.5 Intracellular mechanisms involved in a-synO toxicity 
As a-synOs were proposed as pivotal culprits in neurodegeneration, researchers have 
focused on several cellular targets to explain the potential mechanisms underlying a-synO 
toxicity. Many intracellular targets (mitochondria, proteasome, endoplasmic reticulum, cell 
membrane, lysosome and synapse) as well as related processes, seem to be potentially 
involved in the deleterious activity of a-synOs (Figure 14). However, a complete 
understanding of a-synO-mediated neurotoxicity is not available yet, and it remains the 
subject of intensive investigation (Zhang et al., 2018).  
 
Figure 14. Intracellular targets of α-synOs. Schematic representation of the different cellular 
targets of α-synOs (modified from Wong and Krainc, 2017). 
At the mitochondrial level, a-synOs lead to morphological alterations that in turn result in 
fragmentation and disruption of the cellular organelle (Plotegher et al., 2014). More recently, 
treatment of SHSY-5Y cells with a-synOs has been reported to up-regulate the expression 
of the mitochondrial cytochrome c subunit 2, which leads to the reduction of adenosine three 
phosphate (ATP) and to an increase in reactive oxygen species (ROS) (Danyu et al 2019). 
In a PD mouse model and in post-mortem PD samples, a-synOs are shown to accumulate 
into the endoplasmic reticulum (ER), leading to a chronic ER stress and to a significant 
damage in protein synthesis and in protein quality (Bengoa-Vergniory et al., 2017). 
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The ubiquitin-proteasome system is one of the main cellular mechanisms involved in the 
removal of misfolded and damaged protein. Dysfunction of this protein degradation pathway 
has been linked to PD pathogenesis. In fact, a-synOs have been reported to interact with the 
proteasome subunits and to block the proteasome activity (Lindersson et al., 2004; 
Emmanouilidou et al., 2011). Of note, a-synO-mediated inhibition of the proteasome 
activity is reverted upon exposure to antibodies that neutralise the interaction or compounds 
disrupting α-synOs (Xilouri et a., 2013).  
Maintenance of cell membrane architecture and permeability properties is crucial for cell 
survival and functions. Extracellular oligomers of a-syn may insert into membranes 
generating pore-like structures that could act as non-selective channels, thus resulting in 
abnormal ionic intake which unbalances intracellular homeostasis (Danzer et al., 2007; 
Tsigelny et al., 2012). In addition, a-synOs might also interact with the membrane altering 
the lipid packing. In this regard, Chaudary et al. have recently reported that by interacting 
with damaged cellular membranes, a-synOs may promote the propagation of the membrane 
defects (Chaudary et al., 2016), therefore opening new investigation routes to elucidate a-
synO action mechanisms. 
Autophagic and lysosomal loss of function has been linked to PD. Accordingly, a-synO 
accumulation might result in the autophagic and lysosomal degradation pathway 
disturbance, which in turn could cause a-syn accumulation and further production of 
oligomers (Ingelsson, 2016; Ono, 2017; Zhang et al., 2018). The interest in studying the 
mechanisms of a-synO activity in the context of the lysosomal degradation pathway comes 
from the evidence that oligomers, and not fibrils, are cleared by lysosomes. Furthermore, 
blockage of the lysosomal pathway leads to a-synOs accumulation and toxicity (Lee et al., 
2004). Hitherto, the most commonly accepted hypothesis indicates a possible vicious circle 
between a-synOs and the autophagic/lysosomal pathway. Toxic α-synOs may damage 
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lysosomes leading to an inhibited clearance of α-syn, which in turn causes further production 
of toxic oligomers (Bourdenx et al., 2014). 
Damage and reduction of synapses have been described in PD and PD-related disorders. 
Notably, altered expression of synaptic proteins involved in synaptic transmission occurs 
before neuronal loss. Therefore, synaptic deficit can be considered as starting event for 
neurodegeneration in α-synucleinopathies (Overk and Masliah, 2014; Bridi and Hirh, 2018). 
The relevance of synaptic damage in the pathogenesis of α-synucleinopathies is supported 
by a large amount of data, including the presence of α-synOs in axonal terminals which 
precedes the formation of LBs (Marui et al., 2002), and the relationship between synaptic 
changes and α-synOs in pre-synaptic terminals, that ultimately lead to memory deficit in 
DLB (Kramer and Schulz-Schaeffer, 2007; Overk and Masliah, 2014; Bridi and Hirth, 
2018). Altogether, these considerations allow the definition of α-synucleinopathies as 
synaptopathies, and ask for the elucidation of the mechanisms mediating α-synO detrimental 
effects at the synaptic level. In this regard, several mechanisms have been proposed which 
may co-exist and act in a synergistic manner. Through the binding of proteins involved in 
microtubule assembly and dynamics (tubulin, kinesin and MAP2), α-synOs promote an 
aberrant neurite network morphology and affect anterograde transport (Prots et al., 2013). 
Synaptic vesicles derived from the Golgi apparatus get translocated to the axonal terminals 
by anterograde-mediated microtubules transport. Hence, alterations in the microtubule 
assembly and dynamics could explain the synaptic changes reported by Scoot and colleagues 
in a mouse model over-expressing human α-syn (Scott et al., 2010). Indeed, they found that 
high levels of α-synOs in the synaptic terminals were closely associated with reduction in 
synaptic vesicles density and synaptic proteins (Scott et al., 2010). 
In addition to microtubule alterations, α-synOs inhibit the synaptic docking and decrease 
neurotransmitter release. α-synOs interact with the vesicular protein sinaptobrevin-2, and as 
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a consequence they make the protein unavailable for the interaction with the t-SNARE 
complex, leading to inhibition of neurotransmitter release (Choi et al., 2013). 
Current knowledge suggests that multiple mechanisms at multiple cellular levels may be at 
play in the generation of α-synO-induced damages, supporting the hypothesis that α-
synucleinopathies are multifactorial disorders even from a cellular viewpoint (Overk and 
Masliah, 2014; Bridi and Hirth, 2018). 
 
2.6 Evidence for α-synOs in extracellular fluids and its implications 
The cytosolic localization of α-syn and of its proteinaceous species suggests that cell-
autonomous mechanisms could be involved in mediating α-synO detrimental activities. 
However, compelling evidence confirms the hypothesis that oligomers act also in a non-cell-
autonomous manner. In fact, full-length α-syn could be detected in human extracellular 
fluids such as cerebrospinal fluid (CSF), interstitial brain fluids and blood (Borghi et al., 
2000; El-Agnaf et al., 2003; Emmanouilidou et al., 2011). Intriguingly, the release of α-syn 
occurs in PD patients as well as in healthy controls, therefore suggesting that α-syn secretion 
is a normal physiological process. Of note, the CSF α-syn pool is predominantly derived 
from brain neurons rather than peripheral blood (Mollenhauer et al., 2012). The deep 
investigation of α-syn in extracellular fluids has also revealed that in CSF α-syn was 
detectable in its oligomeric state (Park et al., 2011; Hansson et al., 2014), further supporting 
the potential role of extracellular α-synOs in the pathogenesis of PD and PD-related 
disorders.  
The detection of both monomeric and oligomeric α-syn in extracellular fluids of PD, DLB 
and healthy control patients is consistent with the evidence that neuronal cells release 
monomeric and oligomeric α-syn into the cell medium (El-Agnaf et al., 2003, Lee et al., 
2005; Kim et al., 2013), and with the finding that stress conditions increase the release 
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amount of α-synOs (Jang et al., 2010). Several mechanisms have been put forward while 
attempting to describe the processes underlying α-syn release by neurons. Such mechanisms 
include the release of α-syn by dying neurons, unconventional exocytose type independent 
of the classical ER/Golgi pathway such as exosomes release, and autophagosome-mediated 
exocytosis (Danzer et al., 2012; Gallegos et al., 2015). 
Based on α-syn behaviour and extracellular localization, two possibilities have been 
envisaged: I) α-synucleionopathies, as well as other protein misfolding related 
neurodegenerative disorders, may be a prion-like disease (Marques and Outeiro, 2012), and 
II) the potential of α-syn monomers and α-synOs as biological markers for the diagnosis at 
early stage and for the assessment of benefits deriving from new therapeutic approaches (Lee 
et al., 2014). 
Although the second point was received with excitement by the scientific community, at the 
state of the art, no reliable detection approaches have been developed to distinguish healthy 
control from individual PD or PD-related patients. That is because plasma and CSF levels 
of α-syn are comparable between healthy control and PD patients. Furthermore, levels of α-
synOs are generally higher in PD patients but at the same time they may also overlap with 
healthy individuals, and therefore not useful as diagnostic tools to discriminate individual 
healthy controls to patients (Lee et al., 2014). In contrast, Majbour and colleagues reported 
a novel antibody with a high sensitivity and specificity for α-synOs which allows the 
discrimination of PD from healthy individuals (Majbour et al., 2016). On the other hand, the 
detection of α-synOs in CSF may be useful to distinguish patients with PDD or DLB by AD 
patients (Hansson et al., 2014). Controversies often motivate research and provide new 
stimuli to push our knowledge forward. Validation of reliable biomarkers for early diagnosis 
and for monitoring the disease progression is a hot and urgent topic in the field of 
neurodegenerative disorders, thus requiring further investigation and innovation. 
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The findings reported here show that α-syn and α-synOs are normally secreted by neurons. 
Moreover, stress conditions increase the release of α-synOs, thus highlighting the potential 
role of extracellular oligomers in the pathogenesis of α-synucleinopathies and their potential 
significance as biological markers. 
 
2.6.1 The non-cell-autonomous action of α-synOs 
To explore the mechanisms involved in mediating α-synO detrimental activities, 
investigators mainly focused on the cell-autonomous processes at first. Nevertheless, the 
finding that α-synOs were detectable in extracellular fluids and the direct observation of 
released α-synOs by neurons suggested non-cell-autonomous mechanisms being at play in 
concert with the cell-autonomous ones. 
Among cell types involved in non-cell-autonomous mechanisms, astrocytes and microglial 
cells have received increasing attention over the years. Such an interest raised from a number 
of observations, which include: the identification of reactive astrocytes and microglial cells 
in the brain of patients affected by different α-synucleinopathies (MacKenzie, 2000; McGeer 
and McGeer, 2008; Fellner et al., 2011; Fellner and Stefanova 2013; Dickson, 2018); the 
detection of α-syn inclusions within glial cell bodies (Fellner et al., 2011) and; the activation 
of both astroglial and microglial cells upon exposure to α-syn released by neurons (Alvarez-
Erviti et al., 2011; Fellner et al., 2013; Kim et al., 2013). Therefore, α-synOs may become 
neurotoxic per se or, as shown in figure 15, through an indirect route that involves activation 
of astroglial and microglial cells (Marques and Outeiro, 2012; Lim et al., 2018).  
Astrocytes and microglia are the main components of the innate immunity in the central 
nervous system (CNS). In response to various stimuli (e.g. lesions, infections, chronic 
stress…) they become activated and able to release several pro-inflammatory factors which 
may trigger neuronal dysfunction (Fellner et al., 2011; Morris et al., 2013; Blank and Prinz, 
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2013). Of note, activated glial cells contribute both to the onset and to the progression of the 
pathology. Through the production of pro-inflammatory signals and ROS, activated glial 
cells might lead to a detrimental microenvironment which in turn promotes the detrimental 
activities of oligomers (Lim et al., 2018).  
 
Figure 15. Schematic representation of the non-cell-autonomous action of α-synOs.  Oligomers 
of α-syn can act through non direct mechanisms. They may be transferred between neurons or 
secreted by them. Extracellular α-synOs activate both microglial and astroglial cells, which in turn 
could lead to neuronal damage (modified from Marques and Outeiro, 2012).  
Consistently, Kim and colleagues reported that the α-synO-conditioned medium derived 
from microglial cells leads to neuronal death in vitro (Kim et al., 2016). More recently, di 
Domenico and co-workers demonstrated the pivotal role of astrocytes in mediating 
dopaminergic neuronal death. They indeed reported that induced pluripotent stem cells 
(iPSCs) -derived dopaminergic neurons show a reduction in the length of their neurites and 
an increase in cell death when co-cultured with iPSCs-derived astrocytes form PD patients 
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(di Domenico et al., 2019). The relevance of glial cells in α-synucleinopathies is further 
supported by in vivo experiments showing that LPS-induced neuroinflammation in PD 
mouse models triggers dopaminergic neuronal loss in SN in association with increased 
neuroinflammation and oxidative stress (Gao et al., 2008; Gao et al., 2011). In addition, 
blocking microglial cell activation by drugs, such as minocycline, leads to a decrease in 
neuronal death (Lim et al., 2016). 
Collectively these findings support the idea that glia, in addition to neurons, may contribute 
with non-cell-autonomous mechanisms to the aetiology of α-synucleinopathies. 
The implications of neuroinflammation for α-synucleinopathies as well as the role of 
astroglial and microglial cells in the regulation of neuronal functions will be further 
discussed in chapter III. 
 
2.7 Alpha-synuclein oligomers and cognitive impairment 
As previously described, progressive cognitive decline is a clinical feature of DLB and PDD 
and is an important element in consensus guidelines for the clinical diagnosis of both 
diseases (McKeith et al., 2004). Changes in synaptic organisation have been described in 
DLB and PDD patients and have been linked with cognitive impairment (Kramer et al., 
2007; Schulz-Schaeffer, 2010). 
Mounting evidence suggests a pivotal role for α-syn in the cognitive impairment. As 
mentioned above, over-expression of both WT and mutant forms of human α-syn is 
sufficient to induce memory deficits (Zhou et al., 2008; Lim et al., 2011; Larson et al., 2012). 
Notably, Lim and co-workers demonstrated that suppression of α-syn rescued memory 
dysfunctions (Lim et al., 2011). 
The critical role of α-synOs in mediating memory damage has been demonstrated by 
different groups. Indeed, while LTP is significantly impaired in the hippocampus upon 
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exposure to α-synOs, monomers and fibrils are ineffective (Martin et al., 2012; Diogenes et 
al., 2012). Two different mechanisms have been proposed to explain such a detrimental 
effect: I) an increase in the calcineurin (CaN) activity, a phosphatase with a negative 
modulatory function on synaptic plasticity; II) an increase in basal synaptic transmission 
through an alteration in both AMPA and NMDA receptors permeability (Martin et al., 2012; 
Diogenes et al., 2012). In this regard, it was reported that the application of α-synOs in 
hippocampal cell cultures enhanced both pre- and post-synaptic AMPA receptor 
transmission (Hulls et al., 2011), which might in turn lead to a calcium dyshomeostasis and 
cell death or synaptic loss as described in patients with DLB (Campbell et al., 2000; Danzer 
et al., 2007;  Hulls et al., 2011). 
These data, obtained through electrophysiological approaches on brain slices, have been 
further reinforced by behavioural in vivo experiments. In fact, α-synOs 
intracerebroventricularly (ICV) injected in mice caused cognitive dysfunction as 
demonstrated using the fear conditioning memory task, whereas monomers and fibrils were 
again inactive (Martin et al., 2012). 
More recently, Ferreira et al. showed that the detrimental activity of α-synOs on LTP 
requires the association with the cellular prion protein (PrPC) (Ferreira et al., 2017). In 
particular, they found that PrPC residues 93-109 are crucial to mediate LTP inhibition upon 
exposure to α-synOs, while α-synOs seem to require PrPC to activate the Fyn kinase, which 
in turn leads to NMDAR2B phosphorylation giving rise to LTP inhibition. Moreover, 
Ferreira and colleagues, through immunoprecipitation approaches, demonstrated that α-syn 
and PrPC can interact both in cell cultures treated with α-synOs and in a PD Tg mouse model 
overexpressing the human α-syn (Ferreira et al., 2017).  
Electrophysiological properties of neurons and of neuronal circuitries are tightly associated 
with intrinsic neuronal properties such as the expression of ion channels, neurotransmitter 
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release and receptor modulation. Deregulation of such a complex machinery may result in 
the alteration of neuronal plasticity and eventually in cognitive dysfunctions. While 
collectively these data support a key role for α-synOs in mediating cognitive impairment, a 
clear and univocal mechanism is still missing, and further investigation is required to acquire 
new insights on possible processes which may occur. On this subject, emerging data 
highlight the role of neuroinflammation as a potential culprit leading to neuronal dysfunction 
and impairment of cognitive functions. Pro- and anti-inflammatory cytokines, as well as 
LPS, have been reported to impair memory performance in different animal models (Donzis 
and Tronson, 2014; Richwine et a., 2009; Balducci et al., 2018). The role of 
neuroinflammation in mediating memory damage is strongly supported by existing evidence 
in animal models of AD. In an acute mouse model of AD, amyloid-β oligomers (AβOs) have 
been reported to impair memory performance through activation of glial cells and increase 
of pro-inflammatory cytokines expression (Balducci et al., 2017). Additionally, the block of 
neuroinflammation resulted in the rescue of memory functions both in an acute and in a Tg 
mouse model of AD (Balducci et al., 2017; Balducci et al., 2018). Intriguingly, α-synOs 
may exert detrimental activities through indirect non-cell-autonomous mechanisms which 
include glial cell activation. As mentioned above, activated glial cells produce several 
signals which can subsequently induce neuronal damage and impair cognitive functions. 
Thus, neuroinflammation might represent a process underlying cognitive decline in the 
context of α-synucleinopathies, and an exciting research direction to explain α-synO 
pathological mechanisms. 
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3.1 Evidence for the role of inflammation in a-synucleinopathies 
Initially considered as a mere secondary event and a consequence of the neurodegenerative 
process, neuroinflammation has acquired increasing interest in the context of α-
synucleinopathies. This is partly due to the considerably big amount of data obtained from 
post-mortem analyses, in vivo brain imaging, assessment of pro-inflammatory mediators in 
human fluids, genetic/epidemiological studies and experimental animal models (Hirsch and 
Hunot, 2009; Dzamko et al., 2015; Surendranathan et al., 2015; Lim et al., 2016).  
A broad spectrum of stimuli is capable of eliciting an immediate and short-lived activation 
of the innate immune system within the CNS. Astrocytes and microglia act as brain’s 
sentinels, and through the release of inflammatory mediators like cytokines and chemokines, 
they foster the migration of innate and adaptive immune cells such as 
monocytes/macrophages, neutrophils and lymphocytes (Walsh et al., 2014). Although this 
response is normally self-limiting once the insult is resolved, persistence of inflammatory 
factors might result in pathological consequences and neurodegeneration (Glass et al., 2010). 
The initiation of the inflammatory response generally occurs after the recognition by pattern 
recognition receptors (PRRs) of both exogenous (pathogen associated molecular patterns, 
PAMPs) and endogenous stimuli (damage associated molecular patterns, DAMPs). The 
binding of PRRs and DAMPs, such as misfolded and aggregated proteins including α-syn, 
leads to a signal transduction, which in turn triggers the activation of glial cells and the 
neuroinflammatory response (Heneka et al., 2014). Of note, gliosis is a common feature of 
α-synucleinopathies (Fellner et al., 2011). Microglial cell reaction is commonly observed in 
post-mortem PD brains (McGeer et al., 1988; Chao et al., 2014) and its persistence is linked 
to damaged dopaminergic neurons (Chao et al., 2014). Moreover, in DLB cases increased 
microglial activation positively correlates with the load of LBs (Togo et al., 2001). While 
the activation of the microglial pool in PD/DLB brains is widely accepted, contradictory 
results by different groups were reported for astrocytes which were found either in an active 
Introduction: Chapter III 
 
59 
 
or an inactive state (Tong et al., 2015). In addition to astrocytosis and microgliosis, higher 
levels of pro-inflammatory mediators have been found in both the striatum and the SN of 
post-mortem PD and DLB brains (Togo et al., 2001; Hirsch and Hunot, 2009). 
Despite detecting the presence of an immune response within the brain, the 
neuropathological assessment of inflammation in post-mortem samples does not provide 
evidence enough to directly link neuroinflammation with the pathogenesis of α-
synucleinopathies. Nevertheless, in vivo studies have clearly demonstrated that a 
neuroinflammatory process takes place during the progression of the disorders. PET scans 
with a ligand for microglia revealed the presence of activated microglial cells in PD, PDD 
and DLB patients (Hirsch and Hunot, 2009; Surendranathan eta al., 2015). Intriguingly, 
cortical microglial activation in PDD and DLB patients is characterised by a wider spreading 
compared to PD, and microglial activation negatively correlates with cognitive functions 
(Surendranathan eta al., 2015). Thus, a potential role for microglia in the pathogenesis of 
cognitive dysfunctions in both PDD and DLB has been speculated by researchers. 
Analysis of pro-inflammatory mediators in central and peripheral human biological fluids 
provides further proof supporting a role of inflammation in the pathogenesis of α-
synucleinopathies. Elevated levels of pro-inflammatory cytokines such as IL-1β, IL-6 and 
TNF-α were identified in PD patients compared to age-matched healthy controls (Mogi et 
al., 1994; Blum-Degen et al., 1995; Mueller et al., 1998; Clough et al., 2013). Notably, 
levels of IL-6 are inversely correlated with the severity of the pathology in PD patients 
(Mueller et al., 1998), and they are higher in PD cases with cognitive decline than in PD 
patients with no evidence of cognitive damage. Moreover, patients with cognitive 
dysfunction show an inverse correlation between IL-6 levels and the severity of the cognitive 
function impairment (Yu et al., 2014). Since pro-inflammatory mediators appear increased 
and are detectable in biological fluids, they have been extensively investigated as potential 
biomarkers and diagnostic/prognostic tools. However, controversial results were published 
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(Brodacki et al., 2008; Yu et al., 2014; Gupta et al., 2016; Hall et al., 2018). These disparities 
may depend on several aspects such as the severity of the pathology, difference in the life-
time spent with the pathology, as well as the presence of co-morbidities (Eidson et al., 2017).  
In spite of inconsistent results in the alteration of some pro-inflammatory cytokines in 
biological fluids, the role of the inflammatory response in α-synucleinopathies has also been 
suggested by genetic and epidemiological studies. As summarised in table 4, genes involved 
in PD also play a role on glial cells (Joe et al., 2018).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. PD related genes and their function in astrocytes and microglial cells (Joe et al., 2018).  
Besides, several polymorphisms in inflammatory associated genes increase the susceptibility 
to develop PD (Hirsch and Hunot, 2009).  
As described in chapter I, epidemiological studies have pointed out an inverse correlation 
between the use of NSAIDs, particularly Ibuprofen, and the risk of developing PD (Ascherio 
and Schwarzschild, 2016). On the other hand, systemic pathologies characterised by the 
induction of a neuroinflammation were found to positively correlate with an increasing risk 
of PD (McKenzie et al., 2017). 
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Compelling evidence of neuroinflammation in PD also comes from studies in different 
animal models. Chronic overexpression of the cytokine IL-1β in the SN of adult rat results 
in nigral dopaminergic degeneration and motor deficits, as well as glial activation (Ferrari 
et al., 2006). The MPTP model of PD was shown to cause microgliosis and to increase the 
levels of inflammatory mediators in murine SN (Czlonkowska et al., 1996: Mandel et al., 
2000). The Gram-negative bacterial endotoxin component LPS is a potent activator of 
inflammatory cells, and it has enabled researchers to gather information on the role of 
various inflammatory mediators in PD pathogenesis. As a matter of fact, the systemic 
administration of LPS has been reported to trigger a long-lasting increase in the pro-
inflammatory cytokine TNF-a in the brain, an increase in microglial cell activation in 
hippocampus and SN, as well as a progressive dopaminergic neuronal loss in SN (Qin et al., 
2007). Interestingly, administration of LPS in mice overexpressing α-syn results in the 
enhancement of the dopaminergic neurodegeneration (Gao et al., 2011). In addition, Tanaka 
and colleagues (Tanaka et al., 2013) demonstrated that the sub-chronic intranigral 
administration of LPS in WT but not in IL-1b null mice leads to microglial activation, 
increased pro-inflammatory cytokines production, death of dopaminergic neurons and motor 
behaviour impairment (Tanaka et al., 2013). Of note, the same authors observed that 
microglial activation and motor deficits occur earlier than neuronal loss, thus describing 
neuroinflammation as an early phenomenon which triggers neuronal dysfunction and 
ultimately neuronal death (Tanaka et al., 2013).  
More findings confirming the involvement of neuroinflammation in PD have been provided 
exploiting Tg mouse models. In mice overexpressing WT human a-syn, microglial 
activation and high levels of the pro-inflammatory cytokine TNF-a in both striatum and SN 
were reported, as well as microgliosis and astrogliosis in the hippocampus (Gelders et al., 
2018; Kim et al., 2018). Microglial cells seem to have a key role in dopaminergic 
neurodegeneration. In fact, onset of microglial activation appears before the dopaminergic  
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loss, and inhibition of microglial cell activation through minocycline administration results 
in a significant decrease of neuronal death (Wu et al., 2002; Hirch and Hunot, 2009). 
However, despite promising outcomes of minocycline in pre-clinical studies, a clinical trial 
with minocycline has proven unsuccessful (NINDS NET-PD Investigators, 2008). 
Therefore, further investigations of neuroinflammation in PD and PD-related disorders are 
mandatory to acquire full knowledge of the inflammatory mechanisms underlying these 
disorders. 
 
3.2 Astrocytes and microglial cells are key players in the healthy brain 
Together with oligodendrocytes, which isolate axons and allow the fast and efficient 
propagation of the action potential, astrocytes and microglial cells are the main cellular 
components of the CNS and have essential functions in maintaining brain homeostasis and 
properties (Bacci et al., 1999; Hertz and Chen, 2016). 
Despite their different embryogenic origin, both astrocytes and microglial cells are immune 
competent cells in the brain, and they are crucial players in the fine regulation of neuronal 
activity and synaptic plasticity (Blank and Prinz, 2013; Hertz and Chen, 2016). Synapses are 
specialised structures involved in the processing and transmission of the information 
between neurons and, furthermore, they are involved in learning and memory. Thus, a strict 
survey and tuning of synaptic functions is a milestone for superior functions. 
In healthy brains, astrocytes as well as microglial cells are juxtaposed and directly contact 
synapses at both pre- and post-synaptic levels (Figure 16).  
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Figure 16. Schematic representation of the tight interconnection between neurons, astrocytes 
and microglial cells at synaptic level. Astrocytes and microglial cells finely survey synaptic activity 
and tune it as well as synaptic plasticity. Of note both microglial and astrocyte activities at synaptic 
level are dependent on neuronal activity and is regulated by direct and indirect interconnections 
among all three cell types (Blank and Prinz, 2013). 
A single astrocyte may contact up to two million synapses in human and, such a spatial 
organisation allows the constant monitoring of synaptic activity, which in turn is essential 
for tuning synaptic functions and plasticity (Blank and Prinz, 2013; Hertz and Chen, 2016). 
Astrocytes are essential for providing a metabolic support to neurons. Namely, astrocytes 
uptake glucose from the blood and convert it into lactate through glycolysis. After release 
into the extracellular space, lactate is then utilised in the oxidative metabolism by neurons 
(Bacci et al., 1999; Joe et al., 2018). Astrocytes have also an important function in the 
removal of glutamate from the synaptic cleft. In presence of a sustained neuronal activity, a 
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high release of the excitatory neurotransmitter glutamate takes place. Glutamate is removed 
from the synaptic cleft by astrocytes through a transporter linked with a Na+ inward current. 
The resulting increase in the intracellular Na+ concentration leads to the activation of the 
Na+/K+ ATPase which in turn stimulates glycolysis and the production of lactate. Thus, this 
fine mechanism clearly demonstrates that astrocytes provide lactate to neurons in a synaptic 
activity-dependent manner (Bacci et al., 1999). In addition, astrocytes are involved in ion 
homeostasis, in regulating brain water volume and in modulating oxidative stress through 
the production of glutathione. Moreover, astrocytes provide glutamine to neurons which is 
converted by neurons in glutamate and produces diverse neurotrophic factors essential for 
neuronal health (Joe et al., 2018). 
Aside of astrocytes, also microglial cells have vital functions in healthy brain. In its resting 
state, microglial cells interplay a large number of connections with both neurons and 
astrocytes, and they play a role in synaptic remodelling as well as in providing neurotrophic 
factors to neurons. When in a resting state, microglial cells have a ramified morphology with 
a high number of branching processes and a small body. The extremely dynamic and mobile 
thin processes of microglial cells constantly survey the microenvironment and the synaptic 
activity. Indeed, microglial cells have receptors for several neuronal transmitters and through 
different signals, including inflammatory mediators, may regulate the neuronal activity 
(Morris et al., 2013). Of note, microglial cells in healthy conditions produce physiological 
levels of pro- and anti-inflammatory cytokines such as IL-1β, IL-10 and TNF-α, which are 
involved in synaptic plasticity, learning and memory (Blank and Prinz, 2013; Donzis and 
Tronson, 2014). Therefore, alteration of number, morphology and activation state of 
microglial cells, which generally occur during chronic and not regulated inflammation, may 
lead to synaptic and neuronal damage that ultimately may result in neurodegeneration (Blank 
and Printz. 2013; Morris et al., 2013). 
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Microglial activity at synaptic level is regulated by several mediators. Among these, 
neuronal fractalkine and CD200 have an inhibitory effect on microglial activation. The fine 
regulation of microglial cells is essential for the neuronal and synaptic functions and it 
involves neurons, astrocytes and microglial cells themselves. Thus, impairment of this fine 
and complex mechanism may trigger impaired synaptic plasticity, LTP and in turn memory 
damage (Blank and Prinz, 2013; Morris et al., 2013; Yang et al., 2007). 
As described in Chapter II, synaptic plasticity is an essential process for learning and 
memory. During learning and memory formation many events including creation of new 
synapses, elimination of “unwanted”, not well-working or damaged synapses and synaptic 
remodelling take place. Of note, microglial cells and astrocytes maintain phagocytic 
properties during adulthood, thus allowing remodelling, refinement and clearance of 
synapses (Jung and Chung, 2018).  
 
3.3 General characteristic of microglial cells 
Neuroinflammation triggered by microglial cells is a key player in PD and DLB 
pathogenesis. In fact, microgliosis positively correlates with dopaminergic 
neurodegeneration in SN (Ouchi e t al., 2005).  
Microglia derive from primitive yolk sac myeloid progenitors which seed in the developing 
brain parenchyma where they persist. Of note, microglial cells are exclusively present in the 
CNS and are not found in other organs or tissues (Subramaniam and Federoff, 2017). 
Microglial cells represent 10-15% of cells in the brain, and while they are evenly distributed, 
their density and morphology vary across brain regions (Tremblay et al., 2011; 
Subramaniam and Federoff, 2017). In the healthy brain, microglial morphology and 
distribution are dependent on the local cytoarchitecture. While in high dense cell regions 
microglia occur with a low rate, microglial cells are abundant in low dense cell fields. Thus, 
indicating a negative correlation between local cell density and microglial distribution into 
Introduction: Chapter III 
 
66 
 
the brain (Tremblay et al., 2011). As mentioned above, local cytoarchitecture also influences 
the morphological aspect of microglia. In white matter, microglia show an elongated soma 
with processes oriented along fibres. In contrast, in grey matter microglial cells have an 
elaborated shape with many radially oriented processes (Tremblay et al., 2011). Microglial 
cells, similarly to peripheral macrophages, survey the microenvironment against pathogens 
and damage signals. This function is closely related to the ability of microglial cells, at least 
in their resting state, to perpetually change their morphology by extending and retracting 
their own highly motile processes (Tremblay et al., 2011; Morris et al., 2013; Subramaniam 
and Federoff, 2017). Despite the high motility of their processes, microglia have an 
individual territory and direct contacts between microglial processes are avoided (Tremblay 
et al., 2011). In response to both exogenous and endogenous stimuli, resting microglial cells 
are activated and undergo a changing process. This includes alterations in both cellular 
morphology - from a ramified to an ameboid shape with an enlargement of the soma - and 
in gene/protein expression profile which in turn underlies the brain immune response.  Since 
fine tuning of the immune response in both its initiation and resolution is crucial for the 
clearance of harmful elements as well as for brain homeostasis, an uncontrolled balance of 
microglial activation may result in brain damage and neurodegenerative disorders including 
PD (Cherry et al., 2014; Tang and Le, 2016).  
 
3.3.1 The dual role of microglial activation 
Resting microglia can either be activated in a classical activation way leading to an M1 
proinflammatory microglial phenotype, or via an alternative way, that results in an M2 anti-
inflammatory microglial phenotype (Figure 17). In addition to the classical and alternative 
activation, microglial cells may also undergo an acquired deactivation process which is 
essential for the resolution of the immune response and results in the switching of the M1 
microglia to the M2 microglial phenotype (Tang and Le, 2016). 
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M1 microglia are characterised by pro-inflammatory and pro-killing functions that serve as 
a rapid prime line defence. Several kinds of signals may lead resting microglia to acquire an 
M1 phenotype including IL-1β, TNFα, interferon gamma (IFNγ) as well as α-synOs (Kim 
et al., 2013; Subramaniam and Federoff, 2017). In this activated state, the production of pro-
inflammatory mediators is significantly increased and several markers enabling the 
identification of M1 microglial cells are overexpressed (CD16/32, inducible nitric oxide 
synthase iNOS, IL-1β, TNFα, IL-6…). In contrast to M1 microglia, M2 microglial cells are 
associated with the resolution of the neuroinflammation. In fact, in this activation state 
microglial cells express anti-inflammatory mediators and enzymes such as IL-4, IL-10, IL-
13, transforming growth factor β (TGFβ), arginase 1, YM1, receptors associated with the 
phagocytosis. All these signals, apart from being useful M2 microglial markers, are involved 
in dampening neuroinflammation, in resolving injury as well as in repairing tissues (Cherry 
et al., 2014; Subramaniam and Federoff, 2017). Of note, anti-inflammatory cytokines have 
a double function. Namely, they counteract the production of pro-inflammatory mediators 
and, on the other hand, they promote the acquisition of an M2 phenotype (Cherry et al., 
2014; Tang and Le 2016). The fine and complex regulation of M1/M2 microglial phenotypes 
is crucial for brain homeostasis and health. A clear example of such a fine process is provided 
by the cross-talk between iNOS and arginase 1, that are expressed by M1 and M2 microglia, 
respectively. Both iNOS and arginase 1 are involved in the metabolism of arginine, which 
represents the unique substrate for both enzymes. The metabolism of arginine by iNOS leads 
to the production of citrulline and nitric oxide (NO). Of note, NO is toxic on neurons, and it 
was reported to be involved in dopaminergic neurodegeneration through different 
mechanisms (Zhang et al., 2006b; Choi et al., 2009). Unlike iNOS, arginase 1 converts 
arginine in hydroxyproline, proline and polyamine that contribute to tissue repair (Tang and 
Le, 2016). As arginine is the substrate of both iNOS and arginase 1, the latter counteracts 
NO production and may prevent neuronal damage.  
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Figure 17. Schematic representation of the classical and alternative pattern of microglia. In 
response to diverse stimuli, microglia may acquire an M1 or an M2 phenotype which are associated 
with a different protein expression as well as a divergent effect on neurons (modified from 
Subramaniam and Federoff, 2017). 
Based on the observation of microglial activation in PD and on the observation of possible 
different microglial phenotypes, researchers are attempting to further understand the 
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differential role of M1 and M2 microglia in PD. In this regard, it has been recently reported 
in an LPS-induced PD mouse model that the progressive nigrostriatal dopaminergic 
neurodegeneration is linked to an M1 microglial phenotype. In contrast, the cessation of the 
dopaminergic neurodegeneration strictly occurs in association with the switch of microglial 
cells to an anti-inflammatory M2 phenotype (Beier et al., 2017). In addition to the different 
properties of activated microglia, an emerging concept in the field of microglial cells and 
neurodegenerative disorders is the “priming” of microglial cells. Microglia, indeed, may 
retain features acquired during previous immune challenges, thus becoming “primed” and 
respond to a subsequent stimulus in an exaggerated manner. In turn, such a strong reaction 
may ultimately result in an uncontrolled inflammatory response that may become chronic. 
Once the inflammatory response becomes chronic, it self-sustains through a vicious circle 
and leads to a harmful microenvironment being dangerous for neurons (Tremblay et al., 
2011; Lecours et al., 2018). 
 
 
3.4 Brain and peripheral inflammation: a strong connection 
Neuroinflammation has a key role in the pathogenesis of neurodegenerative disorders 
including α-synucleinopathies. Of note, peripheral inflammation contributes and increases 
brain inflammation, thus suggesting a tight and complex cross-talk between the two immune 
systems (Kempuraj et al., 2017). The direct link between systemic and brain inflammation 
raises from a lot of evidence comprising data from both human samples and experimental 
animal models. As previously described, elevated levels of several pro-inflammatory 
mediators have been detected in both blood and CSF of PD patients. In addition, the 
induction of a peripheral inflammation through a single intraperitoneal injection of LPS 
triggers a self-propelling chronic neuroinflammation which is accompanied by 
dopaminergic neurodegeneration. Remarkably, the LPS-induced neuroinflammation seems 
to be weakly linked to the LPS per se, but instead appears more closely related to the 
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expression of the pro-inflammatory mediator TNF-α, which remains elevated in the brain 
for a long time after LPS treatment (Qin et al., 2007).  
Speaking about the different peripheral immune cells, monocytes have acquired an 
increasing interest in PD pathogenesis. Monocytes are a subset of myeloid cells which 
represent the main component of the peripheral innate immune system (Wijeyekoon et al., 
2018; Mahad et al., 2006). In response to specific signals these cells are recruited from the 
periphery into the brain where they contribute to the neuroinflammatory response (Harms et 
al., 2018). One of the best known and well-established pathways involved in the brain 
monocyte recruitment is the CCL2/CCR2 pathway. Through CCR2, peripheral monocytes 
recognise the circulating chemokine CCL2, which in turn promotes the migration of 
monocytes across the blood-brain-barrier (Wijeyekoon et al., 2018; Harms et al., 2018). 
Once inside the brain, monocytes may differentiate into active macrophages, which 
contribute to neuroinflammation and therefore could be detrimental for brain integrity. 
Intriguingly, CCR2 expression is elevated in peripheral blood monocytes of PD patients 
compared to healthy controls (Funk et al., 2013), and monocytes from the blood of PD 
patients show a higher production of CCL2 than those of age matched healthy controls 
(Reale et al., 2009). As a consequence, such an alteration in the expression of both CCL2 
and CCR2 may contribute to the self-propelling of the inflammation in both periphery and 
brain. A significant evidence of the role of monocytes in PD has been recently provided by 
Harms and colleagues. Exploiting a PD mouse model overexpressing human α-syn, they 
demonstrate a high recruitment of peripheral monocytes in the SNpc. Moreover, genetic 
deletion of CCR2 hampered the α-syn-induced monocyte recruitment, neuroinflammation 
and dopaminergic neurodegeneration (Harms et al., 2018). These lines of evidence shed new 
light into peripheral inflammation in PD pathogenesis. However, a contribution of both 
peripheral and brain inflammation seems to be more plausible that the role of solely 
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peripheral monocytes in PD pathogenesis. In fact, data indicate that a-synOs, as previously 
described, directly interact with and activate microglia. 
 
3.5 The Toll-like receptors 
As mentioned above, the initiation of the inflammatory response generally occurs after the 
recognition of DAMPs or PAMPs by PRRs such as TLRs. TLRs are first line players 
involved in the innate immune response and are able to detect both exogenous and 
endogenous signals including misfolded and aggregated α-syn. TLRs are highly conserved 
throughout species ranging from nematodes to higher eukaryotes, and they are the best 
characterised group of innate immune receptors. To date, 10 and 13 functional TLRs have 
been discovered in humans and mice, respectively (Arroyo et al., 2011). They are type I 
transmembrane proteins with a leucine-rich ectodomain recognising PAMPs/DAMPs, a 
transmembrane domain, and an intracellular Toll-interleukin 1 receptor (TIR) involved in 
downstream signalling (Arroyo et al., 2011).  The outcome of signalling is determined by 
the cell type expressing the receptors and through the selective use of specific sorting adaptor 
proteins. In addition, the response specificity is achieved through the subcellular 
compartmentalisation of the receptors themselves. For example, TLRs involved in the 
recognition of nucleic acids (TLR3, 7, 8 and 9) are normally found on the membrane of 
intracellular endo-lysosomes, while TLRs recognising extracellular PAMPs/DAMPs 
(TLR2, 4, 5, 6) are expressed on the cell surface facing the extracellular environment 
(Arroyo et al., 2011). A large body of evidence indicates that TLR2 and TLR4 are the most 
frequently receptors involved in the pro-inflammatory immune response triggering 
neuroinflammation. Accordingly, microglia lacking TLR2 and TLR 4 fail to mount an 
immune response upon exposure to fibrillar Ab1-42 (Jana et al., 2008). Moreover, AbO-
induced memory damage and neuroinflammation have both been reported to be mediated by 
the TLR4 (Balducci et sl., 2017). While TLR2 agonist is often represented by bacterial 
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lipoprotein, the classical PAMPs for TLR4 is the LPS. Upon binding to circulating lipid 
binding protein (LBP), LPS is engaged in a complex with membrane-bound CD14, that in 
turn combines with TLR4 to build up a functional LPS receptor complex. The downstream 
signalling involves an intricate network of adaptor molecules, protein kinases and 
phosphatases leading to the final activation of NF-kB and AP1 transcription factors that 
promote the expression of pro-inflammatory genes (Rosadini et al., 2017).  
Microglia and astrocytes are the main cell types mediating innate immunity in the CNS. 
Studies in mice revealed that mRNAs of TLR 1-9 are expressed in the brain, whose 
expression can be up-regulated by infections and inflammation, thus amplifying the innate 
immune response (Trudler et al.,2010; McKimmie et al., 2005). 
As previously described, microglia are first line responder cells to various kind of insults 
representing the 10% of cells in an adult CNS, and they are considered the brain’s 
macrophages (Aguzzi et al., 2013). These cells, expressing TLRs 1-9 along with CD14, 
respond to stimulation by producing cytokines that finally trigger phagocytosis of 
microorganisms and aggregated extracellular proteins (Arroyo et al., 2011). Microglia 
harbouring various TLRs are present in different brain areas with some preference to regions 
close to the circulation as meninges and circumventricular organs (Arroyo et al., 2011). 
Aside from microglial cells, astrocytes have been found to express TLRs at lower levels in 
physiological conditions. In healthy human brains these receptors are barely present, but 
upon inflammation onset TLRs are expressed on the surface of astrocytes at levels even 
detectable by immunohistochemical approaches (Arroyo et al., 2011).  
Of note, TLRs are also present in neurons, further providing evidence that they have a 
function in maintaining the cerebral architecture and tissue homeostasis. Specifically, 
humans and rodents express TLR 2, 3 and 4 in their neurons, while mRNAs coding for TLRs 
1-8 have been found in rat and mouse primary neuronal cultures (Tang et al., 2007; Okun et 
al., 2009). It has been established that TLRs activation in neurons might work in brain 
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development, and that in murine CNS TLR3 is involved in the regulation of the growth-
collapse rate of neuronal cones (Arroyo et al., 2011). 
 
3.6 Altered expression of TLR2 and 4 in Parkinson’s disease 
Despite the contribution of TLRs in α-synucleinopathies is controversial and debated, 
evidence for TLR engagement in such pathologies raises from the observation of TLR 
altered expression in in vitro studies as well as in PD patients and animal models (Kouli et 
al., 2019). 
Treatment of primary microglial cells with a preparation of α-syn containing a mixture of 
aggregates, from monomeric to fibrils, leads to microglial activation and altered 
transcriptional profile of TLRs including increased expression of TLR2 and a down-
regulation of TLR4 (Beraud et al., 2011). An altered expression profile of TLRs has been 
also previously reported by Letiembre and co-workers (Letiembre et al., 2009). In the 
brainstem of a Tg PD mouse model these authors found an increase in both transcriptional 
and protein levels of the TLR2, whereas the expression of the TLR4 was unaffected 
(Letiembre et al., 2009). More recently in PD patients, increased levels of both TLR2 and 4 
have been detected in blood peripherical immune cells. However, while the expression of 
TLR2 was significantly higher in monocytes compared to healthy matched controls, TLR4 
expression in the same cells revealed solely a trend in its up-regulation (Drouin-Ouellet et 
al., 2015). Despite the different expression profile of TLR2 and 4 in the blood, in the same 
study Drouin-Ouellet and colleagues found a comparable increase in protein levels of both 
TLRs in the caudate/putamen of post-mortem PD brains. Nevertheless, the same authors 
could not confirm their finding in a Tg mouse model over-expressing the WT human α-syn 
(Drouin-Ouellet et al., 2015). On the other hand, a different TLR2 expression profile has 
been reported by Doorn and colleagues. They found that, post-mortem brain samples from 
patients with prodromal and diagnosed PD displayed stage-dependent expression of TLR2 
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in both the SN and in the hippocampus, with a higher TLR2 expression in prodromal PD 
compared to diagnosed and advanced PD (Doorn et al., 2014). Therefore, these data imply 
that expression of TLR2 in early or advanced PD could be region- and time-specific.  
Because of controversial results being reported on the involvement of TLR2 and 4 in PD, in 
the following paragraph I will provide a brief overview on these two receptors in the context 
of the pathology. 
 
3.6.1 Experimental evidence for TLR2 and TLR4 involvement in α-syn detrimental 
effects 
As described in chapter II, extracellular α-syn could exert its detrimental activities on 
neurons through non-cell-autonomous mechanisms which recruit microglial and astroglial 
cells. Activation of these cells by α-syn may occur through the signal transduction mediated 
by either TLR2 or TLR4. In two distinct papers, Kim and co-workers have demonstrated 
that α-synOs released by SHSY-5Y cells over-expressing human WT α-syn promote 
microglial cell activation and the expression of pro-inflammatory mediators in a TLR2-
dependent manner (Kim et al., 2013; Kim et al., 2016). Indeed, genetic ablation of the 
receptor as well as its functional inhibition completely abrogated the microglial cytokine 
production upon α-synOs treatment (Kim et al., 2013; Kim et al., 2016). In contrast, as the 
depletion of TLR4 had no effects on the α-syn-induced gene expression of microglial pro-
inflammatory cytokines, they concluded that α-synOs act through a TLR4-independent 
pathway (Kim et al., 2013). In post-mortem PD brain, TLR2 is up-regulated in both 
microglia and neurons, even though is more expressed in neurons compared to microglia 
(Dzamko et al., 2017). In addition, neuronal stimulation through TLR2 agonists leads to a 
significant increase in the expression of pro-inflammatory mediators by neurons themselves, 
thus depicting neurons as active players in the neuroinflammatory process in concert with 
glial cells (Dzamko et al., 2017). Evidence for the involvement of TLR2 in α-syn detrimental 
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actions also stems from in vivo studies. Indeed, while TLR2+/+ mice overexpressing the WT 
human α-syn in the SN showed loss of dopaminergic neurons and active microglial cells, 
TLR2-/- mice did not (Kim et al., 2013). As described in the above section, TLR2 levels are 
increased in PD patients. These data and the evidence of TLR2-dependent activation of 
microglial cells by α-synOs allow researchers to speculate that TLR2 may play a pivotal role 
in promoting neurodegeneration in α-synucleinopathies. To follow up this hypothesis, it has 
been recently demonstrated in a Tg PD mouse model that TLR2 blockade through a 
functional inhibiting antibody triggers neuroprotective effect. Specifically, immunotherapy 
against TLR2 leads to the inhibition of both microgliosis and astrogliosis as well as the 
normalisation of IL-1β, IL-6 and TNF-α levels (Kim et al., 2018). Such an overall effect on 
the neuroinflammatory parameters was also accompanied by a significant reduction of 
cortical and hippocampal neuronal degeneration (Kim et al., 2018). 
The data here provided seem to suggest a prominent role for TLR2 in α-synucleinopathies, 
albeit TLR4-dependent activation of microglia and astrocytes upon α-syn treatment has also 
been reported. The exposure of both TLR4+/+ microglial cells and astrocytes to different 
moieties of WT α-syn (soluble full-length, oligomers and C-terminally truncated) triggers 
their activation and the release of pro-inflammatory mediators such as TNF-α and IL-6. 
Remarkably, ablation of the receptor results in the suppression of the pro-inflammatory 
response in both cell types (Fellner et al., 2013). Consistently, the involvement of TLR4 in 
mediating the astrocyte α-syn-induced pro-inflammatory response has also been reported by 
Rannikko and collaborators (Rannikko et al., 2015). In their study the authors described an 
α-syn dose-dependent increase in the transcriptional levels of different pro-inflammatory 
mediators such as IL-1β, IL-6, TNF-α and COX-2 in TLR4+/+, but not in TLR40/0 astrocytes 
(Ramikko et al., 2015). Thus, contradictory results leave the involvement of TLR2 and 
TLR4 in a-synucleinopathies still unclear and demand further efforts to clarify their 
contribution in mediating α-syn detrimental activity. 
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Mounting evidence depicts α-synOs as key players in inducing neuronal and synaptic 
dysfunction in α-synucleinopathies, and highlights the potential harmful effects of 
extracellular α-syn moieties. Therefore, the first aim of this PhD thesis was to develop an 
acute mouse model based on the ICV injection of α-syn monomers, oligomers and fibrils to 
specifically investigate the oligomeric hypothesis in the context of cognitive damage. 
Since researchers have started focusing on the mechanisms involved in mediating the 
dangerous action of α-synOs, non-cell-autonomous mode of actions gained an increasing 
interest. Among these, neuroinflammation and protein-protein interaction are being widely 
explored and currently proposed as crucial events in the pathogenesis of PD and PD-related 
disorders. Specifically, with regard to protein-protein interaction, the PrPC was recently 
shown to interact with α-synOs, and to mediate their effects at a functional level. Based on 
these data, further aims of this PhD thesis included: 
• The elucidation of α-synOs ability to induce a neuroinflammatory response in our 
acute mouse model, and the characterisation of the role of α-synO-induced 
neuroinflammation in mediating the detrimental actions of α-synOs on memory. 
• The in vivo investigation of the PrPC-α-synO interaction to assess the role of PrPC as 
an interactor and mediator of oligomeric α-syn at multiple functional levels (neuronal 
cytotoxicity, memory damage and gliosis). 
As mentioned above, neuroinflammation has emerged as a key player in PD and PD-related 
disorders pathogenesis. Although neuroinflammation may represent a mediator for α-synOs, 
compelling evidence supports a role of neuroinflammation as a bridge linking environmental 
and genetic susceptibility co-fostering PD pathogenesis. These findings together with the 
lack of direct evidence demonstrating that inflammation influences α-synO harmful 
activities or the PD behavioural and neuropathological features, set the stage for the next 
aim of this PhD thesis. Specifically, we intended to verify whether an induced inflammatory 
state potentiates α-synOs effects in our acute mouse model, and whether it influences the PD 
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phenotype in the more complex context of the Tg PD mouse model carrying the A53T 
missense mutation.  
In conclusion, the overall aims of this PhD thesis were to investigate the action of 
extracellular α-synOs at cognitive level, and to elucidate their mechanisms of action focusing 
on neuroinflammation as a mediator of α-synOs effects and as a predisposing factor 
influencing α-synO actions and pathology progression (Figure 18). 
 
Figure 18. Overall aims of the PhD thesis 
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5.1 Mice 
In this PhD thesis different mouse strains were exploited as specified in each result section. 
In particular mice used for our experiments included: eight-week-old C57BL/6N (Charles 
River, Italy) and TLR4 knock-out (TLR40/0 ) male mice (kindly provided by Dr Vezzani, 
Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy); six-/eight- months old PrPC 
knock-out (Prnp0/0) and Prnp+/+ male mice (Bueler et al., 1993) maintained on a pure 
C57BL/6  background were obtained by the European Mouse Mutant Archive (strain 
EM01723), and eight-month-old hemiizygous B6.Cg2310039L15RikTg(Prnp-
SNCA*A53T)23Mkle/J (herein referred as A53T mice) and their non-transgenic matched 
littermates (NTG) (The Jackson Laboraory, USA). Mice were housed individually in 
standard cages in a specific pathogen free conditions and in a controlled environmental 
condition (temperature: 21±1°C; relative humidity: 60% and 12 hours of light). All 
experimental procedures were conducted in conformity with institutional guidelines that are 
in compliance with national (D.L. n.26, G.U. 4 March 2014) and international guidelines 
and laws (EEC Council Directive 86/609, OJ L 358, 1, 12 December 1987, Guide for the 
Care and Use of Laboratory Animals, U.S. National Research Council, 1996), and were 
reviewed and approved by the intramural ethical committee. 
 
5.2 ICV cannulation 
Mice were anaesthetised with isoflurane inhalation and fixed on stereotaxic instrument 
(model 900, David Kopf instrument). A stainless steel guide cannula was implanted 
following the coordinates of the mouse cerebral atlas (anteroposteriority: +0.3, and laterality: 
±1.0 from Bregma; dorsoventrality: -3.0 from Dura). To allow the recovery of animals from 
the surgery, animals entered in the experimental protocol 15 days after the surgical 
procedure. 
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5.3 Alpha-syn assembly preparations 
α-synOs were obtained as previously described (La Vitola et al., 2018; La Vitola et al., 
2019). Briefly, endotoxin free recombinant monomeric human α-syn (241 μM) from E. coli 
cells (kindly provided by Prof. Pollegioni, Università degli Studi dell’Insubria, Varese, Italy; 
Caldinelli et al., 2013) was incubated in 50 mM filtered phosphate buffer (PBS) pH 7.4 at 
37°C without shaking for 48 hours. An incubation of 5 days in the sane conditions used for 
obtaining α-synOs was applied to induce the fibrilization of recombinant monomeric human 
α-syn. At the end of the oligomerisation/fibrilization process, α-syn preparations were 
diluted at 1 and 0.5 μM (as specified in each result section) in 50 mM filtered PBS (Vehicle, 
Veh) for the ICV injection. For in vitro studies, α-synOs were diluted at 1, 5 and 10 μM in 
the neuronal maintaining medium. 
Recombinant human α-syn was characterised by Prof. Pollegioni (Università degli Studi 
dell’Insubria, Varese, Italy) through size-exclusion chromatography on a Superdex 200 HR 
10/30 column (GE Healthcare), SDS-PAGE and circular dichroism analyses. Endotoxins 
were fully eliminated by treatment with Triton X-114. α-synOs and fibrils were characterised 
by atomic force microscopy (AFM) analyses. In addition, α-synOs were characterised by 
western blotting.  
 
5.4 Atomic force microscopy   
AFM characterisation of our preparations were performed by Dr. Laura Colombo (Istituto 
di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy). A Nanoscope® Multimode 
V AFM equipped with a 7415 EV scanner (Veeco, NY, USA) was utilised to investigate the 
surface morphology of α-syn samples. Protein solutions containing oligomers or fibrils were 
diluted to 10 µM with 50 mM PBS or 10 mM HCl, respectively. Once diluted, 50 µL of each 
solution were adsorbed onto freshly cleaved mica (three minutes for the solution containing 
α-synOs, and five minutes for the solution containing fibrils). Then samples were washed 
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with 10 ml of double distilled H2O and dried under gentle flow nitrogen. AFM measurements 
were performed using the tapping mode with a triangular antimony doped silicon cantilever 
(type-RTESP, Bruker). The force constant of the cantilever was 20-80 N/m with a resonance 
frequency of 313 - 370 kHz. The scan rate was 0.7 to 1 Hz, and the image size was 512 x 
512 pixels. Images were obtained from three different locations on each specimen to ensure 
the homogeneity of samples. Analyses of AFM images were performed using Scanning 
Probe Image Processor (SPIP-version-5.1.6) data analysis package. Through the same 
approach we have also performed analyses of α-synO preparations with a final concentration 
of 1, 5 and 10 μM. 
 
5.5 Western blotting of α-synOs 
Double gradient gel (7-12% SDS-PAGE) was used for the analysis of synthetic α-synOs. 
3.75 µg of α-syn were run in duplicate, transferred on nitrocellulose membranes, and probed 
using the mouse anti-α-syn antibody (1:1000, 4°C ON; BD Trasduction Laboratories in BSA 
3%). Then the membranes were incubated with the anti-mouse HRP secondary antibody 
(1:5000; 1 hour at room temperature, RT; Abcam). Immunoreactivity was visualised with 
Lumnia Forte Western HRP substrate (Millipore, Billerica, MA, USA) and ChemiDoc XRS 
(Biorad). 
Through the same approach we also characterised α-synOs at the final concentration of 1, 5, 
10 μM. In this case we run 0.5 μg for each sample.  
 
5.6 Alpha-synOs and vehicle ICV injection 
Monomeric, oligomeric or fibrillar α-syn and Veh were ICV injected (1μL/min) through an 
injection unit inserted inside the previously implanted guide cannula and connected to a 
Hamilton syringe with a flexible plastic tubing, sufficiently long to allow mouse free 
movements within their own cages. At the end of injection, the injection unit was removed 
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two minutes after drug delivery to allow its diffusion. Control mice were injected with the 
corresponding volume of Veh.  To assure the absence of adverse effects due to the ICV 
injection, at the end of the ICV administration mice were monitored in their own homecage. 
 
5.7 Drugs and treatments 
- Veh (50mM PBS), α-syn monomers, oligomers or fibrils were ICV injected (as described 
above and detailed in each result section) using a Hamilton syringe connected to an infusion 
pump (1μL/minute).  
-Indomethacin (Indo; Sigma-Aldrich) dissolved in 0.2M Tris-HCl, pH 8.2 was injected at 
10mg/Kg intraperitoneally (IP) 30 minutes before α-synOs or Veh administration. 
-Ibuprofen (IBF; Sigma-Aldrich) was dissolved in 100mM PBS and IP injected at 5, 10 and 
50mg/Kg 30 minutes before α-synOs or Veh administration. 
-4G8 and anti-α-syn antibodies (Signet and BD Trasduction Laboratories respectively) were 
ICV injected at the dose of 0.25μg/2μL 15 minutes before α-synOs injection. 
-Anti-TLR2 antibody (T2.5) (Invivogen) was dissolved in PBS and ICV injected at the dose 
of 5μg/2μL 15 minutes before α-synOs injection.  
All drugs were injected ICV through an injection unit inserted inside the implanted guide 
cannula and connected to the Hamilton syringe through a flexible plastic tubing, sufficiently 
long to allow mouse free movements within their own cages during injection. The injection 
unit was removed two minutes after drug delivery to allow diffusion. Control mice were 
injected with the corresponding volume of the appropriate vehicle.  
-Ultra-pure LPS from E. Coli (strain 011:B4; InvitroGen, USA) was dissolved in sterile 
water and IP injected at 1 or 2.5 mg/Kg. For the in vitro treatment, LPS was used at the final 
concentration of 0.5 μg/mL.  
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5.8 Novel object recognition task (NORT) and open field 
The task started with a habituation trial (open field; five min) during which mice were placed 
in an empty arena (40x40 cm and 30 cm high) and they were free to explore the new 
environment. In the next day (sample phase; ten min) animals were placed in the arena with 
two identical objects and free to explore them. Twenty-four hours later, animals were 
replaced in the arena where a familiar object was replaced with a novel one (test phase; ten 
min). Time spent by mice to explore both the familiar and the novel object were measured 
by a blind operator.  
The following objects were used: a black plastic cylinder (4 x 5 cm), a glass vial with a white 
cup (3 x 6 cm) and a metal cube (3 x 5 cm). 
Memory was expressed as a discrimination index [DI=(seconds on novel-seconds on 
familiar)/total investigation time]. Animals with memory impairment spent the same time in 
investigating the familiar and the novel object giving a lower DI compared to animals 
without memory impairment.  
 
5.9 Y-maze test 
Short-term spatial memory was assessed in the Y-maze task (Xu et al., 2018). The Y-maze 
apparatus is a Y-shaped maze with three 20 cm length grey arms at the angle of 120° from 
each other. Each arm is large 5 cm and has a high of 10 cm.   
Mice were placed in the centre of the Y-maze apparatus and free to move for eight min. A 
successful alternation was defined as a mouse entering consequentially in three different 
arms of the maze (i.e. ABC, BAC, BCA but not ABA, CAC, BCB). The percentage of 
spontaneous alternation [number of successful alternations/(total entries-2)]*100 was 
calculated by a blinding operator. Since mice prefer to visit a new arm of the maze and show 
a tendency to enter the less recently explored arm, animals displaying a memory impairment 
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have lower spontaneous alternation behaviour than mice not impaired. Of note, an arm entry 
is considered when all the four mouse limbs are into the arm.  
 
5.10 Morris-water maze (MWM) test 
Learning and spatial memory were investigated through the MWM test. A circular arena 
(100 diameter x 50 cm height) was filled to a depth of 0.29 m with water at 21±1°C. The 
water was made cloudy using a nontoxic white dye. A white platform (11x11 cm) was 
positioned in a specific quadrant (Target Quadrant) 0.5 cm below the water and animals were 
trained to find it through a 4-trial training (60 seconds/trial with a 10 minutes inter-trial 
interval) for five consecutive days. The escape latency to find the platform through days was 
measured and expressed as mean±SEM of the 4 trials. On day six, platform was removed 
(probe phase, 60 seconds) and mouse ability to recall the platform location was assessed 
measuring the time spent in both target and opposite quadrant.  
 
5.11 Beam-walk test 
The beam-walk test (Pischiutta et al., 2018) was performed to evaluate mouse gait 
instability. Briefly, the beam-walk test measures the footslips of mouse walking twice on an 
elevated, wooden beam (8 mm wide and 100 cm long). Before test, mice are trained in three 
habituation trials. Data are expressed as the footslips mean±SEM in the two tests. Mice with 
gait instability done a higher footslips number than not impaired animals. 
 
5.12 Open field 
To assess the spontaneous motor behaviour, we have exploited the open field task. Mice 
were placed in an empty arena (40x40 cm and 30 cm high) for 5 minutes and they were free 
to explore the new environment. The spontaneous motor behaviour of each mouse was 
Materials and methods: Chapter V 
 
86 
 
recorded and, through the EthoVision program, both the total distance moved (mean±SEM) 
and the mean velocity (mean±SEM) were measured. 
 
5.13 Extracellular field recordings  
Extracellular field recordings were performed by Dr. Milica Cerovic (Istituto di Ricerche 
Farmacologiche Mario Negri, Milano, Italy). Briefly, coronal brain slices (350 µm) were cut 
in ice-cold modified artificial cerebrospinal fluid (aCSF: 87 mM NaCl, 2.5 mM KCl, 1 mM 
NaH2PO4, 75 mM Sucrose, 7 mM MgCl2, 24 mM NaHCO3, 11 mM D-glucose, and 0.5 mM 
CaCl2). Brain coronal slices were transferred into the incubating chamber, submerged in 
aCSF containing 130 mM NaCl, 3.5 mM KCl, 1.2 mM NaH2PO4, 1.3 mM MgCl2, 25 mM 
NaHCO3, 11 mM D-glucose, 2 mM CaCl2 and constantly bubbled with 95% O2 and 5% CO2 
at room temperature (RT). Slices were incubated for at least 1 hour before recording and in 
a submerged recording chamber, perfused with oxygenated aCSF at a constant rate of 2-3 
ml/min at 28-30°C. The pre-incubation with α-synOs (200nM/90-120 minutes) was 
performed at RT.  
Stimuli were delivered via a Constant Voltage Isolated Stimulator (Digitimer Ltd., Welwyn 
Garden City, UK) with a bipolar twisted Ni/Cr stimulating electrode. LTP was induced by a 
4-theta-burst tetanus stimulation protocol (each burst consists of four 100 Hz pulses with a 
200 ms inter-burst interval). Signals were amplified and filtered (low filter 10 Hz, high filter 
3 kHz) by a DAM 80 AC Differential Amplifier (World Precision Instruments, Sarasota, 
FL), and digitised at 10 kHz with a Digidata 1322 (Molecular Devices, Foster City, CA). 
LTP recordings in which the amplitude of the presynaptic fibre volley changed by more than 
20% were discarded. 
 
 
 
Materials and methods: Chapter V 
 
87 
 
5.14 Immunohistochemistry and immunofluorescence 
Mice were anaesthetised with a mix of ketamine (1.75 mg/Kg) and medetomidine (1 mg/Kg) 
and transcardially perfused with 50 mM PBS pH 7.4 followed by chilled 4% 
paraformaldehyde in 50 mM PBS. Serial coronal hippocampal and SN sections (30 μm) 
were collected in 100 mM PBS for the immunohistochemistry analyses of the astroglial 
marker (GFAP), the microglial marker (IBA1), and the tyrosine hydroxylase (Th). Briefly, 
slices were blocked for 1 hour at RT with an appropriate blocking solution (GFAP: 3% NGS, 
Triton 0.4% in PBS 100 mM; IBA and Th: 10% NGS, Triton 0.3% in PBS 100mM). Then, 
slices were incubated with mouse anti-GFAP antibody (1:3500, Millipore), rabbit anti-IBA1 
antibody (1:1000; Wako) or mouse anti-Th antibody 1:500, Millipore) at 4°C overnight 
(ON). After incubation with the anti-mouse biotinylated secondary antibody (1:200; Vector 
Laboratories; 1 hour RT) or the anti-rabbit biotinylated secondary antibody (1:200; Vector 
Laboratories; 1 hour RT), the immunostaining was developed using the avidin-biotin kit 
(Vector Laboratories) and diaminobenzidine (Sigma, Italy). Image acquisition was done 
using the Olympus VS120-S6-FL-078. Analyses of GFAP-, IBA1- and Th-
immunoreactivity have been performed with a homemade macros and image analyser and 
the Fiji software.  
Immunofluorescence analyses have been performed to evaluate the spreeding of ICV 
injected α-syn (monomers, oligomers and fibrils) and to asses the expression of GFAP, IBA1 
and IL-1β or the expression of the M1 pro-inflammatory marker CD16/32 and its co-
localisation with IBA1 in the hippocampus.  
- Immunofluorescence for α-syn 
Serial coronal hippocampal sections (20 µm) were collected in 100 mM PBS for 
immunofluorescence analysis of the injected human recombinant α-syn. Freely-floating 
brain slices (three/mouse) were blocked (10% NGS, Triton 0.3% in PBS 100mM) for 1 hour 
at RT. Then, sections were incubated with the primary mouse antibodies against human α-
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syn (1:1000, ThermoFisher). Fluorescence was detected using anti-mouse secondary 
antibody conjugated with Alexa 594 (Molecular Probes). 
- Immunofluorescence for IBA1, GFAP and IL-1β  
Serial coronal hippocampal sections (30 µm) were collected in 100 mM PBS for triple-
immunofluorescence analysis of astrocytes, microglial cells and IL-1b. Freely-floating brain 
slices (3/mouse) were incubated at 4°C for 10 min in 70% methanol and 2% H2O2 in Tris-
HCl-buffered saline (TBS, pH 7.4) followed by 30 minutes incubation in 10% foetal bovine 
serum (FBS) in 1% Triton X-100 in TBS. Sections were incubated first with the primary 
antibody against IL-1β (1:200, Santa Cruz Biotechnology; 72 h, 4°C in 10% FBS/1% Triton 
X-100/TBS). Then slices were incubated with the biotinylated secondary anti-goat antibody 
(1:200, Vector Labs) followed by fluorescent signal coupling with a streptavidin Tyramide 
Signal Amplification kit (NEN Life Science Products). Sections were incubated with the 
primary antibodies against GFAP (1:3500; Millipore) and IBA1(1:1000; Wako) and 
fluorescence was detected using anti-mouse or anti-rabbit secondary antibody conjugated 
respectively with Alexa 546 or Alexa 695 (Molecular Probes). 
- Immunofluorescence for CD16/32 and IBA1 
Coronal hippocampal brain slices (three/mouse) were blocked (10% NGS, Triton 0.3% in 
PBS 100mM) for 1 hour at RT. Then, sections were incubated with the primary rat antibodies 
against CD16/32 (1:600, BD Pharmingen) and rabbit anti-IBA1 (1:1000; Wako).  
Fluorescence was detected using anti-rat or anti-rabbit secondary antibody conjugated 
respectively with Alexa 647 or Alexa 546 (Molecular Probes). Immunofluorescence was 
acquired using an IX81 microscope equipped with a motorised stage and a FV500 confocal 
scan unit with three laser lines [argon-krypton (488 nm), helium-neon red (646 nm), and 
helium-neon green (532 nm; Olympus)] and an ultraviolet diode. 
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5.15 Nissl staining  
Three coronal hippocampal brain slices for each sample were hydrated in distilled water (1 
minute). Then, brain slices were dehydrated through an alcoholic scale (Ethanol 70%, 
Ethanol 95%, Ethanol 100% and Xilene; 5 minutes/phase). Brain slices were stained in 0.5% 
Cresyl violet (Santa Cruz Biotechnology) solution in 25% Methanol. The excessive staining 
was removed through 10 consecutive washes in distilled water and then fixed through the 
same inverse alcoholic scale described above (3 minutes/phase). 
 
5.16 Western blotting of synaptic proteins 
Mice (4-5/group) were anesthetised with a mix of ketamine (1.75 mg/Kg) and medetomidine 
(1 mg/Kg) then decapitated. The hippocampus was dissected, frozen on dry ice and stored 
at -80°C. Tissues were homogenised to obtain the total insoluble fraction (TIF) and the 
expression of PSD95 and synaptophysin assessed. Briefly, to obtain the TIF, tissues were 
homogenised in ice-cold lysis buffer (0.32 M sucrose containing 1 mM Hepes, 1 mM 
MgCl2, 1 mM NaHCO3, 0.1 mM, PMSF, at pH 7.4, with a complete set of protease 
inhibitors (Sigma). Total homogenate was centrifuged at 1000 g for 10 min at 4°C and the 
resulting supernatant was centrifuged again at 13000 g for 15 min. The pellet obtained was 
suspended in ipotonic buffer (HEPES 1mM and protease inhibitor cocktails) and 
centrifugated at 100000 g for 1 hour. Then, the pellet was re-suspended in Triton X-100 1% 
with KCl 150 mM and protein inhibitor cocktail. The suspension was centrifuged at 100000 
g (4°C, 1 hour). The pellet obtained (TIF) was then suspended in a buffer containing 
Glycerol 30%, HEPES 1 mM and protein inhibitor cocktail.  
Total protein content was measured in the TIF fraction by the Bio-Rad Protein Assay (Bio-
Rad Laboratories). Gels (8% SDS-PAGE for PSD95 and Synaptophisin) were run under 
reducing conditions; 10 µg proteins from each sample were run in duplicate and 
nitrocellulose membranes obtained from electroblotting were probed using the following 
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antibodies: mouse anti-PSD95 (Neuromab, 1:5000 in non-fat milk/TBS 0.1% Tween-20) 
and rabbit anti-synaptophysin (Synaptic System, 1:5000 in 3% BSA/TBS 0.1% Tween-20) 
at 4°C ON. Then, membranes were incubated with the mouse or rabbit HRP secondary 
antibody (1:5000; RT 1 hour; Abcam). Immunoreactivity was visualised with Lumnia Forte 
Western HRP substrate (Millipore, Billerica, MA, USA) and ChemiDoc XRS (Biorad). 
Optical density of the blots was measured with Quantity-One software (Biorad) and 
normalised using the corresponding signal for β-actin (Santa Cruz Biotechnology). Results 
were expressed as fold change (%) of Veh-treated mice.  
 
5.17 Hippocampal neuron cultures and determination of α-synO toxicity 
Hippocampal neurons were prepared by Dr. Elena Restelli (Istituto di Ricerche 
Farmacologiche Marion Negri, Milano, Italy) as previously described (Restelli et al., 2010). 
Briefly, Two-day-old mouse hippocampi were incubated in neuronal dissociation medium 
(5.8 mm MgCl2, 0.5 mM CaCl2, 3.2 mM HEPES, 0.2 mM NaOH, 30 mM K2SO4, 0.5 μg/ml 
phenol red, pH 7.4; 292 mOsmol) containing 20 U/ml papain (Sigma-Aldrich) at 34°C for 
30 minutes. Trypsin inhibitor (Sigma-Aldrich) was added to a final concentration of 0.5 
mg/ml and the tissue was mechanically dissociated. Cells were plated at 200000-250000 
cells/cm2 on plates coated with poly-d-lysine (25 μg/ml) and maintained in Neurobasal 
medium (Invitrogen) supplemented with B27 (Invitrogen), penicillin/streptomycin, and 
glutamine 2 mM. Cell viability was assessed measuring the cellular reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to formazan previously 
described (or through the lactate dehydrogenase (LDH) assay. In the MTT assay cells were 
incubated at 37°C for 3 hours with 0.4 mg/ml MTT, dissolved in 0.04 N HCl in 2-propanol, 
and analyzed spectrophotometrically at 540 nm with an automatic microplate reader (Tecan 
Infinite M200). In the LDH assay, 50 µL of cell medium were collected from each well at 
the end of treatments. 50 µL of Cytotox96 Reagent (12 mL of Assay buffer in one vial of 
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Substrate mix) were added to the cell medium. The assay plate was mixed gently for 1 minute 
and incubated in the dark (30 minutes, RT). Following the incubation, 50 µL of Stop Solution 
were added to the wells to interrupt the reaction and the absorbance was measured at 490 
nm through automatic microplate reader (Tecan Infinite M200).   
LDH positive control is provided in the LDH assay kit (CytoTox96 non r-radioactive 
cytotoxicity assay, Promega). 
All treatments of neuronal hippocampal cultures started 12 days after neuronal plating. 
Details for each treatment were provided in each result section.  
 
5.18 Surface Plasmon Resonance  
 Surface Plasmon Resonance (SPR) analyses were performed to assess the direct PrPC-α-
synO binding by Dr. Marten Beeg and Dr. Marco Gobbi (Istituto di Ricerche 
Farmacologiche Mario Negri IRCCS, Milano, Italy). α-synOs (1 and 10 M) or Aβ-Os (1µM) 
were injected over the surfaces exposing PrPC captured by 3F4 or 94B4, or those coated with 
3F4 or 94B4 alone (without PrPC, used for reference). Assays were performed at 25 °C. The 
α-syn- or Aβ-dependent signals on the surfaces immobilizing PrPC were obtained by double 
referencing, subtracting the response observed on surfaces immobilizing the antibodies 
alone, and the signal observed injecting the Veh alone (which allows correction for binding-
independent responses, e.g., drift effects). The ProteOn XPR36 Protein Interaction Array 
system (Bio-Rad) was used.  More in detail, anti-PrPC monoclonal antibodies 3F4 and 94B4 
were immobilised by amine-coupling chemistry on the surface of a GLC sensor chip 
(BioRad), according to manufacturer recommendations. The final immobilisation levels 
were ~6,000 resonance units (1 RU = 1 pg protein/mm2) for both 3F4 and 94B4.  
“Reference” surfaces were prepared in parallel following the same immobilisation procedure 
but without antibodies. Then, total brain homogenate (0.5 mg protein/mL  in PBS containing 
0.5% Nonidet P-40 and 0.5% Na-deoxycholate) from WT-E1 Tg mice overexpressing WT 
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mouse PrP carrying an epitope tag for the monoclonal antibody 3F4 (Chiesa et al., 1998) 
were flowed on the surface of chips. While the signal was negligible in the “reference” 
surface after the flowing of total brain homogenate, it was ~900 on the surfaces coated with 
3F4 and ~700 RU on the surfaces coated with 94B4. Since the signal decayed very slowly, 
the dissociation of PrPC from both 3F4 and 94B4 is slow. 
 
5.19 Statistical analysis 
Data were analysed using the GraphPad Prism 7.0 software. Unpaired Student’s T-test, One-
, Two- or Three-way analyses of variance (ANOVA) were used for the statistical analyses 
of our experiments in accordance with the amount of the independent variables 
(factors/treatments) which affect the dependent variable (e.g. the DI, the % of spontaneous 
alternation, the % of GFAP- and IBA1-marked area…)  as specified in each result sections. 
In presence of a significant effect of treatment in the One-way ANOVA or a significant 
interaction among variables in the Two- and Three-way ANOVA, an appropriate post-hoc 
tests was applied (details in each result sections). For all analyses, a p value < 0.05 was 
considered statistically significant.  
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The data presented in this chapter are reported in the manuscript entitled “Alpha-synuclein 
oligomers impair memory through glial cell activation and via Toll-like receptor 2”. Brain 
Behav Immun. 2018 Mar; 69:591-602. doi: 10.1016/j.bbi.2018.02.012.  
 
6.1 Aim of the study and in vivo experimental design 
Based on the evidence previously reported, in this section we aimed to specifically 
investigate the α-syn oligomeric hypothesis in the context of memory impairment. To this 
purpose, we have developed an acute mouse model based on the ICV injection of monomers, 
oligomers or fibrils of α-syn, and we have evaluated their abilities to cause a memory damage 
in the NORT. Of note, unlike Tg PD mouse models, where different α-syn aggregates 
coexist, the use of the acute mouse model specifically allowed us to assess the detrimental 
effects on memory of each extracellular moieties individually, and to characterise this effect 
at behavioural as well as histological level.  
Precisely, two hours before the familiarisation/sample phase of the NORT, C57BL/6 naïve 
mice were ICV injected with Veh or well-characterised solutions enriched in α-syn 
monomers, oligomers or fibrils. The memory performance of each mouse was assessed in 
the test phase 24 hours later (Figure 19A). Thus, an inter-trial time of 24 hours between the 
familiarisation/sample phase and the test phase occurs, such that it allows us to accurately 
test the effect of each moieti on long-term recognition memory. Notably, more than 8 hours 
are required to permit consolidation of long-term memory (Sutton and Schuman, 2006), and 
the 24 hours is the most widely used time point for its evaluation (Balducci et al., 2010; 
Balducci et al., 2017). To further characterise the model, we investigated whether the α-
synO-induced memory damage was specifically mediated by α-syn. To this goal two 
different antibodies, the AβOs specific antibody 4G8 and the Anti-α-syn antibody (ICV, 15 
minutes pre-α-synOs), were tested for their ability to counteract the α-synO-triggered 
memory damage (Figure 19B). Once demonstrated that α-synOs specifically impaired 
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memory performance in the NORT, we further characterised such a detrimental effect. Thus, 
we assessed whether the cognitive impairment was persistent or transient. To address this 
question, mice treated with α-synOs impaired in their memory performance were re-tested 
in the NORT 12 days after the first ICV injection without any other treatment (Figure 19C). 
For a detailed description of drug doses see chapter V about methods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Schematic of treatment schedules for NORT experiments. (A) Monomers, oligomers 
fibrils of α-syn (1μM/7.5μL) ICV injected 2 hours before the familiarisation/sample phase. (B) 
Treatment with 4G8 or Anti-α-syn (0.25μg/2μL) 15 minutes pre-α-synOs injection (1μM/7.5μL).  
(C) Mice re-tested in NORT without any further ICV injection of Veh or α-synOs. 
 
6.2 Results 
6.2.1 Alpha-synOs specifically induce memory deficiency in C57BL/6 naïve mice and 
impair hippocampal LTP on brain slices 
Consistent with the oligomeric hypothesis which pinpoints α-synOs as the main culprits 
underlying a-syn deleterious effects, oligomeric species of α-syn have been demonstrated 
to impair LTP and cause memory damage (Martin et al., 2012).  
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To further assess the detrimental effects of α-synOs on memory in comparison with either 
α-syn monomers or fibrils, we have developed an acute model based on a single ICV 
injection of well-characterised solutions enriched in monomeric, oligomeric or fibrillar α-
syn (7.5μL, 1.0 μM) in C57BL/6 naïve mice. Endotoxin-free recombinant α-syn monomers 
(Figure 20A) were provided by Pollegioni’s team (University of Insubria, Varese, Italy) 
which also characterised the protein and demonstrated the partial random coil structure of 
the protein in solution through far-UV circular dichroism analysis (Caldinelli et al., 2013). 
α-synOs and fibrils used for the experiments were characterised by AFM to verify their 
aggregation status and their distribution in terms of diameter and height (Figure 20B-F). In 
addition, the α-synO solution was further characterised through western blot, which 
confirmed an enrichment in SDS-resistant oligomeric species with a molecular weight 
ranging from 35 to 180 KDa (Figure 20G).   
Figure 20. Native size-exclusion chromatography and tapping mode AFM images. (A) Elution 
profile of purified recombinant α-syn by Superdex-200 column chromatography and SDS-PAGE 
analysis of the eluted protein. (B) α-synO assemblies after incubation for 48 hours, or (C) α-syn 
fibres after 5 days incubation in 50 mM PBS. Scale bars correspond to 2.5 µm for Panels B and C, 
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and 0.5 µm for the Panel B inset. The scale colours correspond to height range of -5/+10 nm for 
Panel B, -30/+50 nm for Panel B inset and -2/+4 for Panel C. (D, E) Oligomer distribution in diameter 
and height. (F) Cross-sectional profiles determined by SPIP and same colour code used to represent 
the regions of images chosen for measurements and their line-profile in samples incubated for 5 days. 
(G) Western blot analysis of α-synO-enriched solution showing SDS-resistant oligomers with a 
molecular weight ranging from 35 to 180 KDa. 
Once verified the nature of our preparations, mice were ICV injected with Veh (7.5 µL), 
monomeric, oligomeric or fibrillar α-syn (1µM/7.5µL) 2 hours before the sample phase of 
the NORT, and memory was investigated 24 hours later. The behavioural assessment of 
long-term recognition memory revealed a significant effect of treatment (F3,41=3.153, 
P=0.03; One-way ANOVA). In particular, we found that mice receiving Veh, monomers or 
fibrils discriminated well between the novel and the familiar object. In fact, as shown in 
figure 21A, they spent more time investigating the novel object than the familiar one, as also 
demonstrated by a comparable DI (mean±SEM) between the three experimental groups 
(0.23±0.06; 0.23±0.06 and 0.22±0.04 respectively). In contrast, α-synO-treated mice did not 
discriminate between the two objects. Indeed, they spent an equal time on both the familiar 
and the novel one, and they showed a significantly lower DI than Veh-treated mice 
(0.23±0.06 and 0.002±0.08 respectively; *p<0.05, One-way ANOVA followed by Dunnet’s 
test; Figure 21A, B).  Of note, it could be speculated that the memory deficiency in α-synO-
treated mice may arise from a reduced exploratory behaviour rather than an effect of α-synOs 
on memory. Thus, such an effect of α-synOs could make treated mice unable to recognise 
the familiar object during the test day. To check whether this bias affected our experimental 
conditions, we compared the total exploration time spent investigating the objects during 
both the sample and the test phase for each experimental group (Figure 21C). As the total 
exploration time during the two NORT phases did not significantly differ between groups, 
as demonstrated by the One-way ANOVA which did not find significant differences among 
groups for both the sample and the test phases (Sample phase: F3,41=0.52 P=0.67; Test phase: 
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F3,41=1.55, P=0.21), we ruled out that the memory impairment triggered by a-synOs was 
due to a lower object exploration. To be noticed that the lower exploratory behaviour during 
the test phase of mice treated with a-syn fibirils (n=11) compared to Veh-treated mice 
(n=11) was due to the presence of two mice in the fibrils-treated group that explored the 
objects for less than 10 seconds. Aside from these mice, the total exploratory behaviour of 
the fibrils-treated group during the test phase became comparable to the Veh-treated group 
(20±3.4 and 24±2.9 sec respectively). Moreover, althought these two mice spent a less time 
in investigating the objects, they did not show a memory impairment having a DI higher than 
0.20 and during these experiments animals did not displayed an impairment of their motor 
performances in the arena.   
To further characterise the α-synO-mediated memory damage, we ascertained whether 
recognition memory was specifically impaired by α-syn. To this aim, we ICV pre-treated 
mice with either a specific anti α-syn antibody or the specific anti-Ab 4G8 antibody with the 
same dose of 0.25μg. As shown in figure 21D, 4G8 pre-treatment did not abolish the effect 
of α-synOs. We found indeed that mice receiving either α-synOs alone or with 4G8 still 
exhibited a significant impairment of their memory performance (DI=-0.12±0.09 and 
DI=0.01±0.0.04 respectively; **p<0.01, One-way ANOVA followed by Tukey’s test) 
compared to Veh-treated mice (DI=0.25±0.04). Conversely, the anti-α-syn antibody pre-
treatment fully abrogated the α-synO-mediated memory deficiency. In fact, mice receiving 
α-synOs alone had a significantly lower DI than mice pre-treated with the anti-α-syn 
antibody (0.02±0.07 and 0.22±0.07 respectively; *p<0.05, One-way ANOVA followed by 
Tukey’s test). Notably, mice receiving the anti-α-syn antibody+α-synOs showed a memory 
performance comparable to Veh-treated mice (DI=0.22±0.07 and DI=0.27±0.05; Figure 
21E).  
Because of the α-synO-mediated memory impairment, and the previous reported ability of 
oligomers to impact on LTP (Diogenes et al., 2012; Martin et al., 2012; Ferreira et al., 2017), 
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we investigated whether our oligomeric preparation could affect this process as well. Mice 
coronal brain slices pre-incubated for 60-90 minutes with α-synOs (200 nM) were used in 
experiments of extracellular field recordings of field excitatory postsynaptic potential 
(fEPSPs) in the CA1 hippocampal region evoked by stimulation of Schaffer collaterals. 
Through this approach, we found that α-synOs significantly reduced LTP (Figure 21F, G).  
Thus, we demonstrated that oligomeric α-syn ICV injected in mice leads to a detrimental 
effect on memory, whereas monomeric and fibrillar α-syn was ineffective. In addition, the 
memory damage we described is not linked to an altered exploratory behaviour of treated 
mice and it is specifically due to α-syn. Consistent with the memory impairment and 
previously reported data, α-synOs affect also the LTP, which is crucial for learning and 
memory. Thus, our findings corroborate the α-syn oligomeric hypothesis, and our acute 
model provides a valuable tool to specifically dissect α-synO detrimental activities on 
memory. 
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Figure 21. A single ICV injection of α-synOs impairs recognition memory and inhibits LTP in 
brain slices.  (A) Histograms are mean±SEM percentage of time spent investigating the familiar and 
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novel object in each experimental group tested in the NORT after treatment with: Veh (n=12), α-syn 
monomers (n=11), α-synOs (n=11) or α-syn fibrils (n=11). (B) Histograms are the mean±SEM of 
the corresponding DI; One-way ANOVA found a significant effect of treatment: F3,41=3.1, P=0.03. 
(*p<0.05, Dunnet’s test). (C) Mean±SEM of total time (sec) spent in the exploration of the objects 
during the familiarisation phase (Sample), and during the test phase (Test) in the different 
experimental groups. One-way ANOVA found no effect of treatment for both the sample and test 
phase (F3,41=0.52, P=0.67; F3,41=1.55, P=0.21 respectively). (D) 4G8 treatment (0.25μg/2μL) 15 
minutes before the ICV injection of α-synOs did not abolish α-synO-mediated memory impairment. 
Histogram are mean±SEM of the DI (Veh+Veh; Veh+α-synOs and 4G8+α-synOs; n=9/group; 
**p<0.01, Tukey’s test). One-way ANOVA found a significant effect of treatment (F2,24=13.4, 
P=0.0001) due to the significant impairment induced by α-synOs and the inability of 4G8 to abolish 
it. (E) Effect of Anti-α-syn (0.25μg/2μL) 15 minutes before the ICV injection of α-synOs. 
Histograms are the DI mean±SEM of mice receiving Veh+Veh (n=9), Veh+α-synOs (n=8) and Anti-
α-syn+α-synOs (n=8). One-way ANOVA found a significant effect of treatment (F2.22=5.8, 
P=0.0096; *p<0.05, Tukey’s test). (F)  LTP in CA1 hippocampal region of Veh- (n=5) versus α-
synO-treated slices (200nM α-synOs 90 min pre-incubation; n=5; p<0.05, Two-way ANOVA for 
repeated measures). Data are presented as time courses (mean ± SEM) of normalised fEPSP slopes. 
Insets are representative traces of fEPSPs before (full line) and after TBS (dashed line), in control 
(black) and α-synOs treated slices (red). (G) fEPSP slope 50-60 min post theta-burst stimulation 
shown as a % (mean±SEM) of pre-stimulation baseline; (***p<0.001, Student’s t-test). 
 
6.2.2 ICV injected α-syn spreads across the hippocampus 
Our behavioural experiments demonstrated an impaired hippocampal-dependent memory 
establishment in the NORT caused by the ICV injection of α-synOs exclusively, whereas 
monomers and fibrils were ineffective. Therefore, we have investigated the ability of each 
moieties to spread from the injection site to the hippocampal parenchyma. As shown in the 
immunofluorescence analysis in Figure 22, monomeric, oligomeric and fibrillar moieties of 
α-syn were detectable in the hippocampus 4 hours after the ICV injection. Thus, our 
observation suggests that either the detrimental effects of α-synOs on memory, or the 
ineffectiveness of α-syn monomers/fibrils were not biased from the inability of our 
aggregates to spread within the hippocampus.   
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Figure 22. ICV injected α-syn moieties spread across the hippocampal parenchyma. 
Representative images of hippocampal section stained with an antibody against human α-syn 
showing green spots of different size across the hippocampus 4 hours after the ICV injection of α-
syn monomers, oligomers and fibrils. 
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6.2.3 Alpha-synO-mediated recognition memory impairment is transient and not 
associated with hippocampal alterations at both neuronal and synaptic level 
To further characterise the α-synO-mediated memory damage, we assessed whether this 
effect was permanent or transient. To this aim, we re-tested α-synO-injected mice which 
previously displayed an impairment in their recognition memory (Veh: DI=0.21±0.04 and 
α-synOs: DI= 0.02±0.0.07; t16=2.24, *P=0.03) 12 days later, with no further injections.  
As shown in figure 23A, mice previously receiving α-synOs performed well in the NORT, 
having a DI comparable to previously Veh-treated mice (0.23±0.06 and 0.29±0.06 
respectively; t16=0.81, P=0.43; Figure 23A). 
 
 
 
 
 
 
 
Figure 23. A single ICV injection of α-synOs transiently impairs recognition memory 
establishment. Histograms are mean±SEM of the corresponding DI at both 24 hours and 12 days 
after the first ICV injection of Veh or α-synOs (n=9/group). 
 
Notably, the transient nature of the α-synO harmful effects on memory was consistent with 
the absence of significant alterations at both cellular organisation and synaptic protein level 
in the hippocampus of treated mice. In fact, we investigated whether the α-synO-mediated 
memory impairment was triggered by hippocampal changes in cellular organisation or 
synaptic structure.  
Two, 4, 8 or 24 hours after α-synO injection mice were sacrificed. By means of a qualitative 
analysis of Nissl stained brain slices we did not find any difference in the neuronal 
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organisation and density in the hippocampal CA1, CA2, CA3 and dentate gyrus of α-synO-
treated mice at any time point considered compared to Veh-treated animals (Figure 24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. A single ICV injection of α-synOs does not alter neuronal organisation in the 
hippocampus. Representative images of Nissl staining coronal hippocampal sections and 
magnification of different hippocampal subfield 2, 4, 8 and 24 hours after α-synOs (3/group). 
Moreover, we did not find any changes in the expression of representative pre- and post-
synaptic proteins such as synaptophysin and PSD-95 at either 4- or 24-hours post-injection 
(Figure 25A-F). In fact, analysis of the optic density for both synaptophysin and PSD 95 had 
demonstrated the absence of significant differences between Veh- and α-synO-treated mice 
(PSD95 4 hours: t8=0.12, P=0.89; PSD95 24 hours: t8=1.03, P=0.33; synaptophysin 4 hours: 
t8=0.26, P=0.82 and, synaptophysin 24 hours: t8=1.07, P=0.31). 
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Together, our findings demonstrate that α-synOs lead to a transient memory impairment 
which is most likely dependent on a synaptic dysfunction rather than synaptic and neuronal 
loss.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. A single ICV injection of α-synOs does not alter synaptic markers in the 
hippocampus. (A-F) Immunoblot analysis for ipsilateral hippocampal (5 mice/group) PSD95 and 
synaptophysin expression, and relative quantification at both 4 and 24 hours. As demonstrated by 
the statistical analyses α-synOs do not affect the protein levels of either PSD95 or synaptophysin in 
each time point considered.  
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6.3 Discussion 
Compelling evidence highlights α-syn as the main factor in the pathogenesis of PD and PD-
related disorders. In pathological conditions, aggregation of α-syn leads to the production of 
small, soluble aggregates, namely oligomers, protofibrils and fibrils. α-synOs are 
heterogeneous and can vary in composition, structure and toxicity (Roberts and Brown, 
2015). Consistent with the heterogeneous toxic profile of α-synOs, they are not all 
recognised as deleterious because hypothetically some of them might exert physiological 
functions, and furthermore the detrimental effects on neurons may be different upon 
exposure to different oligomeric conformations (Danzer et al., 2007; Roberts and Brown, 
2015). Regardless such a variability, the main accepted hypothesis in the field posits that α-
synOs can be secreted by neurons and could be the main detrimental species involved in the 
pathogenesis of α-synucleinopathies, leading to cognitive dysfunction (Martin et al.,  2012; 
Diogenes et al., 2012; Forloni et al., 2016; Ono, 2017), which is commonly found among 
PD and LBD patients.  
To test the “oligomeric hypothesis”, we took advantage of an acute mouse model based on 
a single ICV injection of different well-characterised α-syn moieties (monomer, oligomers, 
fibrils) in C57BL/6 naïve mice. Treated mice were tested for their memory in the NORT. 
We demonstrate that a single ICV injection of a solution enriched in α-synOs specifically 
caused a significant impairment in long-term memory. In contrast, monomers and fibrils 
were ineffective. The memory impairment we describe is specifically triggered by α-syn. In 
fact, while pre-treatment with an anti-α-syn antibody completely prevented the memory 
damage, pre-treatment with 4G8, which does not recognise α-syn but binds to oligomeric 
assemblies of Aβ (Stravalaci et al., 2012), was inactive.  
The memory deficit was not associated with neuronal loss or disorganisation in hippocampal 
cell layers. Similarly, no changes were detected in the expression of representative synaptic 
proteins. In fact, we did not find alterations of pre- and post-synaptic markers such as 
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synaptophysin or PSD95. In line with the absence of hippocampal structure alterations, we 
demonstrate that 12 days after the ICV injection of α-synOs, mouse memory was restored 
and comparable to the Veh-treated mice. Thus, in our acute mouse model, α-synOs lead to 
a transient rather than a persistent memory impairment. 
To further address the detrimental action of α-synOs on memory, we investigated their effect 
on LTP, an experimental paradigm for studying the synaptic plasticity, which is a vital 
process in the consolidation of new memories. In fact, the absence of changes in synaptic 
structure would not rule out the occurrence of synaptic dysfunction. In agreement with 
previous reported data (Diogenes et al., 2012; Martin et al., 2012; Ferreira et al., 2017), 
electrophysiological recordings confirmed that pre-incubation of brain slices with α-synOs 
severely reduces the amplitude of LTP. In addition, while we clearly depict α-synOs as the 
sole moieties leading to memory impairment in mice, we rule out the effectiveness of α-syn 
monomers and fibrils in the same process. 
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Alpha-synO-mediated memory impairment is 
dependent on glial activation and TLR2 
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The data presented in this chapter are reported in the manuscript entitled “Alpha-synuclein 
oligomers impair memory through glial cell activation and via Toll-like receptor 2”. Brain 
Behav Immun. 2018 Mar; 69:591-602. doi: 10.1016/j.bbi.2018.02.012.  
 
7.1 Aim of the study and experimental design 
In the following section we sought to address the role of neuroinflammation in mediating 
the harmful activities of α-synOs on memory. In fact, despite initially considered as a mere 
secondary event, neuroinflammation has acquired an increasing interest in the pathogenesis 
of α-synucleinopathies.  
Astrocytes and microglial cells are the main cellular components within the CNS. In spite of 
their different embryogenic origin, both astrocytes and microglial cells are immune-
competent cells in the brain, and they play essential functions in maintaining brain 
homeostasis (Hertz and Chen, 2016). In healthy brains, astrocytes and microglial cells are 
juxtaposed to neurons and directly contact synapses at both pre- and post-synaptic level. 
This way, they are strictly involved in the surveillance of synaptic function and synaptic 
plasticity, which is a key player in governing learning and memory (Blank and Prinz, 2013). 
In response to various stimuli, including α-synOs, they become activated and able to release 
several pro-inflammatory factors which may trigger neuronal dysfunction (Fellner et al., 
2013; Kim et al., 2013; Morris et al., 2013; Blank and Prinz, 2013; Ramikko et al., 2015: 
Kim et al., 2016). 
As a consequence, the uncontrolled activation of glial cells might deprive neurons of 
regulatory surveillance, and lead to impairment of synaptic plasticity and cognitive functions 
(Morris et al., 2013; Richwine et al., 2009). 
As described in chapter III, initiation of an inflammatory response generally occurs after the 
recognition of DAMPs or PAMPs by PRRs such as TLRs. TLRs have been widely 
investigated in the context of PD (Kouli et al., 2019). In particular, as previously described, 
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TLR2 and TLR4 have been identified as potential interactors for α-synOs. However, the 
precise contribution of the two receptors in mediating α-synO detrimental effects still 
remains unknown and a matter of debate (Kouli et al., 2019). 
Based on the evidence reported here, and on the gap of knowledge about the TLRs 
involvement in mediating α-synO detrimental effects, we herein aimed at: I) assessing 
whether α-synOs are capable of activating microglial and astroglial cells in the hippocampus 
in our acute mouse model; II) evaluating the contribution of the α-synO-induced 
neuroinflammation in triggering the memory damage as reported in chapter VI; and III) 
investigating the role of both TLR2 and TLR4 as mediators for α-synO-induced memory 
damage to get new insights on the mechanisms underlying α-synO detrimental effects. 
To assess the presence of α-synO-induced astrogliosis and microgliosis in our acute mouse 
model, C57BL/6 naïve mice were ICV injected with α-synOs (1μM/7.5μL) or Veh and 
sacrificed at different time points (2, 4, 8, 24 hours) post-treatment. Then, activation of both 
astroglial and microglial cells in the hippocampus was investigated through 
immunofluorescence. 
Once confirmed that the ICV injection of α-synOs was able to trigger a neuroinflammatory 
response, we addressed whether the α-synO-induced neuroinflammation was involved in 
mediating the memory damage taking place in α-synO-treated mice. To this purpose, we 
tested whether two different anti-inflammatory drugs (Indo and IBF, IP injected 30 minutes 
before α-synO ICV injection) could counteract the α-synO-induced memory deficiency 
(Figure 26A). In addition, through immunohistochemical approaches we assessed the 
activation state of astroglial and microglial cells in the hippocampus of mice treated with the 
anti-inflammatory drugs and α-synOs. Of note, assessment of the activation of glial cells 
was performed at the time point corresponding to the peak of glial activation (4 hours post 
α-synO ICV injection as described in the results). To get new insight into the role of TLRs 
in mediating α-synO detrimental effects on memory, we investigated the role of TLR4 and 
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TLR2. Specifically, TLR4 knock-out mice (TLR40/0) and WT mice were ICV injected with 
either α-synOs or Veh, and their memory performance tested in the NORT (Figure 26B). 
Consistent with the large body of evidence reporting the involvement of TLR2 in the 
pathogenesis of PD and PD-related disorders (Kim et al., 2013; Kim et al., 2016; Kim et al., 
2018), we also assess the role of TLR2 in mediating α-synO-induced memory deficiency in 
our acute mouse model. To this goal, we ICV pre-treated C57BL/6 naïve mice with the 
functional blocking antibody against TLR2 (T2.5) 15 minutes before α-synO or Veh 
injection (Figure 26C). For a detailed description of drug doses please see chapter V. 
 
 
Figure 26. Schematic representation of treatment schedules for NORT experiments. (A) IP 
treatment with Indo (10mg/Kg) and IBF (5,10 and 50mg/Kg) 30 minutes before the ICV injection of 
α-synOs (1μM/7.5μL). (B) α-synOs treatment (1μM/7.5μL) in C57BL/6 naïve mice and TLR40/0 
mice. (C) ICV treatment with the functional inhibiting anti-TLR2 antibody T2.5 (5μg/2μL) 15 
minutes before the ICV injection of α-synOs (1μM/7.5μL). 
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7.2 Results 
7.2.1 Alpha-synO-mediated memory impairment is associated with hippocampal 
neuroinflammation  
To determine whether α-synOs triggered the activation of glial cells in our acute mouse 
model, C57BL/6 naïve mice were ICV injected with α-synOs (1µN/7.5µL) and their gliosis 
was investigated at 2, 4, 8 and 24 hours post-injection. By immunofluorescence, we found 
that both astrocyte (GFAP) and microglial (IBA1) activation in the hippocampus was mainly 
detectable 4 hours after the α-synOs injection (Figure 27), whereas at 8 and at 24 hours post-
treatment glial cells returned close to a resting state similar to that of Veh-treated mice.  
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Figure 27. A single α-synO injection induces transient glial cell activation in hippocampus. 
Representative immunofluorescence images showing hippocampal slices stained for astrocytes 
(blue), microglia (red) and IL-1β (green). While a significant glial cell activation occurs 4 hours after 
α-synOs injection compared to mice receiving Veh, no difference in the expression of IL-1β is 
detectable. 
We recently reported that a single injection of AbOs in a similar acute mouse model impaired 
memory in close association with gliosis and increased expression of the pro-inflammatory 
cytokine IL-1b which peaks at 8 hours post-injection, and mediated AbO-induced memory 
damage (Balducci et al., 2017). Based on this evidence, we investigated whether a similar 
outcome also occurred in α-synO-treated mice.  In contrast to AbOs, we found that α-synOs 
treatment did not lead to increased IL-1b levels (Figure 27 and 28). Thus, we hypothesised 
that different pathways may at play in mediating the neuroinflammatory response triggered 
by α-synOs or AbOs. Of note, the different time point chosen for our investigation in α-
synO- or AbO-treated mice was based on our previous evidence (Balducci et al., 2017) 
showing that in AbO-treated mice gliosis picked at 8 hours after the ICV injection. Thus, we 
have investigated IL-1b expression at the time points corresponding to the maximal glial 
activation (4 hours after α-synOs and 8 hours after AbOs ICV injection). 
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Figure 28. A single α-synO injection does not increase the expression of the pro-inflammatory 
cytokine IL-1β.  Representative images comparing hippocampal astrogliosis (blue), microgliosis 
(red) and IL-1β (green) expression after ICV injection of Veh, α-synOs (4 hours post-injection; top 
line) and AβOs (8 hours post-injection; bottom line). Of note, the two time points were chosen based 
on the maximal glial activation triggered by α-synOs or AβOs in our acute mouse models. 
 
 
7.2.2 Neuroinflammation is a crucial mechanism involved in α-synO-mediated memory 
damage 
As we demonstrated that α-synOs lead to activation of astrocytes and microglial cells, we 
checked whether neuroinflammation is implicated in the α-synO-induced recognition 
memory impairment in our model. To address such a question, we tested whether two 
NSAIDs (Indo and IBF) could prevent α-synO-induced memory damage. 10mg/Kg Indo, 
which was previously found to be active in abolishing AβO-induced memory impairment 
(Balducci et al., 2017), was IP administered 30 minutes before the ICV injection of α-synOs. 
We found that Indo pre-treatment significantly abolished the memory impairment caused by 
α-synOs (Figure 29). In fact, while mice injected with Veh+α-synOs had a significantly 
lower DI (mean±SEM) than Veh+Veh-treated animals (0.005±0.06 and 0.26±0.05 
respectively; **p<0.01, Two-way ANOVA followed by Tukey’s test), mice treated with 
Indo+α-synOs had a DI comparable to Veh+Veh-treated mice (0.30±0.04), and higher than 
mice receiving Veh+α-synOs (0.005±0.06; **p<0.01, Two-way ANOVA followed by 
Tukey’s test). Thus, these data support the hypothesis that α-synOs trigger a 
neuroinflammatory response which in turn contributes to the induction of memory 
impairment.  
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Figure 29. Indo pre-treatment counteracts α-synO-induced memory impairment. Effect of 
10mg/Kg Indo pre-α-synOs on memory. Two-way ANOVA found a significant effect of α-synOs 
(F1,65=4.4, P=0.04), a significant effect of Indo (F1,65=8.0, P=0.0061) and a significant interaction 
Indo x α-synOs (F1,65=6.9, P=0.01). Mean±SEM of the DI of mice tested in the NORT (Veh+Veh 
n=20; Indo 10mg/Kg+Veh n=15; Veh+α-synOs n=19 and Indo 10mg/Kg+α-synOs n=15; **p<0.01, 
Tukey’s test). 
To confirm that the amelioration of mouse memory performances triggered by Indo pre-
treatment was due to the lack of α-synO-mediated neuroinflammation, we histologically 
evaluated the extent of hippocampal gliosis 4 hours post the ICV injection. As described 
above, this time point was selected based on the evidence that 4 hours post α-synO-treatment 
corresponded to the time point with the peak of glial cell activation in our model. As shown 
in figure 30A, we found that Indo pre-treatment led to a reduction of both IBA1- and GFAP-
immunoreactivity compared to Veh+α-synO-treated mice, which was also confirmed by the 
quantitative analysis of the percentage of IBA1- and GFAP-immunopositive area (Figure 
30B and C).  
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Figure 30. Glial cell activation induced by α-synOs is hampered by Indo pre-treatment. (A) 
Representative staining for IBA1 (top) and GFAP (bottom) in hippocampal CA1 region of Veh+Veh 
(n=4), Veh+α-synOs (n=4) and Indo 10mg/Kg+α-synOs (n=4) 4 hours post ICV injection. 
Histograms are the quantitative analysis of the percentage (mean±SEM) of marked area for IBA1 
(B) and GFAP (C); (*p< 0.05, **p<0.01 and ****p<0.001 compared to Veh+α-synOs; Bonferroni’s 
test). 
To further ascertain that the glial response is involved in the detrimental action of oligomers 
on memory, we pre-treated C57BL/6 mice with a second NSAID, IBF at 5, 10 and 50 mg/Kg 
(IP 30 minutes before α-synOs). As shown in figure 31, we demonstrated that IBF 
counteracted the α-synO-mediated memory deficiency. In fact, mice receiving IBF at the 
dose of 50 mg/Kg and α-synOs (IBF 50+α-synOs) performed well in the NORT, having a 
significantly higher DI (mean±SEM) than those treated with Veh+α-synOs (0.24±0.04 and 
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-0.06±0.07 respectively; *p<0.05, One-way ANOVA followed by Tukey’s test), and 
comparable to that of Veh+Veh treated animals (0.27±0.03). In contrast, IBF at the lower 
doses of 5 and 10 mg/Kg were ineffective. 
 
 
 
 
 
 
Figure 31. IBF pre-treatment counteracts α-synO-induced memory impairment. Effect of 5,10 
and 50mg/Kg IBF pre-α-synOs on mouse memory performances. One-way ANOVA found a 
significant effect of treatment (F5,37=6.095, P=0.0003) due to the significant impairment induced by 
α-synOs and the ability of IBF at the dose of 50mg/Kg to abolish it. Histograms are the DI 
(mean±SEM) of mice tested in the NORT (Veh+Veh n=10; IBF 50mg/Kg+Veh n=6; Veh+α-synOs 
n=10; IBF 5mg/Kg+α-synOs n=5; IBF 10mg/Kg+α-synOs n=6 and IBF 50mg/Kg +α-synOs n=6; 
**p<0.01 and *p<0.05, Tukey’s test). 
To pinpoint whether the IBF effect on memory was linked to the blocking of α-synO-
mediated glial cell activation, we evaluated the IBF ability in preventing α-synO-mediated 
hippocampal gliosis 4 hours post ICV injection. As shown in figure 32A, IBF at the active 
dose of 50 mg/Kg induced a significant reduction of both IBA1- and GFAP-
immunoreactivity compared to Veh+α-synOs-treated mice. Qualitative data were then 
confirmed by quantitative analysis of the percentage of IBA1- and GFAP-marked area 
(Figure 32B and C).  
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Figure 32. Glial cell activation induced by α-synOs is hampered by IBF pre-treatment. (A) 
Representative staining for IBA1 (top) and GFAP (bottom) in hippocampal CA1 region of Veh+Veh 
(n=4), Veh+α-synOs (n=4) and IBF 50mg/Kg+α-synOs 4 hours after the ICV injection (n=4). 
Histograms are the quantitative analysis of the percentage (mean±SEM) of marked area for IBA1 
(B) and GFAP (C); (*p< 0.05 and **p<0.01 compared to Veh+α-synOs; Bonferroni’s test). 
Thus, we herein demonstrate that α-synOs triggered the activation of both astroglial and 
microglial cells. Moreover, our data show that neuroinflammation is a mechanism involved 
in mediating the detrimental effects of oligomers on memory. In fact, two different NSAIDs 
restore mice memory performances suppressing the α-synO-induced neuroinflammatory 
response. 
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7.2.3 Alpha-synOs lead to gliosis in the hippocampus whereas monomers and fibrils 
are ineffective 
Our findings indicate that the detrimental effect of oligomeric α-syn on memory 
establishment is tightly associated to microglial and astroglial cell activation. Hence, we 
addressed whether monomeric or fibrillar α-syn, which did not affect cognitive performance 
(described in section 6.2.1), were also ineffective in triggering hippocampal gliosis. 
To this aim, we ICV injected C57BL/6 naïve mice with α-syn solutions enriched in 
monomers, oligomers or fibrils, and both hippocampal IBA1- and GFAP-immunoreactivity 
were investigated 4 hours post-injection. Consistent with the results reported above, the ICV 
injection of α-synOs led to a significant increase in both GFAP- and IBA1-marked area 
compared to Veh-treated animals (Figure 32A-C). In contrast, we found that monomeric and 
fibrillar α-syn were ineffective (Figure 33A). In fact, our quantitative analysis of both GFAP- 
and IBA1-marked area confirmed the absence of glial cell activation in mice receiving either 
monomers or fibrils compared to Veh-treated animals (Figure 33B and C).  
Therefore, we herein demonstrate that the neuroinflammatory response is specifically caused 
by α-synOs. Intriguingly, monomers and fibrils, which do not affect memory establishment 
are also ineffective in triggering either astrogliosis or microgliosis, strongly supporting the 
hypothesis that neuroinflammation is a crucial mechanism involved in mediating the harmful 
effects of oligomers.  
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Figure 33. Hippocampal gliosis is specifically induced by α-synOs whereas monomers and 
fibrils are ineffective. (A) Representative images showing hippocampal slices immunostained for 
IBA1 (top) or GFAP (bottom) of mice receiving Veh, monomeric, oligomeric or fibrillar α-syn 4 
hours post-treatment (4/group). (B, C) Histograms are the quantitative analysis of the marked area 
percentage (mean±SEM) of Veh-, monomer-, α-synO- and fibril-treated mice for either the 
microglial marker IBA1 (B) or the astroglial marker GFAP (C). One-way ANOVA found a 
significant effect of treatment for both IBA1 (F3,12 = 25.89, P < 0.0001) and GFAP (F3,12 = 6.37, P < 
0.01); (***p < 0.0001, *p < 0.05 compared to Veh; Bonferroni’s test). 
 
7.2.4 Alpha-synO-mediated memory impairment is TLR2-dependent 
To get more insight into the immune mechanism underlying the α-synO-mediated memory 
impairment we focused on TLR4 and TLR2.  
Based on the evidence collected through our AD acute mouse model, which indicated that 
both AbO-mediated memory impairment and neuroinflammation are TLR4 dependent 
(Balducci et al., 2017), we investigated whether TLR4 could also be responsible for the 
harmful actions of α-synOs. To this end, α-synOs were ICV injected in TLR40/0 and 
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subsequently their memory performance was tested in the NORT. As shown in figure 34, 
we found that α-synOs retained their detrimental action on memory in TLR40/0 mice as well 
as in WT mice. In fact, TLR40/0 mice receiving α-synOs displayed a significantly lower DI 
(mean±SEM) than TLR4+/+ mice injected with Veh (0.01±0.04 and 0.28±0.05 respectively; 
**p<0.01, Two-way ANOVA followed by Tukey’s test).  
 
 
 
 
 
 
 
Figure 34. Alpha-synO-triggered memory damage is TLR4-independent. Histograms are the DI 
(mean±SEM) of either C57BL/6 naïve mice or TLR40/0 mice ICV injected with Veh or α-synOs 
(C57+Veh n=11, C57+α-synOs n=7, TLR40/0+Veh n=7 and TLR40/0+α-synOs n=7). Two-way 
ANOVA found a significant effect of α-synOs (F1,28=23.3) but a not significant effect of genotype 
(F1.28=0.02, P=0.89), and a not significant interaction genotype x α-synOs (F1.28=0.07, P=0.79; 
*p<0.05 and**p<0.01, Tukey’s test). 
 
Accordingly, as described in chapter III, Kim and colleagues reported that α-synO non-cell-
autonomous mechanisms, such as activation of glial cells, might occur via TLR2 and are 
independent of TLR4 (Kim et al., 2013; Kim et al., 2016). To address whether α-synOs exert 
their deleterious action on memory in a TLR2-dependent manner, we pre-treated C57BL/6 
naïve mice with the functional blocking antibody T2.5 at the dose of 2.5μg/2μL ICV 15 
minutes before the injection of Veh or oligomers. In stark contrast with the data we obtained 
in TLR40/0 mice, the T2.5 pre-treatment completely abolished the α-synO-mediated memory 
deficiency (Figure 35). In fact, T2.5+α-synO-treated mice performed well in the NORT, 
showing a DI (mean±SEM) significantly higher than those receiving Veh+α-synOs 
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(0.38±0.05 and 0.01±0.05 respectively: ****p<0.0001, Two-way ANOVA followed by 
Tukey’s test). 
 
 
 
 
 
 
 
Figure 35. Alpha-synO-triggered memory damage is TLR2-dependent. Histograms are the DI 
(mean±SEM) of mice ICV injected with Veh+Veh, T2.5+Veh, Veh+α-synOs and T2.5+α-synOs 
(n=7/group). Two-way ANOVA found a significant interaction T2.5 x α-synOs (F1,24=29.24, 
P=0.0001; **p<0.0001 and ****p<0.00001, Tukey’s test). 
Collectively, our data are consistent with the evidence provided by Kim and colleagues, and 
indicate that α-synOs impair memory establishment through pathways other than those 
involved in mediating AβO deleterious effects. In particular, our findings indicate that α-
synOs act in a TLR2-dependent manner and independently of TLR4.  
 
7.3 Discussion 
Originally introduced in the context of AD, the oligomeric hypothesis has been recently 
applied to PD and PD-related disorders. Consistently, oligomeric aggregates of Aβ as well 
as α-syn are identified as the main harmful species underlying the pathogenesis of AD and 
PD, respectively (Scott et al., 2010; Winner et al., 2011; Mucke and Selkoe, 2012; Balducci 
and Forloni, 2014; Forloni et al., 2016; Ono, 2017). In fact, while both AβOs and α-synOs 
have been reported to affect synaptic plasticity and to impair memory, their monomers and 
fibrils are ineffective (Balducci et al., 2010; Diogenes et al., 2012; Martin et al., 2012; La 
Vitola et al., 2018).  
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As previously described, in pathological and stress conditions neurons increase the amount 
of α-synOs being secreted in their milieu. Thus, extracellular α-synOs may contribute to the 
pathogenesis of PD and PD-related disorders by exerting their detrimental action in a non-
cell autonomous fashion which involves neurons, astrocytes and microglial cells. In this 
regard, many groups started focusing their efforts on the non-cell autonomous actions of α-
synOs. Their data demonstrate that oligomeric α-syn triggers the activation of glial cells, 
which in turn produce and release several pro-inflammatory mediators leading to 
neuroinflammatory damage of neurons (Fellner et al., 2013; Kim et al., 2013; Ramikko et 
al., 2015; Kim et al., 2016). The role of neuroinflammation in mediating memory damage 
is strongly supported by evidence from animal models of AD. In an acute mouse model of 
AD, AβOs impair memory performance through glial activation and increase of pro-
inflammatory cytokines expression (Balducci et al., 2017). Intriguingly, the block of 
neuroinflammation resulted in the rescue of memory functions both in an acute and in the 
APP/PS1 Tg mouse model of AD (Balducci et al., 2017; Balducci et al., 2018). Since α-
synOs have been detected in the extracellular fluids, researchers have speculated that α-
synOs like AβOs may exert their own detrimental activities through indirect non-cell-
autonomous mechanisms which include glial cell activation. Thus, neuroinflammation might 
represent a process underlying cognitive decline in the context of α-synucleinopathies. 
Despite initially considered as a consequence of the neurodegenerative process which takes 
place in PD and its related disorders, neuroinflammation is now emerging as a mechanism 
fostering α-synO deleterious activities. 
Astrocytes as well as microglial cells have vital roles at the neuronal level, and they are 
crucial players in the fine tuning of neuronal activity and synaptic plasticity (Bacci et al., 
1999; Blank and Printz, 2013; Hertz and Chen, 2016). Therefore, perturbation of their 
function/state might lead to neuronal damage, dysfunction and ultimately death (Morris et 
al., 2013; Blank and Prinz, 2013).  
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To decipher the role of the neuroinflammatory response in mediating the memory damage 
triggered by α-synOs, we investigated whether the memory deficit mediated by α-synOs in 
our acute mouse model was associated with glial cell activation. Our results indicated that, 
a single ICV injection of α-synOs triggered a transient activation of glial cells in the 
hippocampus. In fact, we found that 4 hours after treatment glial cells displayed an increase 
in cell density and body enlargement compared to mice receiving Veh. In contrast to AbOs, 
the expression of IL-1β after α-synOs did not change. This difference is intriguing and highly 
significant. In fact, although protein-misfolding neurodegenerative disorders share common 
neuropathological features, they may differ in the action mechanism of oligomers derived 
from their own related causative protein. 
To ascertain whether α-synO-mediated neuroinflammation was involved in the memory 
damage caused by α-synOs in the acute mouse model we developed, we pre-treated mice 
with either Indo or IBF, two NSAIDs able to cross the BBB and to inhibit both 
cyclooxygenase I (COX1) and cyclooxygenase II (COX2). We found that Indo and IBF both 
ameliorated the memory performances of α-synO-treated mice. Moreover, the behavioural 
effect of Indo and IBF pre-treatment correlated with a drastic protection against α-synO-
mediated hippocampal gliosis. Thus, our findings highlight the implication of glial cell 
activation in the α-synO-mediated memory impairment, and they are consistent with 
previous data reported by Drouin-Ouellet and co-workers. In fact, they demonstrate that the 
treatment of a Tg PD mouse model with a COX-2 inhibiting anti-inflammatory drug 
abrogates neuroinflammation and restores motor behaviour performances (Drouin-Ouellet 
et al., 2015). 
The initiation of the inflammatory response generally starts after the recognition of DAMPs 
or PAMPs by PRRs such as TLRs. TLRs are first line players involved in the innate immune 
response and are able to detect both exogenous and endogenous signals including misfolded 
and aggregated α-syn. TLRs have been widely investigated in the context of PD, and despite 
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their contribution in α-synucleinopathies is controversial and debated, evidence for TLR2 or 
TLR4 engagement in such pathologies raises from several observations (Letiembre et al., 
2009; Béraud et al., 2011; Fellner et al., 2013; Kim et al., 2013; Drouin-Ouellet et al., 2015; 
Rannikko et al., 2015 Kim et al., 2016; Kouli et al., 2019). 
To shed light on this aspect and to reveal potential mechanisms of action of α-synOs, we 
investigated whether TLR4 mediates memory loss. Our findings demonstrate that memory 
impairment caused by α-synOs is TLR4-independent. Indeed, α-synOs ICV injected either 
in C57BL/6 naïve mice or in TLR40/0 mice equally impaired their memory. On the other 
hand, we showed that the functional block of TLR2 completely preserved memory loss in 
mice ICV treated with oligomers.  
To assess the role of TLR4 in mediating α-synO detrimental effect on memory we used 
TLR40/0 mice, whereas to investigate the involvement of TLR2 a pharmacological approach 
with a specific inhibitor was carried out. The reason why we opted for such a tool is that a 
reliable model of TLR20/0 is available solely on the 129 mouse background,  which are not 
suitable for cognitive behavioural studies.  
One may speculate that the effect of our TLR2 functional blocker (T2.5) could result from a 
direct interaction of T2.5 with α-synOs, which might prevent oligomers from exerting their 
detrimental actions. Although this possibility has not been addressed in this thesis, some 
evidence exists that can rule out this hypothesis: 1) T2.5 has been described as a high specific 
blocker for TLR2, and 2) several studies exploiting the TLR2 blocker did not report any 
direct binding with α-synOs, but only indirect effects such as block of α-synO neuron-to-
neuron transmission or inhibition of the inflammatory response after α-synOs exposure (Kim 
et al., 2013; Kim et al., 2016; Kim et al., 2017).   
Thus, our data clearly indicate that α-synOs exert their harmful effects in a TLR2-dependent 
manner and they support TLR2 as a potential candidate for therapeutic approaches. 
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Consistently, Kim and colleagues recently report that the immunotherapy against the TLR2 
in a Tg PD mouse model leads to neuroprotective effects (Kim et al., 2018). 
Collectively the results here described pinpoint the modulation/inhibition of inflammatory 
mediators (COX1, COX2 and TLR2) as valuable strategies to counteract α-synO-mediated 
deleterious effects. However, as COX1, COX2 and TLR2 are also expressed by neurons, we 
cannot rule out a direct action of α-synOs on neurons resulting in subsequent glial activation. 
Of note, recently, Dzamko and co-workers showed that TLR2 is up-regulated in both 
microglia and neurons within the brain of PD patients and that the neuronal stimulation 
through TLR2 agonists leads to a significant increase in the expression of pro-inflammatory 
mediators by neurons themselves (Dzamko et al., 2017). Thus, neurons appear to play an 
active role in the neuroinflammatory process in concert with glial cells. A synergistic action 
of α-synOs both on neurons and glial cells is more likely plausible than an effect of 
extracellular oligomers exclusively on neurons.  
In conclusion, our findings strongly support the involvement of the neuroinflammatory 
response in mediating detrimental effects of α-synOs and further depict neuroinflammation 
as a crucial player in the pathogenesis of α-synucleinopathies, and not merely as a secondary 
event triggered by the underlying neurodegeneration. Moreover, the acute mouse model we 
developed appears as a valid tool to specifically investigate the detrimental activities of α-
synOs and to investigate their action mechanisms. 
Results: Chapter VIII 
 
 
127 
 
 
 
 
Results 
Chapter VIII 
Alpha-synO harmful actions are not dependent on 
the cellular Prion protein 
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The data presented in this chapter are reported in the manuscript entitled “Cellular prion 
protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects”. 
Brain. 2019 Feb 1;142(2):249-254. doi: 10.1093/brain/awy318. 
8.1 Aim of the study and experimental approaches 
To uncover the mechanisms underlying the detrimental effects of α-synOs, several 
biological fields have been widely explored. The most common scenarios taken into account 
to explain how oligomers induce cellular dysfunction and eventually death include: I) 
alterations in membrane permeability (Danzer et al., 2007; Tsigelny et al., 2012;); II) 
neuroinflammation (Fellner et al., 2013; Kim et al., 2013; Kim et al., 2016; La Vitola et al., 
2018); III) protein-protein interaction (Betzer et al., 2015).  
With regard to protein-protein interaction, a recently emerged oligomer-protein interactor is 
PrPC, which was initially described as mediator of AβOs detrimental effects and more 
recently proposed as interactor of α-synOs (Lauren et al., 2009; Ferreira et al., 2017).  
Based on these findings, we aimed to further investigate the α-synO-PrPC interaction using 
direct approaches. In vitro, we compared the toxicity of α-synOs in either PrP+/+ or PrP0/0 
primary hippocampal neurons. In vivo, attempting to elucidate the role of the PrPC in 
mediating the α-synO-induced memory deficit, we exploited the acute mouse model 
described in chapters VI and VII. Specifically, both PrP+/+ and PrP0/0 mice were ICV injected 
with Veh or α-synOs (1μM/7.5μL) 2 hours before the familiarisation/sample phase of the 
NORT. Thus, memory performance of each mouse was assed 24 hours later (Figure 36).  
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Figure 36. Schematic representation of treatment schedule for the NORT experiments. α-synOs 
(1μM/7.5μL) in both Prnp+/+ and Prnp0/0 were ICV injected 2 hours before the familiarisation/sample 
phase. 
We previously reported that the neuroinflammatory response triggered by the ICV injection 
of α-synOs is crucial in mediating their detrimental activities on memory (chapter VII and 
La Vitola et al., 2018). Therefore, we further investigated the role of the PrPC in mediating 
the hippocampal astroglial and microglial cell activation in either PrP+/+ or PrP0/0 mice 4 
hours after the ICV injected with Veh or α-synOs (1μM/7.5μL). Of note, assessment of the 
activation of glial cells has been performed at this time point since it corresponds to the 
maximal glial activation in our acute model (chapter VII and La Vitola et al., 2018). In 
addition, at the molecular level, we verified the existence of a direct binding between α-
synOs and PrPC by SPR, using the same approach previously exploited in our laboratory in 
the biochemical studies on the AβO-PrPC interaction (Balducci et al., 2010). 
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8.2 Results 
8.2.1 Alpha-synO-mediated detrimental effects are PrPC-independent    
To specifically address the PrPC involvement in mounting α-synO harmful effects, we took 
advantage of both in vitro and in vivo approaches. In particular, to assess whether the PrPC 
is required for triggering α-synO-induced toxicity in vitro, we measured both Prnp+/+ and 
Prnp0/0 primary hippocampal neuron survival upon 48 hours exposure to α-synOs at 1, 5 and 
10 μM. In order to ascertain the presence of α-synOs, we had previously characterised  
our preparation at all doses being used in our experiments through AFM and Western 
Blotting. As shown in figure 37, the results obtained through our AFM analyses proved the 
presence of oligomeric assemblies with similar diameter ranging from 15 to 40 nm and 
notably demonstrate the absence of larger aggregates in each condition investigated (Figure 
37A-C left and middle panel). In line with the AFM data, a comparable distribution of 
oligomeric assemblies at 1, 5 and 10 μM was also demonstrated by our western blotting 
analyses (Figure 37A-C right panel), which showed the presence of SDS-resistant α-synOs 
with a molecular  weight ranging from 35 to 100 KDa in each preparation. 
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Figure 37. Atomic Force Microscopy and Western Blotting: characterisation of α-synO 
preparation (1, 5 and 10 μM).  Representative tapping mode of AFM images (left panels) as 
determined by amplitude data of oligomeric samples at 1 (A), 5 (B) and 10 µM (C). The colour scale 
bars correspond to an amplitude range of − 15 to + 15 mV for the main figures and – 12 to + 20 mV 
for insets. Histograms (middle panels) show the diameter frequency distribution of the different 
assemblies obtained for 1 (A), 5 (B) and 10 µM (C). The diameter frequency is similar for the 3 
preparations with a distribution between 15 and 40 nm. Western blot analysis (right panels) of α-
synOs at 1 (A), 5 (B) and 10 µM (C) showing different SDS-resistant assemblies ranging from 35 to 
100 KDa.  
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In vitro, we found that the PrPC was not a prerequisite for α-synO detrimental effects. In fact, 
independently of the genotypes considered (Prnp0/0 and Prnp+/+), the 48 hours exposure of 
hippocampal neurons to α-synOs (1, 5, and 10 μM) led to a significant reduction of the 
neuronal viability measured through the MTT assay (Figure 38), and as proved by the two-
way ANOVA showing a significant effect of α-synOs (F3, 46=24.7; P<0.0001) but a non-
significant interaction α-synOs x genotype (F3, 46=0.70; P=0.56). Thus, our evidence 
indicates that α-synO cytotoxicity is not dependent on the PrPC.   
 
 
 
 
 
 
 
 
Figure 38. Alpha-synO-mediated cytotoxicity is PrPC-independent. (A) Scatter plots with bars 
are the percentage of cell survival in MTT assay 48 hours after treatment with Veh or α-synOs at 1, 
5 and 10μM (*p<0.05 and ****p<0.0001 against Veh; Two-way ANOVA followed by Tukey’s test). 
To further investigate whether α-synO detrimental effects are PrPC-mediated, we tested the 
memory performance in both Prnp0/0 and Prnp+/+ mice ICV injected with either Veh or α-
synOs (1μM/7.5μL). Thus, this direct and simple approach, which exploited the acute mouse 
model previously described, allowed us to specifically assess the effects of α-synOs on long-
term memory (chapters VI and VII; La Vitola et al., 2018). As shown in figure 39, both 
Prnp+/+ and Prnp0/0 mice displayed a significant memory impairment after ICV treatment 
with α-synOs compared to mice receiving Veh. In fact, the DI (mean±SEM) of both Prnp+/+ 
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and Prnp0/0 receiving α-synOs (-0.04±0.06 and 0.02±0.05 respectively) was significantly 
lower than those of both Prnp+/+ and Prnp0/0 receiving the Veh (0.24±0.07 and 0.31±0.05 
respectively; **p<0.01, Two-way ANOVA followed by Tukey’s test). Our findings suggest 
that, at the functional level, α-synOs act independently of PrPC. In fact, the Two-way 
ANOVA showed a significant effect of α-synOs (F1,28=24.89; P<0.0001), but a non-
significant interaction α-synOs x genotype (F1,28=0.003; P=0.96).  
 
 
 
 
 
 
 
 
 
 
Figure 39. Alpha-synO-mediated detrimental action on memory is PrPC-independent. Scatter 
plots with bars are the DI (mean±SEM) of Prnp+/+ and Prnp0/0 mice treated with Veh or α-synOs 
(**P<0.01, Two-way ANOVA followed by Tukey’s test; n=8/group).  
 
Based on our previous findings (chapter VII and La Vitola et al, 2018), showing that in our 
acute mouse model α-synO-mediated memory damage was tightly associated to a transient 
hippocampal gliosis, we addressed whether a similar outcome could also take place in 
Prnp0/0 mice. Through histological analysis of astrocytes (GFAP) and microglia (IBA1), we 
assessed the extent of glial activation 4 hours after treatment. As shown in figure 40A and 
B, we found that α-synOs led to an increased expression of GFAP and IBA1 in both Prnp+/+ 
and Prnp0/0 mice when compared to those receiving Veh. Accordingly, as shown in figure 
40C and D, our qualitative analyses were also confirmed by quantifications. Specifically, 
comparing the percentage of hippocampal GFAP- or IBA1-immunopositive area in the 
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different experimental groups investigated, we discovered that the α-synO-induced gliosis 
was PrPC-independent. In fact, the Two-way ANOVA indicated a significant effect of α-
synOs (GFAP: F1,16=24.45; P=0.0001. IBA1: F1,16=57.31, P<0.0001) but a non-significant 
interaction α-synOs x genotype (GFAP: F1,16=0.041, P=0.84. IBA1: F1,16=0.50, P=0.49).  
 
Figure 40. Alpha-synO-induced hippocampal gliosis is PrPC-independent. (A) Representative 
images of GFAP-immunostaining in the hippocampus of mice treated with either Veh or α-synOs.  
(B) Representative images of IBA1-immunostaining in the hippocampus of mice treated with either 
Veh or α-synOs. (C) Scatter plots with bars of the relative GFAP-marked area quantification in 
Prnp+/+ and Prnp0/0 mice treated with Veh or α-synOs (*p<0.05. Two-way ANOVA followed by 
Tukey’s test; n=5/group). (D) Scatter plots with bars of the relative IBA1-marked area quantification 
in Prnp+/+ and Prnp0/0 mice treated with Veh or α-synOs (**p<0.01 and ***p<0.001. Two-way 
ANOVA followed by Tukey’s test; n=5/group).  
Together, our findings indicate that from a functional standpoint the PrPC is not mandatory 
for mediating the detrimental effects of α-synOs at multiple levels, such as neuronal cell 
toxicity, memory impairment and neuroinflammation. 
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8.2.2 Alpha-synOs and PrPC do not directly interact  
To assess the PrPC-α-synO direct binding, we exploited the SPR approach. PrPC from mouse 
brain homogenates was captured on SPR sensor chips coated with 3F4 or 94B4 anti-PrPC 
antibodies. Of note, we selected 3F4 and 94B4 based on the evidence that the PrPC residues 
93-109 have been identified as crucial for the α-synO interaction (Ferreira et al., 2017), and 
on the evidence that our two antibodies recognise epitopes lying within regions 106-111 and 
186-193 respectively. In a previous paper, we had verified that the captured protein is 
actually PrPC, as no capture was detected when flowing brain homogenate obtained from 
Prnp0/0 mice (Balducci et al., 2010). Moreover, PrPC captured by either 94B4 or 3F4 retained 
its ability to bind 6D11, an anti-PrPC antibody directed against the same region (93-109) 
which was described to be involved in α-synO-induced toxic effects (Balducci et al., 2010; 
Ferreira et al., 2017). Under all these conditions, when α-synOs (1 and 10 µM) were flowed 
over captured PrPC we could not find any α-synO-PrPC binding (Figure 41A and B). In 
contrast, 1 µM AβOs, injected in parallel as positive control, produced the expected binding 
signal (Figure 41A and B).  
Figure 41. Alpha-synOs do not directly bind to PrPC.  SPR analysis were performed flowing α-
synOs (1 or 10 μM) and Aβ1-42Os (1 μM), as positive control, for 3 min over sensor surfaces exposing 
PrPC, captured by 3F4 (A) or 94B4 (B) antibodies. Sensorgrams show the time course of the specific 
PrPC-dependent SPR binding signal. 
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Therefore, our results clearly demonstrate the absence of a PrPC-α-synO direct binding in 
different experimental conditions and provide molecular evidence of our functional data on 
the PrPC-independent action of α-synOs. 
 
8.3 Discussion 
Initially considered as mere intermediates forming during the aggregation process of α-syn, 
the small soluble oligomeric assemblies of α-syn are now widely accepted as crucial players 
and main pathological drivers in the pathogenesis of PD and PD-related disorders (Winner 
et al., 2011; Scott et al., 2010; Diogenes et al., 2012; Martin et al., 2012; Ono, 2017; Bengoa-
Vergniory et al., 2017). Attempting to elucidate the pathways underlying the α-synO harmful 
properties, researchers have focused their efforts on both cell-autonomous and non-cell 
autonomous mechanisms. However, despite a large body of evidence, a clear and univocal 
mechanism has not been defined yet. Recently, Ferreira and colleagues (Ferreira et al., 2017) 
have proposed the PrPC as a novel interactor of α-synOs, which is apparently implicated in 
mediating their detrimental activities. Particularly, in their study Ferreira and co-workers 
found that PrPC interacts with α-synOs, and the PrPC-α-synO interaction induces the 
phosphorylation of Fyn kinase and the consequent phosphorylation of NMDAR2B, 
triggering a signalling cascade that leads to synaptic dysfunction (Ferreira et al., 2017).  
To elucidate the role of the PrPC as mediator for the deleterious activities of α-synOs, in the 
present study we further investigated this emerging hypothesis through direct in vitro and in 
vivo approaches. In order to provide evidence of the oligomeric state in our experimental 
conditions, we firstly characterised our three α-synO preparations (1, 5 and 10 μM) through 
both AFM and Western Blotting. Of note, in our three samples we found a similar 
distribution of small assemblies without evidence of larger aggregates. Since our protocol 
for obtaining α-synOs at the three different concentrations is solely based on the incubation 
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of α-syn monomers at 241 μM for 48 hours at 37°C with subsequent dilution at 1, 5 and 10 
μM, the similarities in our preparations were expected. Once verified the quality of our 
oligomers, we performed analyses of the PrPC-α-synO interaction at multiple levels. 
Notably, our SPR analysis did not confirm the existence of a direct PrPC-α-synO binding in 
different conditions. Moreover, α-synOs impaired mouse memory and induced gliosis 
regardless of presence of PrPC, thus indicating the not mandatory role of the PrPC as mediator 
of the α-synO detrimental effects.  
Of note, while our findings clearly depict PrPC as not mandatory for mediating α-synO 
detrimental effects at functional level, we should take into account some aspects of the SPR 
approach herein exploited to assess the PrPC-α-synOs binding. Although, SPR is widely used 
to detect protein-protein interaction, and provides an efficient tool to investigate direct 
interactions (Balducci et al., 2012; Shirasaka et al., 2019), bias may occur to a certain extent. 
In fact, the technique is based on the immobilisation of a protein (PrPC in our study) on the 
surface of a sensor chip via binding to a specific antibody. Such an antibody-protein 
interaction could result in a conformational change of the immobilised protein, that may 
make the binding site required for the interaction with the analyte (α-synOs in our study) 
unaivailable or masked by steric hindrance. To rule out, at least partially, such a possibility, 
we ascertained that PrPC retains its ability to bind AβOs as well as the antibody 6D11, which 
shares the same binding site of α-synOs on PrPC (Ferreira et al., 2017). Moreover, as we 
obtained consistent results using two different antibodies for on-chip immobilisation of PrPC, 
it is highly improbable that the same conformational changes take places in both cases. 
Nonetheless, although our data seem to exclude a PrPC-α-synOs direct interaction, we cannot 
completely rule out that our SPR analyses are partially biased by the events described above.  
On the other hand, it is also relevant to note that the PrPC-α-synOs interaction described in 
the work of Ferreira and colleagues, was revealed  by  an indirect immunoprecipitation 
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approach. In fact, in the context of a cell lysate several proteins may mediate the PrPC-α-
synOs complex, and therefore the physical protein-protein direct binding cannot be 
confirmed and demonstrated . 
To be noticed that, while our SPR analyses may be biased, our functional studies completely 
ruled out the role of PrPC in mediating α-synO-induced neuronal toxicity, cognitive damage 
and neuroinflammation. Thus, assuming that a PrPC-α-synOs binding exists, it does not 
appear to be involved from a neuropathological and behavioural perspective  
As demonstrated in chapter VI and recently published, the ICV injection of α-synOs triggers 
a neuroinflammatory response which drives the α-synO-induced impairment of new memory 
establishment in C57BL6 naïve mice (La Vitola et al., 2018). Intriguingly, herein our 
findings depict the occurrence of a neuroinflammatory response caused by α-synOs also in 
Prnp0/0 mice. Thus, our data may further support the role of neuroinflammation as potential 
non-cell autonomous mechanism mediating the harmful activities of α-synOs (La Vitola et 
al., 2018; La Vitola et al., 2019).  
Our data are in contrast with those of Ferreira (Ferreira et al., 2017), and although we have 
no explanations for this at the state of the art, it could be argued that different α-synO 
preparations were used. Moreover, a further possible explanation is that other α-synOs 
conformers might associate with PrPC, and that both PrPC-dependent and PrPC-independent 
pathways may co-exist in PD as previously reported also for AβOs in the context of AD 
(Purro et al., 2018).  
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Peripherally induced neuroinflammation influences 
α-synO harmful actions and the PD phenotype in an 
acute and transgenic mouse model 
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The data presented in this chapter are reported in the recently submitted manuscript entitled 
“Peripherally-induced neuroinflammation exacerbates alpha-synuclein oligomer toxicity 
and neuropathology in Parkinson’s disease mouse models”. 
 
9.1 Aim of the study and experimental design 
As far, our results highlight neuroinflammation as a mediator for α-synO detrimental 
activities on memory. However, as previously described in the introduction section, 
compelling evidence from clinicians and experimental studies depicts neuroinflammation as 
a link between genetic susceptibility and environmental factors co-fostering PD and PD-
related pathogenesis (Gao et al., 2011; McKenzie et al., 2017). 
Based on these findings and the lack of direct evidence proving that inflammation influences 
α-synO harmful activities or PD neuropathology, we investigated whether an induced or 
exacerbated inflammatory state potentiates α-synO effects in the acute mouse model 
previously described and PD phenotype in A53T mutated mice, respectively. To this goal 
we have developed two different “double-hit” mouse models. The former is an acute 
“double-hit” model based on the peripheral administration of LPS and the subsequent ICV 
injection of α-synOs. The latter is a Tg “double-hit” mouse model, which is based on the 
peripheral administration of LPS in either NTG or A53T mice. Of note, in this second model 
the two challenges are represented by the pathologic genetic PD-related background and the 
inflammatory stimulus LPS. For this study we have performed several experiments aimed at 
identifying the best experimental conditions. Firstly, we have identified a dose of α-synOs 
which did not affect memory in the NORT. Thus, C57BL/6 naïve mice were ICV injected 
with 0.5 µM α-synOs (7.5µL) 2 hours before the familiarisation/sample phase and their 
memory performances assessed 24 hour later (Figure 42A). To identify a dose of LPS 
inducing the activation of both microglial and astroglial cells in the hippocampus without 
affecting memory performances, 1 or 2.5 mg/Kg were IP injected in C57BL/6 naïve mice. 
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One month later, their neuroinflammatory state was investigated through immunohistology, 
and memory performance were tested in the NORT (Figure 42B). 
To address whether the peripherally LPS-induced neuroinflammation influences the effect 
of the ineffective dose of α-synOs, we have developed an acute “double-hit” mouse model. 
C57BL/6 naïve mice were IP treated with either Veh or 2.5 mg/Kg LPS. One month later, 
mice were ICV injected with either Veh or 0.5 µM α-synOs and their memory performances 
tested 24 hours later in the NORT or in the Y-maze. In the NORT the ICV injection of Veh 
or 0.5 µM α-synOs was performed 2 hours before the familiarisation/sample phase, and 
memory was investigated 24 hours later the ICV treatment. Immunohistological assessment 
of the neuroinflammatory response in the hippocampus was carried out 24 hours after the 
ICV injection (Figure 42C). 
To elucidate whether the peripherally LPS-induced neuroinflammation influences cognitive 
and motor performances in a Tg PD mouse model, A53T mice were treated with a single IP 
injection of Veh or 2.5 mg/Kg LPS. Twenty-five days later, A53T and NTG mice were tested 
in cognitive tools (NORT, Y-maze and MWM) and in motor tools (open field and Beam 
walk test). At the end of behavioural experiments, a group of mice was sacrificed and both 
hippocampal neuroinflammation and dopaminergic neurodegeneration in the SNpc were 
evaluated through immunohistology (Figure 42D). 
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Figure 42. Schematic representation of the in vivo experiments. (A) Veh or 0.5 μM α-synOs ICV 
injected in C57BL/6 naïve mice 2 hours pre-sample phase of the NORT. (B) Veh, 1 or 2.5 mg/Kg 
LPS IP injection in C57BL/6 naïve mice one month before cognitive and histological 
characterisation. (C) 2.5 mg/Kg LPS or Veh IP injected in C57BL/6 naïve mice one month before 
the ICV injection of Veh or 0.5 μM α-synOs. 24 hours after the ICV treatment mice were tested in 
the test phase of NORT or in the Y-maze. (D) 2.5 mg/Kg LPS or Veh IP injected in either NTG or 
A53T mice. Starting 25 days after treatment mice were behaviourally characterised for their 
cognitive and motor performances in several behavioural tasks. 
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9.2 Results 
9.2.1 LPS-preconditioning enhances α-synO-induced toxicity in primary hippocampal 
neuronal cultures 
To assess whether inflammation would influence α-synO cytotoxicity, we initially exposed 
primary hippocampal neurons to α-synOs (1, 5 and 10 μM) to identify a dose of oligomers 
ineffective in inducing neuronal death. We found that, upon 48 hours exposure, α-synOs 
induced cellular damage at the two highest doses (Figure 43), leading to a significant 
increase in the amount of LDH released in the cell medium (% of Veh mean±SEM; 
132.2±6.4 and 137.3±1.6, respectively; *p<0.05 and **p<0.01, One-way ANOVA followed 
by Dunnet’s test). In contrast, since the LDH released by neurons upon exposure to 1 μM α-
synOs was comparable to Veh-treated cells (100.0±9.40 and 113.7±10.3, respectively), we 
demonstrate that 1 μM α-synOs did not affect cell survival.  
 
Figure 43. α-synO-mediated neuronal damage in primary hippocampal cell cultures. (A) 
Scatter plots and bars (mean±SEM) of the LDH percentage of primary hippocampal cultures exposed 
for 48 hours to Veh (n=7 wells), or 1 μM (n=6 wells), 5 μM (n=7 wells) and 10 μM (n=7 wells) α-
synOs (One-way ANOVA found a significant effect of treatment; F2,23=4.70, P=0.011; *p<0.05 and 
**p<0.01, Dunnet’s test). 
Once characterised 1 µM as ineffective dose, we evaluated whether the neuronal culture pre-
conditioning with the inflammatory stimulus LPS could influence neuronal susceptibility to 
α-synOs. Thus, primary hippocampal cultures were exposed to an inactive dose of LPS (0.5 
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μg/mL) for 24 hours. After LPS wash-out, we treated neurons for 24 and 48 hours with α-
synOs (1 μM), then we assessed the cell toxicity through LDH assay. At both time points, 
we found that the 24-hour LPS pre-conditioning enhanced primary hippocampal cell 
susceptibility to α-synOs. In fact, as shown in figure 44A and B, while LPS 0.5 µg/mL or 1 
µM α-synOs did not affect neuronal survival per se at both time points tested (LDH 24 hours: 
97.51±1.50 n=8 wells and 98.52±.1.13 n=8 wells, respectively; 48 hours: 109.30±6.50 n= 8 
wells and 139.59±.11.82 n= 9 wells, respectively), which was comparable to Veh-treated 
cells (LDH 24 hours: 100.00±2.31, n=9 wells; 48 hours: 100.00±3.29, n=9 wells), cell death 
was significantly higher in neurons treated with both 0.5 µg/mL LPS and 1 µM α-synOs 
(LDH 24 hours: 125.56±7.13, n=7 wells; 48 hours: 185.13±15.16, n=7 wells; **p<0.01, 
***p<0.001 and ****p<0.0001, Two-way ANOVA followed by Tukey’s test).  Therefore, 
we herein demonstrate that LPS pre-conditioning of hippocampal neurons potentiates α-
synOs detrimental effects in vitro. 
 
Figure 44. LPS pre-conditioning enhances α-synO-mediated neuronal damage in primary 
hippocampal cell cultures. (A) Scatter plots with bars (mean±SEM) of the LDH percentage of 
primary hippocampal cultures pre-conditioned with 0.5 μg/mL LPS and then exposed to 1 μM α-
synOs for 24 hours (Two-way ANOVA demonstrated a significant interaction LPS x α-synOs: 
F1,28=17.67, P=0.0002; ***p<0.001 and ****p<0.0001, Tukey’s test). (B) Scatter plots with bars 
(mean±SEM)  of the LDH percentage of primary hippocampal cultures pre-conditioned with 0.5 
μg/mL LPS (n=8 wells), and then exposed to 1 μM α-synOs for 48 hours (Two-way ANOVA showed 
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a significant interaction LPS x α-synOs: F1,28=6.374, P=0.017; **p<0.01 and ****p<0.0001, Tukey’s 
test). 
 
9.2.2 Establishment of the two challenges for the “double-hit” experimental model 
Based on our in vitro data, by exploiting the acute α-synO-induced mouse model described 
above, we ascertained whether a pre-established neuroinflammatory condition could 
potentiate α-synO detrimental effects in vivo. To such a purpose, we developed a “double-
hit” acute mouse model exploiting two challenges. As initial approach, we identified the 
inactive α-synO concentration in C57BL/6 naïve mice in terms of memory impairment. As 
reported in chapters VI and VII and in our recent publications (La Vitola et al., 2018; La 
Vitola et al., 2019), 1 µM ICV injection of α-synOs is able to induce memory impairment. 
Thus, we investigated the efficacy of the lower 0.5 µM concentration in mice subsequently 
tested in the NORT. Mice receiving either Veh (n=7) or 0.5 µM α-synOs (n=8) discriminated 
well between the familial and the novel object exhibiting comparable DIs (0.28±0.02 and 
0.31±0.03, respectively; Student’s t-test t13=0.70, P=0.49; Figure 45A).  
Thereafter, we set up the LPS-induced neuroinflammatory treatment with the purpose of 
defining an LPS dose leading to a persistent neuroinflammatory response without inducing 
mouse suffering and cognitive deficiency. We injected IP C57BL/6 naïve mice with either 
1 or 2.5 mg/Kg LPS (n=7 and n=8, respectively). Both LPS doses altered body growth 
(Figure 45B). Indeed, we observed a significant reduction in body weight three days after 
treatment compared to mice receiving Veh (n=7) (23.06±0.54 g, 23.24±0.76 g and 
26.30±0.30 g, respectively; ****p<0.0001, Two-way ANOVA followed by Tukey’s test). 
Such an effect was transient, as the body weight recovered to Veh-treated mice one-month 
post-injection (28.34±0.54 g, 29.45±0.39 g and 29.93±0.39 g, respectively). Thus, we 
selected the one-month post-injection as the time point for both LPS doses in order to 
establish the best treatment condition propaedeutic to evaluate the α-synO effects.   
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To choose the final LPS dose, we compared the memory performance and the extent of 
neuroinflammation at 1 and 2.5 mg/Kg. As shown in figure 45C, both LPS doses 
(n=4/group) induced hippocampal astrogliosis (marked by GFAP) compared to Veh-treated 
mice (n=4/group). The subsequent quantitative analysis (Figure 45D) of the percentage of 
GFAP-marked area (mean±SEM of Veh-treated mice) confirmed our qualitative result (1 
mg/kg = 1119.39±1.99; 2.5 mg/kg = 144.59±2.4; Veh = 100±1.17; ***p<0.001 
and****p<0.0001, One-way ANOVA followed by Tukey’s test). Notably, we found that the 
GFAP expression was significantly increased in 2.5 mg/Kg LPS-treated mice compared to 
the lower dose (****p<0.0001, One-way ANOVA followed by Tukey’s test).  
In contrast to the astroglial activation, microglial cells were significantly activated in the 
hippocampus solely at the higher LPS dose (Figure 45C). Moreover, as shown in figure 45E, 
the quantitative analyses of the IBA1-marked area, confirmed a significant increase in the 
percentage of IBA1 expression (mean±SEM of Veh-treated mice) in mice receiving LPS 2.5 
compared to both LPS 1 mg/Kg and Veh-treated animals (250.2±7.52, 133.19±23.99 and 
100±7.01, respectively, n=4/group; **p<0.01 and ***p<0.001, One-way ANOVA followed 
by Tukey’s test). Thus, our immunohistochemical analyses demonstrated that 2.5 mg/Kg 
LPS efficiently leads to a significant hippocampal glial response one month after treatment. 
We, thus, assessed the memory performance of LPS-treated mice in the NORT at the same 
time point (Figure 45F). As suggested by comparable DIs (mean±SEM), we demonstrated 
that neither 1 nor 2.5 mg/Kg LPS (0.26±0.11 and 0.27±0.10 respectively, n=8/group) 
affected memory compared to Veh-treated mice (DI=0.27±0.08, n=8).  
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Figure 45. Identification of an α-synO dose ineffective in mediating memory damage in the 
NORT, and characterisation of the peripheral LPS-induced neuroinflammatory mouse model 
(A) Scatter plots and bars are the DI (mean±SEM) of C57BL/6 naïve mice ICV injected with Veh or 
0.5 μM α-synOs. (B) Body weight growth (mean±SEM) of mice receiving a single IP administration 
of Veh, 1 or 2.5 mg/Kg LPS at different time points (Two-way ANOVA found a significant 
interaction time x treatment (F6,57=4.89, P=0.0004; Day 3: ****p<0.0001, Tukey’s test). (C) 
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Representative images of hippocampal astrocytosis (GFAP) and microgliosis (IBA1) one month after 
the IP administration of Veh, 1 or 2.5 mg/Kg LPS. (D) Scatter plots with bars (mean±SEM) are the 
quantitative analysis in the hippocampus of the percentage GFAP-marked area in Veh, 1 and 2.5 
mg/Kg LPS treated mice (One-way ANOVA found a significant effect of treatment: F2.9=112.1, 
P<0.0001; ***p<0.001 and ****p<0.0001, Tukey’s test). (E) Scatter plots and bars (mean±SEM) 
are the quantitative analysis of the percentage IBA1-marked area in mice receiving Veh, 1 and 2.5 
mg/Kg LPS (One-way ANOVA found a significant effect of treatment: F2.9=27.35, P=0.0001; 
**p<0.01 and ***p<0.001, Tukey’s test), (F) Scatter plots and bars are the DI (mean±SEM) of mice 
receiving Veh, 1 or 2.5 mg/Kg LPS one month after treatment. One-way ANOVA did not find any 
significant effect of treatment (F2,21=0.0003; P=0.99). 
Collectively, our findings depict 0.5 µM α-synOs and LPS 2.5 mg/Kg as valuable 
experimental conditions for our further investigation. Based on this, we have developed the 
“double-hit” acute model in order to test whether the presence of a peripherally pre-
established neuroinflammatory state could influence α-synO effects at both cognitive and 
neuroinflammatory level. 
 
9.2.3 Peripherally LPS-induced neuroinflammation enhances α-synO-mediated 
memory damage 
One month after the LPS injection, C57BL/6 naïve mice were ICV injected with α-synOs 
(0.5µM/7.5µL) and their memory performance was assessed in the NORT (Figure 46). As 
demonstrated above, we confirmed that LPS 2.5 mg/Kg did not impair memory. In fact, LPS 
mice had a DI (mean±SEM) comparable to those receiving Veh (0.29±0.3 and 0.30±0.02, 
respectively; n=7/group). Moreover, since mice treated with Veh+α-synOs (n=7) had a DI 
comparable to that of Veh-treated animals (0.32±0.06 and 0.30±0.02, respectively), we 
confirmed again that no effects on memory performance were detectable upon 0.5 µM α-
synOs application. In contrast, we found that mice receiving both LPS and α-synOs (n=7) 
showed a significant impairment in their recognition memory having a DI significantly lower 
than Veh-injected mice (DI=-0.03±0.06; ***<0.001, Two-way ANOVA followed by 
Tukey’s test). Furthermore, we found that double-hit-treated mice displayed a DI 
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significantly lower than both Veh+α-synOs and LPS+Veh (0.32±0.06 and 0.29±0.3, 
respectively; ***p<0.001, Two-way ANOVA followed by Tukey’s test).  
Figure 46. 0.5 μM α-synO detrimental effects on recognition memory is enhanced by the 
peripheral 2.5 mg/Kg LPS pre-treatment. Scatter plots with bars (mean±SEM) of the DI of mice 
ICV injected with either Veh or 0.5 μM α-synOs one month after a single IP administration of either 
Veh or 2.5 mg/Kg LPS (Two-way ANOVA found a significant interaction LPS 2.5 x α-synOs: 
F1,24=13.51; P=0.0012; **p<0.01 and ****p<0.001, Tukey’s test). 
To further assess the role of the pre-established LPS-induced neuroinflammation in 
promoting α-synO detrimental effects on memory, we also evaluated the short-term spatial 
working memory through the Y-maze test. One month after the 2.5 mg/Kg LPS treatment, 
mice were ICV injected with α-synOs (0.5µM/7.5µL) and their spatial working memory was 
tested 24 hours later. As shown in figure 47A, mice receiving LPS+α-synOs (n=6) had a 
significant impairment in their spatial working memory having a lower spontaneous 
alternation behaviour (% mean±SEM) compared to Veh+Veh- (n=6), LPS+Veh- (n=8) and 
Veh+α-synOs-treated mice (n=6), (52.65±5.45, 86.45±3.79, 85.66±3.60 and 82.85±3.88, 
respectively; ***p<0.0001 and ***p<0.001, Two-way ANOVA followed by Tukey’s test). 
Of note, the impaired spontaneous alternation behaviour was not due to an impairment of 
mouse motor performances. In fact, as shown in figure 47B, all treated mice had a 
comparable number of total arm entries.  
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Thus, our findings demonstrated that the peripherally LPS-induced neuroinflammation is 
able to promote the harmful activities of per se ineffective α-synOs on two different memory 
domains such as the long-term recognition memory and the short-term spatial working 
memory. 
Figure 47. Peripheral 2.5 mg/Kg LPS pre-treatment enhances 0.5 μM α-synO detrimental 
effects on spatial working memory. (A) Scatter plots and bars (mean±SEM) are the percentage of 
the spontaneous alternation behaviour in the Y-maze of mice ICV injected with either Veh or 0.5 μM 
α-synOs one month after a single IP administration of either Veh  or 2.5 mg/Kg LPS  (Two-way 
ANOVA found a significant interaction LPS x α-synOs: F1,22=12.18; P=0.0024; ***p<0.001 and 
****p< 0.0001, Tukey’s test). (B) Scatter plots and bars (mean±SEM) are the total arms entries of 
mice tested in the Y-maze. Two-way ANOVA did not find a significant interaction LPS x α-synOs 
(F1,22=0.036; P=0.95) and a significant effect of both LPS-treatment (F1,22=0.43; P=0.52) and of α-
synO-treatment (F1,22=1.282; P=0.27).  
 
9.2.4 Microglial cells and astrocytes differentially respond in the “double-hit” acute 
mouse model 
Since we have previously demonstrated that a single ICV injection of α-synOs (1μM/7.5μL) 
leads to hippocampal gliosis in tight association with memory damage (La Vitola et al., 
2018; chapter VII), we have investigated whether the peripherally pre-established LPS-
induced glial cell activation would influence the action of α-synOs on both microglial and 
astroglial cells in our new “double-hit” acute model. At the end of the NORT, we sacrificed 
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mice and performed immunohistochemical analyses. As shown in figure 48A, mice pre-
treated with LPS and ICV injected with α-synOs showed IBA1+ cells 
characterised by an enlargement of their soma and with an amoeboid shape, typical features 
of activated microglia. Of note, we confirmed our qualitative analysis by the quantification 
of the percentage of IBA1-marked area (Figure 48B). Specifically, mice receiving LPS+α-
synOs (n=7) had an IBA1-marked area (% of Veh mean±SEM) significantly higher than 
animals treated with Veh+Veh (n=7), LPS 2.5 mg/Kg+Veh (n=7) and Veh+α-synOs (n=6) 
(338±34.39, 100±18.25, 227.25±23.36 and 103.14±19.71, respectively; *p<0.05, **p<0.01 
and ****p<0.0001, Two-way ANOVA followed by Tukey’s test).  
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Figure 48. Peripherally LPS pre-activated microglial cells are primed to α-synOs and 
potentiate their activation state. (A) Representative images showing the activation of microglial 
cells (IBA1) in the CA1 region of mice ICV injected with either Veh or 0.5 μM α-synOs one month 
after a single IP administration of either Veh or 2.5 mg/Kg LPS. (B) Scatter plots and bars 
(mean±SEM) are the quantitative analysis in the hippocampus of the percentage IBA1-marked area 
of the different experimental group considered (Two-way ANOVA revealed a significant interaction 
LPS x α-synOs: F1,23=4.615, P=0.04; *p<0.05, **p<0.01 and ****p<0.0001, Tukey’s test). 
To further characterise the microglial cell phenotype in our “double-hit” model, we 
measured the expression of CD16/32, representative of an M1 pro-inflammatory microglial 
phenotype (Subramaniam and Federoff, 2017). We found that CD16/32 was poorly 
expressed in Veh+Veh, Veh+α-synOs and LPS+Veh-treated mice. In contrast, it was 
dramatically increased in mice receiving LPS+α-synOs (Figure 49A). Accordingly, the 
quantitative analysis of the CD16/32-marked area (% mean±SEM) normalised on the 
hippocampal area, confirmed our qualitative results (Figure 49B). Specifically, we found 
that LPS+α-synOs (n=5) had a significant higher CD16/32-marked area than Veh+Veh, 
LPS+Veh and Veh+α-synOs (n=4/group) (3.19±0.79, 0.11±0.04, 0.28±0.14 and 0.36±0.14, 
respectively; **p<0.01, Two-way ANOVA followed by Tukey’s test).  
 
Figure 49. Peripherally LPS pre-activated microglial cells are primed to α-synOs and 
potentiate their activation state acquiring an M1 pro-inflammatory phenotype. (A) 
Representative immunofluorescence images of the M1 pro-inflammatory phenotype marker 
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CD16/32 in the CA1 hippocampal region of mice ICV injected with either Veh or 0.5 μM α-synOs 
one month after a single IP administration of either Veh or 2.5 mg/Kg LPS. (B) Scatter plots and 
bars (mean±SEM) are the quantitative analysis of the hippocampal normalised percentage CD16/32-
marked area of the different experimental group considered (Two-way ANOVA revealed a 
significant interaction LPS x α-synOs: F1,23=4.615, P=0.04; **p<0.01, Tukey’s test). 
To confirm that CD16/32+ were indeed microglial cells, we co-localised CD16/32 with the 
microglial marker IBA1. As shown in figure 50, in mice receiving LPS+α-synOs, CD16/32 
completely co-localised with IBA1. Thus, confirming that CD16/32+ were microglial cells. 
 
Figure 50. CD16/332+ cells in “double-hit” mice are microglial cells. Representative 
immunofluorescence images showing the complete colocalization of the M1 marker CD16/32 and 
the pan-microglial marker IBA1 in the hippocampal CA1 region of LPS2.5+α-synO treated mice 
In contrast to the synergistic effect of LPS and α-synOs on microglial cell activation, 
astrocytes differently responded to the “double-hit” stimulation. In fact, we found a 
significant reduction in the expression of the astroglial marker GFAP. In particular, while α-
synOs alone did not alter the expression of GFAP, and LPS induced a significant increase 
when compared to mice receiving Veh, “double-hit” mice surprisingly showed a reduction 
in the GFAP-immunoreactivity (Figure 51A and B). The GFAP quantification (% of Veh 
mean±SEM; Figure 51C) found that the percentage of GFAP-marked area was increased in 
LPS-treated mice compared to mice receiving Veh (134.3±5.81 and 100±4.35 respectively; 
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n=7/group; *p<0.05, Two-way ANOVA followed by Tukey’s test), but was significantly 
reduced in LPS+α-synO-treated mice (65.69±4.51, n=7) compared to all the other 
experimental groups considered (Veh+Veh: 100±4.35; Veh+α-synOs: 96.16±13.46, n=6 and 
LPS 2.5mg/Kg+Veh: 134.3±5.81; *p<0.05 and ****p<0.0001, Two-way ANOVA followed 
by Tukey’s test). 
In order to establish whether the GFAP reduction was attributable to cell loss, we counted 
the number of GFAP+ cells (% of Veh mean±SEM; Figure 51D), which was unchanged. 
Thus, this result suggested that the dampening of the GFAP-immunoreactivity might be the 
result of a reduced GFAP expression and astrocyte branches rather than cell loss.  
 
 
 
 
 
 
 
 
 
Figure 51. Alpha-synO challenge triggers the atrophy of peripherally LPS pre-activated 
astrocytes. (A and B) Representative images showing astroglial cells (GFAP) in the CA1 region of 
mice ICV injected with either Veh or 0.5 μM α-synOs one month after a single IP administration of 
either Veh or 2.5 mg/Kg LPS. (C) Scatter plots with bars (mean±SEM) are the quantitative analysis 
of the percentage GFAP-marked area in the hippocampus of the different experimental groups 
considered (Two-way ANOVA found a significant interaction LPS x α-synOs: F1,23=19.64, 
P=0.0002; *p<0.05, ****p<0.0001, Tukey’s test). (D) Scatter plots and bars (mean±SEM) are the 
quantitative analysis of the percentage hippocampal GFAP+ cell density of the different experimental 
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groups investigated. Two-way ANOVA did not find any significant interaction LPS x α-synOs 
(F1,23=0.065; P=0.80). 
9.2.5 Peripheral administration of LPS negatively influences cognitive performances in 
the A53T PD-related transgenic mouse model 
Since through our acute “double-hit” mouse model we demonstrated that the peripherally 
LPS-induced neuroinflammation increases the susceptibility to α-synO detrimental actions 
on both memory and glial activation, we further investigated whether the harmful effects of 
the induced neuroinflammation are detectable also in the more complex scenario provided 
by a Tg mouse model of PD. To this purpose, eight months old A53T mice and their age-
matched NTG were IP injected with either Veh or 2.5 mg/Kg LPS and, starting from day 25 
after treatment, we behaviourally characterised them to assess both memory and motor 
performances. Thereafter, mice were sacrificed and their hippocampal gliosis, as wells as 
dopaminergic neurodegeneration in the SNpc, were addressed.  
We found that LPS aggravated memory performance of A53T mice tested in the NORT. In 
fact, as shown in figure 52A, while NTG mice treated with either Veh or LPS discriminated 
well between the novel and the familial object, showing a comparable DI (mean±SEM) 
(0.26±0.02 and 0.30±0.01, respectively; n=7/group), A53T+Veh mice did not (0.11±0.01, 
n=7; **<0.01, Two-way ANOVA followed by Tukey’s test). Intriguingly, we found that the 
memory deficiency of A53T mice was further exacerbated by the LPS administration (DI=-
0.004±0.05, n=7; *p<0.05 and ****p<0.0001, Two-way ANOVA followed by Tukey’s test). 
To further prove the exacerbating effect of the LPS-induced neuroinflammation at cognitive 
level in A53T mice, we tested mice also in spatial memory tasks. 
Spatial memory was tested in both the Y-maze measuring the spontaneous alternation 
behaviour (% mean±SEM), and in the MWM for learning and memory assessment.  
Despite the recognition memory impairment, spontaneous alternation behaviour (Figure 
52B) was not damaged in Veh-treated A53T mice (66.37±4.48), which was comparable to 
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that of NTG (+ Veh: 74.44±2.98; + LPS: 74.44±2.98). In contrast, a significant impairment 
was detectable in LPS-treated A53T mice (42.73±5.10; **p<0.01 and ***p<0.001, Two-
way ANOVA followed by Tukey’s test). To rule out possible motor deficits underlying the 
spontaneous alternation behaviour impairment, we analyzed the total mouse arm entries in 
the Y-maze. Two-way ANOVA neither found a significant interaction genotype x LPS 2.5 
(F1,24=0.002; P=0.96) nor a significant effect of either genotype (F1,24=1.46; P=0.24) or LPS 
2.5 (F1,24=1.684; P=0.21).  
When mice were tested in the MWM (Figure 52C), NTG receiving Veh progressively learnt  
platform position and reduced their latency to reach it (mean±SEM) (d1: 34.4±2.8 ; d5: 
11.8±1.4; *p<0.05, Three-way ANOVA followed by Tukey’s test) as well as NTG+LPS (d1: 
41.8±5.5; d5: 13.6±2.1; ***p<0.001, Three-way ANOVA followed by Tukey’s test) and 
A53T receiving Veh (52.4±3.5 sec and 14.6±1.5; ***p<0.001, Three-way ANOVA followed 
by Tukey’s test). In contrast, LPS-treated A53T animals did not and they showed a similar 
latency throughout the learning phase (d1: 55.0±3.1; d5: 44.8±4.7). Furthermore, we 
specifically analyzed the differences between A53T mouse groups through a Student’s t-test 
for days 3 to 5 and, we found a significant longer latency for LPS-treated A53T mice at all 
three training days compared to A53T mice receiving Veh (d3: t12 = 2.53, *p = 0.03; d4: t12 
= 3.2, **p = 0.008; d5: t12 = 6.1, ****p<0.0001). Besides hampering A53T learning, LPS 
impaired also their ability to recall platform location in the probe test phase (Figure 52D and 
E). Specifically, A53T+LPS spent a lower time (% mean±SEM) in the target quadrant 
compared to A53T mice receiving Veh and NTG animals treated with either Veh or LPS 
(19.50±5.15, 47.74±3.85, 47.78±4.39 and 43.98±4.02 respectively; **p<0.01 and 
***p<0.001, Three-way ANOVA followed by Tukey’s test). Consistently, in the opposite 
quadrant, A53T mice receiving LPS spent a longer time (33.00±5.41) compared to Veh-
treated A53T mice (12.50±1.41) and NTG animals receiving either Veh or LPS (9.60±2.76 
and 13.20±2.31 respectively; **p<0.01 and ***p<0.001, Three-way ANOVA followed by 
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Tukey’s test). Of note, lack of spatial learning and memory deficits in A53T mice at the age 
tested is in accordance with recent data showing that in heterozygous A53T mice, these 
effects become detectable at 12 months of age (Singh et al., 2019). 
Collectively our findings demonstrate that the peripheral administration of LPS in A53T 
mice dampens their memory performances in diverse domains.  
 
Figure 52. Peripheral LPS worsens cognitive functions in A53T mice. (A) Scatter plots and bars 
(mean±SEM) are the DI of both NTG and A53T mice receiving a single IP administration of either 
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Veh or 2.5 mg/Kg LPS (Two-way ANOVA that found a significant interaction genotype x LPS: 
F1,24=8.315, P=0.008;.*p<0.05, **p<0.01 and ****p<0.0001, Tukey’s test). (B) Scatter plots and 
bars (mean±SEM) are the percentage of the spontaneous alternation behaviour of mice tested in the 
Y-maze (Two-way ANOVA found a significant interaction genotype x LPS: F1,24=5.587, P=0.027; 
**p<0.01 and ***p<0.001, Tukey’s test). (C) Latency in finding the hidden platform (mean±SEM) 
during the five training days of the different experimental groups tested in the MWM (Three-way 
ANOVA found a significant interaction time x genotype x LPS: F14,120=29.19, P=0.0001). Focusing 
on differences between A53T mouse groups through a Student’s t-test for days 3 to 5 we found 
significant longer latencies for A53T mice treated with LPS at all 3 training days (d3: t12 = 2.53, *p 
= 0.03; d4: t12 = 3.2, **p = 0.008; d5: t12 = 6.1, ****p<0.0001). (D and E) Scatter plots and bars 
(mean±SEM) are the percentage of total time spent in the target and opposite zone during the probe 
phase by the different experimental groups investigated Target quadrant: two-way ANOVA 
demonstrated a significant interaction genotype x LPS (F1,24=4.375, P=0.047; **p<0.01 and 
***p<0.001, Tukey’s test).  Opposite quadrant: two-way ANOVA demonstrated a significant 
interaction genotype x LPS (F1,24=6.459, P=0.018; **p<0.01 and ***p<0.001, Tukey’s test). 
 
9.2.6 Peripheral LPS induces a different response of microglial and astroglial cells in 
the A53T PD-related transgenic mouse model 
Since in the “double-hit” acute model we have demonstrated a different effect on glial cell 
activation, we further addressed whether these outcomes occurred also in A53T mice. 
Through IBA1 immunostaining we evaluated microgliosis in the hippocampus (Figure 53A). 
We found an increased IBA1-immunoreactivity in NTG mice receiving LPS as well as in 
either Veh- or LPS-treated A53T mice compared to Veh-treated NTG. Quantitatively, the 
analysis of the hippocampal normalised IBA1-marked area (% mean±SEM) confirmed our 
qualitative observations (Figure 53B). Specifically, LPS-treated NTG (n=5) and A53T mice 
receiving Veh (n=5) had a significantly higher IBA1-marked area than Veh-treated NTG 
(n=6) (2.66±0.13, 2.51±0.12 and 1.96±0.09, respectively; *p<0.05 and **p<0.01, Two-way 
ANOVA followed by Tukey’s test). Notably, in accordance with the acute “double-hit” 
model, LPS treatment further elicited microglial activation. In fact, A53T mice receiving 2.5 
mg/Kg LPS (n=5) had a higher IBA1 expression with respect to all the other experimental 
groups (3.74±0.16; ****p<0.0001, Two-way ANOVA followed by Tukey’s test).  
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As aforementioned, microglia and astroglia differentially responded to the LPS and α-synO 
challenges in the “double-hit” acute model. Thus, we investigated in A53T mice how 
astrocytes responded to the peripheral LPS stimulation (Figure 53C). While both NTG mice 
receiving LPS and A53T animals receiving Veh (n=5/group) had an increased GFAP 
expression compared to Veh-treated NTG mice (n=6), A53T+LPS mice (n=5) did not. 
Quantitative analysis (Figure 53D) confirmed that NTG mice treated with LPS and A53T 
mice receiving Veh had a significantly higher GFAP-marked area (% mean±SEM) than the 
NTG Veh-treated group (11.09±0.40, 11.51±0.26 and 9.49±0.36, respectively; *p<0.05 and 
**p<0.01, Two-way ANOVA followed by Tukey’s test). In contrast, astroglial cell 
activation in A53T mice receiving LPS was comparable to NTG mice treated with Veh. To 
be noticed that, in line with results we obtained in the “double-hit” acute model, although 
the GFAP-marked area in A53T mice receiving LPS was not significantly lower than 
NTG+Veh-treated mice, it was significantly lower than both LPS-treated NTG and Veh-
treated A53T mice (9.24±0.50; *p<0.05 and **p<0.01, Two-way ANOVA followed by 
Tukey’s test).  
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Figure 53. Microglial and astroglial cells differentially respond to the peripheral 2.5 mg/Kg 
LPS challenge in A53T mice. (A) Representative images showing the activation of microglial cells 
(IBA1) in the hippocampal CA1 region of both NTG and A53T mice treated with a single IP 
administration of either Veh or 2.5 mg/Kg LPS. (B) Scatter plots and bars (mean±SEM) are the 
quantitative analysis of the hippocampal normalised percentage IBA1-marked area of the different 
experimental group considered (Two-way ANOVA found a significant interaction genotype x LPS 
2.5: F1,17=4.59, P=0.047; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001, Tukey’s test). (C) 
Representative images showing astroglial cells (GFAP) in the CA1 region of both NTG and A53T 
mice treated with a single IP administration of either Veh or 2.5 mg/Kg LPS. (D) Scatter plots and 
bars (mean±SEM) are the quantitative analysis of the hippocampal normalised percentage GFAP-
marked area of the different experimental groups investigated (Two-way ANOVA confirmed a 
significant interaction genotype x LPS: F1,17=25.15, P=0.0001; *p<0.05 and **p<0.01, Tukey’s test). 
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9.2.7 Peripheral LPS does not affect motor behaviour and dopaminergic 
neurodegeneration in A53T mice 
It has been previously reported that the peripheral administration of LPS triggers a 
progressive dopaminergic neurodegeneration in an α-syn Tg mouse model (Gao et al., 2011). 
Thus, we have investigated whether the IP administration of 2.5 mg/Kg LPS in either NTG 
or A53T mice influences their motor behaviour and dopaminergic loss in the SNpc of A53T 
mice.  
As initial approach we measured at functional level the spontaneous motor behaviour of both 
NTG and A53T mice treated with either Veh or LPS in the open field. As shown in figure 
54A and B, A53T mice receiving Veh or LPS (n=7/group) were hyperactive. In fact, the 
two-way ANOVA found a significant effect of genotype for both the parameters considered 
(Velocity: F1,24=32.69; P<0.00001. Distance: F1,24=36.70; P<0.0001). In addition, we 
showed that the peripheral LPS challenge did not exacerbate A53T spontaneous motor 
hyperactivity. Consistently, the two-way ANOVA did not find either a significant interaction 
genotype x LPS (Velocity: F1,24=7.916; P=0.096.  Distance: F1,24=8.047; P=0.009) or a 
significant effect of LPS (Velocity: F1,24=3.183; P=0.087. Distance: F1,24=3.202; P=0.086). 
Of note, hyperactivity in A53T mice has been already reported by other investigators 
(Graham and Sidhu, 2010; Paumier et al., 2013; Singh et al., 2019), and herein we 
demonstrate that the peripheral administration of LPS did not worsen it one month after 
treatment. To further investigate the motor behaviour in our “double-hit” Tg mouse model, 
we evaluated the mouse gait instability through the Beam-walk test (Figure 54C). As for the 
spontaneous motor behaviour, the LPS treatment did not influence the number of A53T foot-
slips. Indeed, the two-way ANOVA did not find a significant interaction genotype x LPS 2.5 
(F1,24=1.689; P=0.21) or a significant effect of LPS 2.5 (F1,24=2.712; P=0.11). However, we 
demonstrated that the genetic PD-related background led to a significant increase in the 
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mean number of A53T mouse foot-slips compared to those of their NTG littermates. In fact, 
the two-way ANOVA found a significant effect of genotype (F1,24=54.77; P<0.0001). 
Of note, despite the lack of a significant difference in motor performances comparing 
A53T+Veh- and A53T+LPS-treated mice, a trend in their worsening due to the peripheral 
LPS challenge was detectable. 
Since motor impairment in PD is attributable to the selective loss of dopaminergic neurons 
in the SNpc, we assessed the extent of dopaminergic neurodegeneration in the SNpc 
investigating the expression of the limiting Th enzyme involved in dopamine synthesis. 
Particularly, we evaluated whether the trends in the aggravation of motor performances in 
A53T+LPS-treated animals were due to an LPS-induced loss of dopaminergic neurons. Our 
analyses revealed both qualitatively and quantitatively (Figure 54D and E) the lack of a 
significant neuronal loss between A53T+Veh- and A53T+LPS-treated mice.  
In conclusion our findings demonstrate that the peripheral LPS treatment does not exacerbate 
motor behaviour performances of A53T mice. Moreover, our evidence is supported by the 
lack of LPS-induced dopaminergic neurodegeneration in our “double-hit” Tg model. Of 
note, our results are consistent with previous data reporting peripheral LPS-induced 
dopaminergic neurodegeneration in A53T mice not earlier than three months after treatment 
(Gao et al., 2011). 
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Figure 54. Peripheral administration of 2.5 mg/Kg LPS does not influence motor behaviour of 
A53T mice and does not trigger dopaminergic neurodegeneration within the SNpc. (A) Scatter 
plots and bars (mean±SEM) are the total moved distance in the open field of both NTG and A53T 
mice treated with either Veh or 2.5 mg/Kg LPS (****P<0.0001, Two-way ANOVA). (B) Scatter 
plots with bars (mean±SEM) are the velocity in the open field of both NTG and A53T mice treated 
with either Veh or 2.5 mg/Kg LPS (****P<0.0001, Two-way ANOVA). (C) Scatter plots with bars 
(mean±SEM) are the number of foot-slips in the beam walk test of both NTG and A53T mice treated 
with either Veh or 2.5 mg/Kg LPS (*****P<0.01, Two-way ANOVA). (D) Representative images 
showing the dopaminergic neurons (Th+) in the SNpc of A53T mice treated with a single IP 
administration of either Veh or 2.5 mg/Kg LPS. (E) Scatter plots with bars (mean±SEM) are the 
quantitative analysis of SNpc Th+ neurons in A53T-treated mice (t8=o.51, P=0.51; Student’s T-
test).  
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9.3 Discussion 
Alpha-synucleinopathies are multi-factorial disorders raising from the interaction between 
modifiable, and non-modifiable risk factors including genetic susceptibility (Kalia and Lang, 
2015; Outeiro et al., 2019). Aimed at elucidating the link between these factors, 
neuroinflammation has acquired a new light. Accordingly, epidemiological studies reveal 
that inappropriate management of systemic diseases, turning into an inflammatory response 
within the CNS, correlates with an increased risk to develop PD (McKenzie et al., 2017). 
Consistently, experimental data highlight how chronic neuroinflammation, which triggers a 
deleterious microenvironment, represents a vital link between α-syn pathology and 
progressive neurodegeneration (Qin et al., 2007; Gao et al., 2011; Wang et al., 2019).  
In addition, glial cells interact with α-synOs, mediating their detrimental effects on both 
memory and neuroinflammation (Kim et al., 2013; Fellner et al., 2013; Kim et al., 2016; La 
Vitola et al., 2018; La Vitola et al., 2019). Thus, such a condition would promote a 
neuroinflammatory vicious circle likely favouring and/or aggravating both 
neuropathological and clinical PD features. 
In this chapter we corroborated the theory that inflammation is a driving force for the 
development of PD or LBD. 
In vitro, we proved that non-toxic concentration of α-synOs induced hippocampal neuronal 
cell death when neurons were pre-exposed to LPS, thus indicating that the presence of an 
inflammatory milieu increases neuronal susceptibility to α-synOs. To further investigate the 
influence of LPS pre-conditioning on α-synO effects we have developed an in vivo “double-
hit” acute mouse model.  
We first identified 0.5 μM as an inactive α-synO concentration which did not affect memory 
when ICV injected in C57BL/6 naïve mice. In addition, we demonstrated that a single IP 
administration of 2.5 mg/Kg LPS in C57BL/6 naïve mice led to an immune response within 
the CNS characterised by persistent activation of glial cells up to one month with no effects 
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on memory. In contrast, through the “double-hit” mouse model we found that the 
combination of the two per se inactive challenges led to an impairment of both long- and 
short-term memory. Collectively, our in vivo findings are consistent with in vitro data and 
further demonstrate that a peripherally pre-established LPS-induced neuroinflammation 
influences α-synO harmful effects. Moreover, our findings highlight a synergistic action 
occurring between neuroinflammation and α-synOs.  
Since astroglial and microglial cells are crucial players in tuning synaptic functions and in 
mediating the α-synO detrimental activities (Bacci et al., 1999; Blank and Printz, 2013; Jang 
et al., 2011; Hertz and Chen, 2016; La Vitola et al., 2018), we have investigated the extent 
of hippocampal glial activation in our “double-hit” acute model immediately after the 
NORT. We found a different response of microglia and astrocytes to the LPS+α-synOs 
challenge. While α-synOs potentiate the activation of LPS-primed microglia, which acquired 
an M1 pro-inflammatory phenotype, astroglial cells appeared atrophic. Such a different 
response was unexpected and will require further investigation to unveil the mechanisms 
involved. However, in line with our findings, while microgliosis is widely accepted and 
reported in PD, contradictory results were obtained for astrocytes which were described as 
active, inactive or in an atrophic state (McGeer et al., 1988; Chao et al., 2014; 
Surendranathan eta al., 2015; Tong et al., 2015). Thus, although the clear role of astrocytes 
in PD remains unclear, loss of astrocytic support to neurons might contribute to its 
development and/or pathogenesis (Sorrentino et al., 2019). Moreover, it is possible to 
speculate that the acquisition of an M1 pro-inflammatory phenotype of microglial cells 
together with the astrocytic dysfunction/alteration, likely act in concert to promote neuronal 
damage, which in turn may underlie the memory impairment in our “double-hit” acute 
model. 
To get more insight on the impact of the peripherally LPS-induced neuroinflammation in a 
more complex neuropathological context, we developed a “double-hit” model exploiting a 
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Tg mouse model which carries the A53T PD-related mutation. In agreement with the results 
obtained in the acute “double-hit” model, we found that A53T mice treated with 2.5 mg/Kg 
LPS displayed a further impairment in their recognition and spatial memory in association 
with an increased microgliosis. Of note, in these mice we identified again a reduction in the 
expression of the astroglial marker GFAP when compared with A53T+Veh mice. In contrast 
to this deleterious effect at cognitive level, the LPS-treatment did not further impair motor 
performances in A53T mice. Notably, such an effect was associated with the lack of a 
significant increased dopaminergic neurodegeneration in the SNpc of A53T mice receiving 
2.5 mg/Kg LPS compared to Veh-treated Tg mice.  
Taken together our findings demonstrate for the first time that peripherally induced 
neuroinflammation modulates α-synO action potentiating their detrimental effects. In 
addition, in a genetic pathologic PD context, the peripheral LPS administration aggravates 
cognitive deficiencies in A53T mice. In a translational prospect, these results are compelling 
because, in line with the aforementioned clinical data, clearly indicate how inflammatory 
events, even from the peripheral compartment, and especially if perpetuating throughout 
time, represent a concrete risk for the development or exacerbation of PD pathogenesis.  
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10.1 Summary and final remarcks 
PD and LBD are progressive and devastating neurodegenerative disorders which share 
common clinical and neuropathological features (Bengoa-Vergniory et al., 2017; Poewe et 
al., 2017; Jellinger, 2018; Outeiro et al., 2019). Collectively such pathologies represent the 
second most common neurodegenerative disorders in elderly after AD, and since they 
frequently lead to institutionalisation, they account for high public health costs (Emre, 2003; 
Biundo et al., 2016; Hanagasi et al., 2017; Aarsland et al., 2017). To date, PD/LBD are 
orphans of valuable therapies, and the existing treatments do not affect disease 
onset/progression being solely symptomatic. Thus, the understanding of the mechanisms 
underlying their pathogenesis as well as the identification of therapeutic targets aimed at 
developing new disease modifying therapeutic strategies is a crucial and urgent topic. 
As mentioned above, PD and LBD are closely related disorders. Indeed, they share common 
non-motor clinical features such as cognitive deficits which can evolve in dementia, and 
common neuropathological hallmarks which include proteinaceous neuronal inclusions 
known as LBs and LNs (McKeith et al., 2004; Wakabayashi et al., 2013; Aldridge et al., 
2018; Sanford, 2018). 
Although the first description of PD was provided in 1817 by James Parkinson, the 
understanding of the underlying mechanisms remained foggy until the identification of 
different mutations in the gene encoding for α-syn in familial forms of PD and LBD 
(Polymeropoulos et al., 1997; Krüger et al., 1998; Singleton et al., 2003; Chartier-Harlin et 
al., 2004; Ibáñez et al., 2004; Zarranz et al., 2004; Proukakis et al.  2013; Kiely et al. 2013; 
Lesage et al., 2013; Pasanen et al., 2014), and the first observation that α-syn is the main 
constituent of both LBs and LNs in post-mortem brain from both PD and DLB patients 
(Spillantini et al., 1997; Spillantini et al., 1998; Baba et al., 1998). Thus, these findings 
pinpoint α-syn as a crucial protein involved in the pathogenesis of PD and PD-related 
disorders.  
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α-syn is a partially unfolded protein mainly located in the pre-synaptic terminals within the 
CNS. Its physiological function is still poorly understood. However, it is widely accepted 
that α-syn is a key protein involved in the neurotransmitter release as well as in the vesicle 
pool distribution and organisation (Lashuel et al., 2013; Burré et al., 2015; Calo et al., 2016).  
Although α-syn is a cytoplasmatic protein and LBs and LNs are located within the cells, 
numerous findings suggest that α-syn can be secreted by human neuronal cells and can be 
detected in human fluids (i.e. plasma and cerebrospinal fluid) (Borghi et al. 2000; El-Agnaf 
et al., 2003; Ohrfelt et al., 2009). These observations raised the interest for the extracellular 
role of α-syn in the pathogenesis of the so called α-synucleinopathies. 
As described above, α-syn is a naturally unfolded protein lacking a well-organised secondary 
structure, and like other proteins involved in protein-misfolding related neurodegenerative 
disorders (Aβ, PrPC), it is able to self-aggregate. In fact, α-syn undergoes a nucleation 
process that generates oligomeric species (Maries et al., 2013; Roberts and Brown, 2015). 
Oligomers are able to grow through further monomer addition and form protofilaments and 
eventually mature fibrils. Several kinds of oligomers that vary in composition, conformation 
and toxicity (Danzer et al., 2007; Roberts and Brown, 2015) are generated during this process, 
and compelling evidence highlights their pathogenetic role in α-synucleinopathies (Winner 
et al., 2011; Cremades et al., 2012). In addition, it has been reported that stress conditions 
increase the amount of α-synOs being released (Jang et al., 2010), further supporting the 
hypothesis that extracellular moieties of α-syn, and particularly extracellular α-synOs, may 
lead to neuronal damage and contribute to disease pathogenesis. In this regard, it has been 
demonstrated that α-synOs can impair the LTP, an experimental paradigm aimed at assessing 
synaptic plasticity, whereas monomers or fibrils of the protein are ineffective (Diogenes et 
al., 2012. Martin et al., 2012 Ferreira et al., 2017). On the same line, through behavioural in 
vivo experiments, it has been demonstrated that the ICV injection of α-synOs in mice triggers 
cognitive dysfunction in the fear conditioning paradigm (Martin et al., 2012). All together, 
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these data support the “oligomeric hypothesis”, originally introduced in the context of AD, 
and allow researchers to introduce a new definition of a-synucleinopathies as pathologies 
related to oligomers, and to classify them under the name of “oligomeropathies” (Forloni et 
al., 2016; Ono, 2017; Ono, 2018).  
Based on these findings, the first aim of this PhD thesis was to investigate the α-syn 
“oligomeric hypothesis” in the context of memory impairment. Of note, our interest in 
cognitive decline stems from the fact that it is a common PD-related non-motor symptom, 
and that it contributes to a significant extent to morbidity, worsening life quality of patients 
(Aarsland et al., 2017; Hanagasi et al., 2017). Moreover, cognitive impairment may develop 
in dementia, that in PD as well in LBD accounts for high public health cost thus being an 
urgent issue to cope with (Emre, 2003; Biundo et al., 2016; Aarsland et al., 2017; Hanagasi 
et al., 2017). 
To serve such a purpose we have developed an acute mouse model based on a single ICV 
injection of different and well-characterised α-syn moieties (monomers, α-synOs and fibrils) 
in C57BL/6 naïve, and we have assessed their memory performance in the NORT. To be 
noticed that, although this model represents a simplification of what really happens in the 
complex context of PD and PD-related disorders, it allows us to punctually dissect the 
harmful effects of the different α-syn assemblies without any bias due to their co-existence, 
which for instance occurs in PD Tg mouse models. Through our acute approach we 
demonstrate that while monomeric and fibrillar α-syn were ineffective in mediating the 
memory impairment, a single ICV injection of α-synOs was able to cause a memory 
deficiency in the NORT. Moreover, since pre-treatment with an anti-α-syn antibody 
completely abrogated the memory deficit in α-synO-treated mice, we can conclude that the 
memory damage was specifically due to α-syn. Accordingly, our in vivo results are supported 
by ex vivo observations that the exposure of coronal brain slices to α-synOs significantly 
impaired the hippocampal LTP as also previously reported by others (Diogenes et al., 2012; 
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Martin et al., 2012; Ferreira et al., 2017). To further investigate the α-synO-mediated 
memory impairment, we assessed whether it was persistent and whether it could be ascribed 
to macroscopic morphological alterations in the hippocampus or in the expression of 
representative hippocampal synaptic proteins. Our results demonstrate that α-synO-
mediated memory impairment was transient. In fact, mice re-tested in the NORT 12 days 
after the first α-synO ICV injection performed well in the NORT. Of note, this result is 
consistent with the absence of significant macroscopic alterations in the different 
hippocampal subfields as well as with the absence of changes in the expression of both 
hippocampal synaptophysin and PSD95 at different time points.  
Collectively, through our acute mouse model we demonstrate that α-synOs specifically lead 
to a transient cognitive impairment. Moreover, since the different assemblies of α-syn do not 
co-exist in our model, it appears as a valuable tool to specifically dissect the mechanisms 
underlying α-synO-detrimental activities (La Vitola et al., 2018). 
As previously described, in pathological and stress conditions neurons increase the amount 
of α-synOs being secreted in their milieu. Thus, extracellular α-synOs may contribute to the 
pathogenesis of PD and PD-related disorders by exerting their detrimental action in a non-
cell autonomous fashion which involves neighbouring neurons, astrocytes and microglial 
cells (Marques and Outeiro, 2012). In this regard, many groups started focusing their efforts 
on the non-cell autonomous actions of α-synOs, which include neuroinflammation and 
protein-protein interaction. 
As extensively described in the introduction (chapter III), several lines of evidence point out 
the potential role of glial cells in the pathogenesis of PD and PD-related disorders.  
Astrocytes as well as microglial cells are immune competent cells within the CNS, and they 
play vital roles for neurons, being crucial effectors in the fine tuning of neuronal activity and 
synaptic plasticity (Bacci et al., 1999; Blank and Printz, 2013; Hertz and Chen, 2016). 
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Therefore, perturbation of their function/state might lead to neuronal damage, dysfunction 
and ultimately death (Morris et al., 2013; Blank and Prinz, 2013; Sorrentino et al., 2019).  
Because of a growing body of evidence, the second aim of this PhD thesis was to decipher 
the role of the neuroinflammatory response in mediating the memory damage triggered by 
α-synOs. As TLRs are first line receptors involved in eliciting the innate immune response, 
and α-synOs have been described as one of their endogenous ligands (Kouli et al., 2019), 
we have investigated whether the memory deficit mediated by α-synOs in our acute mouse 
model was associated with glial cell activation and was mediated by TLRs. In this regard, 
based on their controversial role, we have focused our attention mainly on TLR2 and TLR4. 
Indeed, both TLR2 and TLR4 were reported to mediate astroglial and microglial cell 
activation upon exposure to different α-syn aggregates (Fellner et al., 2013; Kim et al., 2013; 
Ramikko et al., 2015; Kim et al., 2016; Kouli et al., 2019), and their expression is altered in 
PD/LBD patients as well as in PD Tg animal models (Letiembre et al., 2009; Doorn et al., 
2014; Drouin-Ouellet et al., 2015; Dzamko et al., 2017; Kim et al., 2018; Zhao et al., 2018). 
Taking advantage of our acute mouse model, we demonstrate that the single ICV injection 
of α-synOs (1μM/7.5μL) triggered a rapid and transient activation of both microglial and 
astroglial cells in the hippocampus. However, in contrast to the ICV injection of AβOs 
(1μM/7.5μL), α-synOs do not lead to an increased expression of the pro-inflammatory 
mediator IL-1β. Such a difference is particularly relevant in the context of protein-
misfolding related neurodegenerative disorders. As a matter of fact, while oligomeric 
assemblies of α-syn and Aβ are recognised as key moieties in the pathogenesis of α-
synucleinopathies and AD, respectively, and share common harmful properties, they 
probably differ in the underlying signalling pathways. 
Once demonstrated that α-synOs trigger the activation of glial cells in our acute mouse 
model, we addressed whether such a neuroinflammatory state was merely a secondary event 
or represented a key point and a mechanism eliciting the α-synO-mediated memory damage. 
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As previously reported for AβOs in a comparable acute mouse model (Balducci et al., 2017), 
we demonstrate that neuroinflammation is a crucial player also in mediating the detrimental 
effect of oligomeric α-syn on cognitive performance. In fact, through the pre-treatment with 
two different NSAIDs (Indo and IBF), we show that modulation of inflammatory mediators 
such as COX1 and 2 completely abrogates α-synO-induced memory deficiency and 
hippocampal gliosis. Furthermore, in contrast to AβOs (Balducci et al., 2017), α-synO-
induced memory impairment is not mediated by TLR4 but is TLR2-dependent (La Vitola et 
al., 2018). Remarkably, our findings on the involvement of TLR2 are consistent with recent 
data provided by Kim and co-workers (Kim et al., 2018), and depict TLR2 and 
neuroinflammation as valuable targets to counteract α-synO detrimental effects.  
 As mentioned above, α-synOs and AβOs share common toxic properties. Indeed, both α-
synOs and AβOs are capable to trigger a memory damage closely related to the induction of 
hippocampal gliosis (Balducci et al., 2017; La Vitola et al., 2018). In addition, 
neuroinflammation appears as a key mechanism underlying the detrimental effects of both 
α-synOs and AβOs on memory (Balducci et al., 2017: La Vitola et al., 2018).  
Focusing on common interactors between these different oligomers, it has been recently 
reported that the PrPC, initially described with contradictory results as an interactor for 
AβOs, also represents an interactor and a mediator for α-synOs (Lauren et al., 2009; 
Balducci et al., 2010; Forloni and Balducci, 2011; Ferreira et al., 2017). 
In the context of α-synucleinopathies, it has been found that PrPC residues 93-109 are crucial 
to mediate LTP inhibition upon exposure to α-synOs, and α-synOs seem to require PrPC to 
activate the Fyn kinase, which in turn leads to NMDAR2B phosphorylation giving rise to 
LTP inhibition. Moreover, Ferreira and colleagues, demonstrated through 
immunoprecipitation approaches that α-synOs and PrPC can interact in lysates from both cell 
cultures treated with α-synOs and in a PD Tg mouse model overexpressing the WT human 
α-syn (Ferreira et al., 2017). Based on these data we have further investigated the α-synO-
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PrPC interaction at multiple levels. By means of Prnp+/+ and Prnp0/0 neuronal hippocampal 
cultures, we demonstrate that α-synOs lead to neuronal death in a PrPC-independent manner. 
Moreover, through the ICV injection of α-synOs (1μM/7.5μL) in both Prnp+/+ and Prnp0/0 
mice, we functionally show that the PrPC was not required to trigger α-synO-detrimental 
effects on memory. Besides, in the same model we report that α-synOs caused hippocampal 
gliosis (La Vitola et al., 2019), thus suggesting that neuroinflammation may represent a non-
cell autonomous mechanism eliciting α-synO effects independently of the genetic 
background considered. In addition to functional data, we also demonstrate at the molecular 
level that α-synOs do not interact directly with PrPC (La Vitola et al., 2019), further 
indicating that α-synOs exert their harmful actions independently of the presence of PrPC. 
Our results are in contrast with the findings of Ferreira and colleagues (Ferreira et al., 2017) 
but, as previously reported for AβOs, both PrPC-dependent and -independent mechanisms 
may co-exist. Nevertheless, our findings are also in line with a recent study in A53T mice 
reporting the absence of Fyn activation and phosphorylation of the NMDARs subunit 
GluN2B, two downstream outcomes of PrPC activation (Singh et al., 2019). 
Hitherto, our data depict α-synOs as the main culprits eliciting cognitive dysfunctions in 
mice, and neuroinflammation as a key player in mediating their actions. Thus, although 
neuroinflammation has been initially considered as a mere secondary event and a 
consequence of the underlying neurodegenerative process in α-synucleinopathies, we 
pinpoint neuroinflammation as a non-cell-autonomous mechanism (La Vitola et al., 2018). 
Our evidence is consistent with previous data, and strongly supports the modulation of 
neuroinflammatory mediators as valuable strategies to develop new therapies aimed at 
counteracting α-synOs effects (Kim et al., 2013: Drouin-Ouellet et al., 2015; Kim et al., 
2018).  
While we depict neuroinflammation as an action mechanism of α-synOs, emerging findings 
propose neuroinflammation as a potential bridge between non-modifiable (genetic 
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susceptibility) and modifiable (environment, systemic pathologies) factors co-fostering PD 
and PD-related disorders (Qin et al., 2007; Gao et al., 2011; Ascherio and Schwarzschild, 
2016; McKenzie et al., 2017; Biosa et al., 2018).  However, a direct proof demonstrating 
that inflammation influences α-synO harmful activities or the PD behavioural and 
neuropathological features is still missing. Hence, the last aim of this PhD thesis was to 
verify whether a peripherally induced neuroinflammatory state could enhance α-synO 
effects in our acute mouse model, and whether it influenced the PD phenotype in the more 
complex context of the A53T Tg PD mouse model. 
Taking advantage from a “double-hit” acute mouse model based on the IP injection of the 
widely used proinflammatory stimulus LPS (2.5mg/Kg) followed one month later by the 
ICV injection of an ineffective dose of  α-synOs (0.5μM/7.5μL), we demonstrate that the 
combination of the two per se inactive challenges led to an impairment of both long- and 
short-term memory. Thus, our findings highlight a synergistic action occurring between 
peripherally LPS-induced neuroinflammation and α-synOs.  
As astroglial and microglial cells are immune competent cells within the CNS, and they are 
crucial in tuning synaptic functions and in mediating the α-synO detrimental activities (Bacci 
et al., 1999; Blank and Printz, 2013; Jang et al., 2011; Hertz and Chen, 2016; La Vitola et 
al., 2018), we have investigated the hippocampal glial activation in our newly established 
“double-hit” acute model immediately after the NORT. Intriguingly, microglial and 
astroglial cells differentially responded to the double challenge. In fact, while α-synOs 
potentiated the activation of peripherally LPS-primed microglia, astroglial cells were not 
activated. Such a different response was unexpected. However, consistent with our findings, 
while microgliosis is widely accepted and reported in PD and LBD, controversial results 
were presented for astrocytes which are shown as active, inactive or in an atrophic state 
(McGeer et al., 1988; Chao et al., 2014; Surendranathan eta al., 2015; Tong et al., 2015). 
Thus, although the role of astrocytes in PD/LBD still remains unclear, loss of astrocytic 
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support to neurons might contribute synergistically with the acquisition of an M1 pro-
inflammatory phenotype of microglial cells towards the memory impairment appearing in 
our “double-hit” acute model. 
To further elucidate and validate the relevance of the peripherally LPS-induced 
neuroinflammation in PD, we have developed a “double-hit” model exploiting a Tg mouse 
model which carries the A53T PD-related mutation, and which represents a more complex 
neuropathological context. In line with the acute “double-hit” model, we found that 2.5 
mg/Kg LPS worsened both recognition and spatial memory performance of A53T mice in 
association with an increased hippocampal microgliosis. Of note, in these mice we show 
again a reduction in the expression of the astroglial marker GFAP when compared with 
A53T+Veh mice. In contrast to this deleterious effect at cognitive level, the LPS-treatment 
did not further aggravate the motor performances and the dopaminergic neurodegeneration 
in A53T mice. Altogether, we demonstrate for the first time that peripherally induced 
neuroinflammation modulates α-synO action by potentiating their detrimental effects. In 
addition, in a genetic PD context, the peripheral LPS administration aggravates cognitive 
deficiencies in association with a potentiation of microglial cell activation. Intriguingly, 
while microglial cells are potentiated in their activation state in both our “double-hit” 
models, astroglial cells are not. Therefore, such a comparable microglial and astroglial 
outcome in both our models may allow the speculation that in complex contexts, where both 
peripheral and central events take place, microglial activation and loss of astroglial support 
to neurons together contribute to the cognitive failure. 
In conclusion, the data here reported pinpoint α-synOs as the sole moieties capable of 
inducing a memory damage in strict association with glial cell activation and independent of 
the PrPC in mice (La Vitola et al., 2018; La Vitola et al., 2019). Moreover, although we 
cannot rule out that extracellular α-synOs act on neurons, we demonstrate that 
neuroinflammation is not a secondary event but actively participates to the detrimental 
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effects of oligomers. Of note, since neurons express several inflammatory mediators 
including TLRs it is possible to speculate that α-synOs exert their effect at multiple levels 
involving neurons, astroglial and microglial cells at the same time (Dzamko et al., 2017). 
On the other hand, our results also propose inflammation as a bridge between genetic 
susceptibility and environmental factors co-fostering PD/LBD pathogenesis. We indeed 
reported that in vitro the LPS neuronal pre-conditioning enhances α-synO-mediated cell 
toxicity, and that in vivo the peripherally LPS-induced neuroinflammation potentiates α-
synO detrimental effects on different memory domains as well as the cognitive deficiencies 
in A53T mice. These findings are compelling from a translational standpoint as they clearly 
demonstrate how inflammatory events from the peripheral compartment represent a risk 
factor for the development and/or the exacerbation of PD pathogenesis. Because α-
synucleinopathies are now recognised as multifactorial disorders, our discoveries describe 
the concomitant action of α-syn aggregates and neuroinflammation, and depict them as 
valuable targets for developing disease modifying strategies. 
 
10.1.1 Conclusions 
Protein misfolding-related neurodegenerative disorders such as PD and LBD are 
multifactorial pathologies where several factors act in concert leading to neurodegeneration. 
Aside from the enormous amount of factors involved in PD/LBD pathogenesis, several 
cellular pathways may be affected and synergistically contribute to the disorder onset and 
progression (Marques and Outeiro, 2012; Forloni et al., 2016; Bengoa-Vergniory et al., 
2017; Wong and Krainc. 2017; Kouli et al., 2019).  
The results described here pinpoint for the first time the tight interplay between α-synOs and 
neuroinflammation in mediating cognitive deficits in both an acute and a transgenic PD/LBD 
mouse model.  
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α-synOs have emerged as the main detrimental aggregate in PD/LBD (Winner et al., 2010; 
Martin et al., 2012 Diogenes et al., 2012). Our data further corroborate previous evidence 
providing new insights into the crucial role of glial cells. Moreover, we described the novel 
connection between α-synO-triggered cognitive deficit and non-cell autonomous 
mechanisms involving glial activation and TLR2 in an acute mouse model, where the 
detrimental effects at cognitive level are specifically mediated by oligomeric assemblies, 
and not by the coexistence of larger aggregates.  
As mentioned above, PD and LBD are multifactorial pathologies arising from alterations in 
several pathways (e.g. altered neurotransmitter release, reduced neuroplasticity, damage of 
mitochondria, changes in membrane permeability, increase neuroinflammation, neuronal 
death, etc.). Such a complexity generates controversy in pre-clinical and clinical studies. In 
fact, while a number of compounds have been shown to ameliorate or block PD/LBD 
pathology (e.g. minocycline, ibuprofen ...) in several animal models, they failed in clinical 
trials. Therefore, it becomes clear that a therapy based on a molecule affecting solely a single 
target cannot be beneficial in the complex scenario of these pathologies when applied to 
humans.  
As a consequence, it is conceivable to assume that a multitarget approach could be more 
effective than a single target therapy. Based on the results reported here, a therapeutic 
approach that may affect at the same time α-syn aggregation as well as neuroinflammation 
may offer a useful tool to halt PD/LBD progression. In this regard, it has been recently 
demonstrated that the antimicrobial drug Doxycycline inhibits the aggregation of α-syn, 
leading to the production of non-toxic off-set α-synOs (Gonzalez-Lizarraga et al., 2017) . In 
addition, Doxycycline has proven effective in drug-induced PD mouse model (Bortolanza 
et al., 2018), and we have recently demonstrated that the antimicrobial drug administered at 
sub-antibiotic doses efficiently counteracts memory impairment and neuroinflammation in 
a transgenic mouse model of AD, and in an acute mouse model based on the ICV injection 
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of the pro-inflammatory toxin LPS (Balducci et al., 2018). Thus, we are now investigating 
whether the chronic treatment of A53T mice with Doxycycline is effective in counteracting 
cognitive and motor deficits as well as neuropathology in our model. In particular, we will 
focus on the effect of Doxycycline on glial activation, α-syn aggregation and TLR2, which 
we have demonstrated being crucial in α-synO-induced cognitive damage. 
In conclusion, this PhD thesis provides new evidence on the role of α-synOs and 
neuroinflammation in the pathogenesis of PD/LBD, and puts forward the hypothesis 
whereby drugs affecting simultaneously these two factors may be valuable therapeutic 
approaches acting on two discrete elements which are closely connected. 
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